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Chi mette il piè su l’amorosa pania, 
     Cerchi ritrarlo, e non v’inveschi l’ale; 
     Che non è in somma amor, se non insania, 
     A giudizio de’ savi universale: 
     E se ben come Orlando ognun non smania, 
     Suo furor mostra a qualch’altro segnale. 
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     Che, per altri voler, perder se stesso?  
L’Orlando Furioso (Canto XXIV, [I]) 
 
 
Let him make haste his feet to disengage, 
    Nor lime his wings, whom Love has made a prize; 
    For love, in fine, is nought but phrensied rage, 
   By universal suffrage of the wise: 
   And albeit some may show themselves more sage 
   Than Roland, they nut sin in other guise. 
   For, what proves folly more than on this shelf, 
   Thus, for another, to destroy oneself? 
L’Orlando Furioso (Canto XXIV, [I]) 
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Abstract 
Enhancers regulate transcription of target genes and gene expression. They act as recruitment 
sites for multiple transcription factors (TFs) and RNA polymerase II (RNAPII) and favour 
transcription of target genes through chromatin contacts. RNAPII at enhancer regions transcribes 
short and mostly non-polyadenylated transcripts, called enhancer RNAs (eRNAs).  
The mechanisms of RNAPII recruitment and regulation at enhancers remain ill understood, in 
particular how signalling through RNAPII modifications may influence chromatin states, looping 
and gene activation. In this study, I compare enhancer lists defined with different approaches and 
find that their relation is very complex. However, I find that RNAPII binding co-occurs with TF 
binding at regulatory regions, independently of the identification approach used. I characterize 
the state of RNAPII activation at enhancers and its transcriptional activity. I find that RNAPII 
state reflects enhancer activation state and correlates with different transcriptional outputs. In 
addition, I demonstrate that extragenic RNAPII is a novel tool to identify regulatory regions. I 
successfully identified putative regulatory regions in mESC and during neuronal differentiation, 
with enhancer activity in vivo. Extragenic RNAPII regions have specific activation patterns 
during neuronal differentiation, are finely regulated at the transcriptional level by kinases and 
transcribe differently mature RNAs. 
In conclusion, I establish RNAPII as a tool to identify and characterise regulatory regions in a 
cell type of interest. With minimal RNAPII datasets it is possible to simultaneously identify 
regulatory regions, infer their state of activation, and the state of activation of coding gene 
promoters. 
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Zusammenfassung 
Enhancer regulieren die Transkription ihrer Zielgene und deren Expression. Sie bieten eine 
Bindestelle für verschiedenste Transkriptionsfaktoren (TF) und RNA Polymerase II (RNAPII) 
und unterstützen die Gentranskription durch das Zustandekommen von Chromatinkontakten. 
Zusätzlich transkribiert RNAPII in Enhancer-Regionen kurze, non-polyadenylierte Transkripte, 
die man Enhancer-RNA (eRNA) nennt. Der Mechanismus der RNAPII-Rekrutierung und –
Regulation an Enhancern ist bisher wenig verstanden, insbesondere wie das Vorhandensein von 
RNAPII-Modifikationen den Chromatinstatus, -faltung sowie die Genaktivierung beeinflusst. 
In dieser Arbeit wurden verschiedene Ansätze der Enhancer-Bestimmung miteinander 
verglichen. Während eine klare Bestimmung des besten Ansatzes sich als komplex erwies, 
konnte gezeigt werden, dass die Bindung von RNAPII an regulatorische Regionen in 
Zusammenhang mit TF eine universelle Konstante darstellte. Weiterhin wurden der Status der 
Enhancer-gekoppelten RNAPII-Aktivierung und deren Transkriptionsaktivität untersucht. Als 
Hauptergebnis ergab sich, dass der RNAPII-Status mit der Enhancer-Aktivität und daraus 
folgend mit veränderter Transkriptionsaktivität korreliert ist. Weiterhin konnte gezeigt werden, 
dass das Vorhandensein extragenischer RNAPII ein neues Werkzeug zur Identifikation von 
regulatorischen Regionen ist. Erfolgreich konnten regulatorische Regionen in embryonalen 
Stammzellen der Maus sowie während der neuronalen Differenzierung vorhergesagt und mittels 
Enhancer-Aktivität in-vivo bestätigt werden. Dabei zeigte sich, dass im Laufe der der neuronalen 
Differenzierung extragenische RNAPII-Bindung spezifische Aktivierungsmuster aufweist: ihr 
Transkriptionslevel wird durch Kinasen feinmaschig reguliert und es werden verschiedene 
Formen maturierter RNA erzeugt. 
Zusammenfassend konnte RNAPII als Werkzeug zur Identifikation und Charakterisierung 
regulatorischer Regionen in verschiedenen Zelltypen ausgemacht werden. Selbst mit minimalen 
RNAPII-Datensätzen ist es möglich, gleichzeitig regulatorische Regionen zu identifizieren als 
auch ihren eigenen Aktivierungsstatus sowie den ihrer kodierender Genpromotoren zu 
bestimmen.
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H3K64ac Histone 3 lysine 64 acetylation 
Hi-C  High-throughput sequencing Chromosome conformation capture 
HM  Histone Modifications 
IGV  Integrative Genomics Viewer 
IP  Immunoprecipitation 
kb  kilo bases 
KD  Knock Down 
KO  Knock Out 
LCR  Locus Control Region 
Lif   Leukaemia inhibitory factor  
lncRNAs  long non-coding RNAs  
Lys  Lysine 
MACS2 Model-based Analysis of ChIPSeq 
Me  Methylation 
mESC  mouse Embryonic Stem Cells 
MLL  Mixed-Lineage Leukaemia, mammalian homolog of TRX 
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mock IP  Immunoprecipitated in the absence of antibody  
mRNAs  messenger RNA 
mRNA-seq  messenger RNA high-throughput sequencing  
Nipbl  Nipped-B-like protein, Cohesin Loading factor 
nt   Nucleotides 
Oct4  Octamer-binding transcription factor 4 
PCR  Polymerase Chain Reaction 
PIC  Pre-Initiation Complex 
polyA   poly Adenylation 
PRC  Polycomb repressive complex 
PROMPTs PROMoter uPstream Transcripts 
P-TEFb  positive transcription elongation factor 
Rbp  Retinol binding protein  
RefSeq Reference Sequence 
RNA  Ribonucleic acid 
RNAi  RNA interference 
RNAPII-CTDRNA Polymerase II C-Terminal Domain 
RNAPIIS2p RNA Polymerase II S2 phosphorylated 
RNAPIIS2u RNA Polymerase II S2 unpshopshorylated 
RNAPIIS5p RNA Polymerase II S5 phosphorylated 
RNAPIIS7p RNA Polymerase II S7 phosphorylated 
RPKMs Reads Per Kilobase of exon per Million reads mapped 
RSEM  RNA-Seq by Expectation-Maximization 
SE  Super enhancer 
Ser  Serine 
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SHH  Sonic Hedgehog 
STAR  Spliced Transcripts Alignment to a Reference  
STARR-seq Self Transcribing Active Regulatory Regions sequencing  
TES  Transcription End Site 
TF  Transcription Factor 
TFBM  Transcription Factor Binding Motif 
TFIIH  Transcription factor II Human 
Thr  Threonine 
TPMs  Transcripts Per Million  
TSS  Transcription Start Site 
Tyr  Tyrosine 
UCSC  Univeristy of California Santa Cruz 
WAP  Whey Acid Protein 
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1. Introduction 
All known biological life depends on genetic information, hence the expression of genomes is 
tightly regulated. Genes comprise regions of the genome that are transcribed to mRNA and code 
for proteins, and occupy only a fraction (~3% if only the coding region is considered, 40% from 
transcription start site (TSS) to transcription termination site (TES)) of the entire human genome 
(Dunham et al., 2012). The remaining genomic sequences can have structural functions, e.g. 
telomeres and centromeres, transcribe structural RNAs (rRNAs, tRNAs), or be occupied by 
regulatory regions which have the function of regulating the expression of specific genes at 
specific times. Gene regulation is pivotal to assure cell identity, proper development (Johnson et 
al., 2018; Osterwalder et al., 2018), and reaction to stimuli (De Santa et al., 2010; Oishi et al., 
2017) with regulatory regions activating or enhancing gene activity. In addition, transcription at 
genes and the downstream processes are tightly regulated. As can be appreciated in the 
biological world, different regulatory systems cooperate to assure the right timing and expression 
levels for each gene that will lead to the specific phenotype of every single cell. 
1.1 Regulatory elements 
1.1.1 Enhancers 
Regulatory regions are scattered through the genome and were described to exert different 
functions. Enhancers are one such regulatory region which can enhance or activate transcription 
of specific target genes (Heinz et al., 2015). Enhancers were found in bacteria and eukaryotic 
cells and are extensively studied as major players in gene-expression regulation. Their 
mechanisms of action are not fully understood, but the formation of a chromatin loop that brings 
in proximity enhancers and target genes is one of them (Beagrie and Pombo, 2016). Enhancers 
act as dock of transcription factors (TFs), co-factors such as Cohesin or Mediator, RNAPII, and 
are marked by specific histone modifications (HMs) (Calo and Wysocka, 2013) (Fig 1.1). 
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Enhancers can reside very far from their target genes; a historical example is the Sonic 
Hedgehog (SHH) locus, spanning ~900kb, where enhancers regulating the SHH gene are located 
inside a SHH intron (for neuronal expression) and as far as 849kb, inside a neighbouring gene 
(for limb expression) (Anderson et al., 2014). It has been calculated that every cell can have 
~10000 – 50000 enhancers (Andersson et al., 2014a; Arner et al., 2015; Heintzman et al., 2009b; 
Nord et al., 2013), though even more interesting is that enhancers will not be active at the same 
time in the same cells  (Andrey et al., 2017). As an example, Sonic Hedgehog gene is expressed 
during development in different cell types, such as lungs or limbs. The specificity of its 
expression is achieved by the activity of enhancers, which is restricted for cell types. A SHH 
enhancer active in limbs will be silent in lungs and vice-versa (Anderson and Hill, 2014) (Fig 
1.2). 
Fig 1.1: Schematic of enhancer regions features 
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Fig 1.2:  Schematic of enhancer and gene activity. A hypothetical locus containing five enhancers (coloured ovals; A-E) and four 
genes (grey boxes; 1-4) is shown. The regulatory activities of enhancers A-E in embryonic day 10.5 mouse embryos are 
represented by coloured shading in the diagrams above, and the transcriptional activities of genes 1 to 4 are shown in the 
diagrams below. A comparison of enhancer activities and gene expression, marked with the same colour code, shows that 
enhancers A and B contribute to gene 1 transcription, and that enhancers C-E contribute to gene 3 transcription. Gene 2 is 
repressed in all tissues at this embryological stage, whereas gene 4 displays a ubiquitous expression pattern. From (Andrey and 
Mundlos, 2017). 
Importantly, enhancer deletions or ectopic activity(Lupiáñez et al., 2015), and enhancer 
mutations (Lettice et al., 2018) are associated with diseases, such as a subset of b-talassemias 
(Van der Ploeg, 1980) and developmental diseases (Johnson et al., 2018).  
1.1.2 Transcription factor binding at enhancers 
TFs are found at enhancers and are important for enhancer identity and regulation. Transcription 
factors are proteins which bind to a specific sequence of DNA, the binding motif (TFBM), and 
recruit co-factors that can: a) modify the chromatin environment (remodeller of chromatin) and 
b) recruit other factor such as Cohesin or Mediator that are implicated in chromatin loop 
formation (Kagey et al., 2010). The influence of transcription factors on genomic regulators is 
well studied in different cells types and upon various stimuli (Heinz et al., 2010; Zaret and 
Carroll, 2011). Transcription factors are known to bind promoters of coding genes and regulatory 
regions, however, some TFs bind preferentially to regulatory regions over promoters, such as 
FoxA1 and Pu.1 in activated macrophages (Gosselin et al., 2014). 
Some TFs are able to bind closed chromatin (Zaret and Carroll, 2011), these “pioneer” 
transcription factors bind compact chromatin and recruit factors that help opening the locus, 
facilitating other TFs binding and enhancer activation. Pioneer transcription factors can be 
important to define the identity of the cell, as well as a response to stimuli, such as Pu.1 
(Ghisletti et al., 2010). After pioneer TFs binding, regulatory regions become nucleosome 
depleted and accessible to factors involved in chromatin remodelling. In this way, enhancers 
acquire marks specific of their state of activation. 
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1.1.3 Enhancer activation states 
Enhancers can be classified in different states of activation based on combinations of histone 
modifications, Transcription Factors (TFs) binding, and DNA modifications (Choi et al., 2014). 
Enhancers can be classified into different states: inactive, active, primed, poised (Calo and 
Wysocka, 2013), super (Hnisz et al., 2013; Whyte et al., 2013) and non-canonical (Pradeepa et 
al., 2016) enhancers . While the exact role of different enhancer states and their definition is 
currently investigated and debated, there is some consensus on different chromatin 
characteristics of each activation state. Moreover, for some classes, such as primed and active, 
there is not direct switch, but more likely a gradual transition from one class to the other. 
Historically, enhancers are defined as regions of DNA outside of promoters enriched for 
H3K4me1 and depleted of nucleosome (Calo and Wysocka, 2013). It was recently found that 
H3K4me1 marks not only active enhancers, but also primed, poised (Calo and Wysocka, 2013), 
super (Hnisz et al., 2013) and non-canonical (Pradeepa et al., 2016) enhancers, and only being 
depleted only from inactive enhancers. H3K4me1 therefore is a general mark of putative 
regulatory regions, and not sufficient to classify their state precisely.  
Active, Primed and Inactive enhancers 
Active enhancers are the ones engaged in enhancing target gene expression. Active enhancers 
are marked by H3K4me1, H3K27ac and show high abundance of TFs binding (Calo and 
Wysocka, 2013). It is currently understood that the binding of transcription factors is of high 
importance for enhancer activity (Spitz and Furlong, 2012). Active enhancers were shown to 
come in proximity to their target genes via chromatin looping and to modulate target gene 
expression (Beagrie and Pombo, 2016; Krivega and Dean, 2012). P300, the acetylase that acts on 
H3K27 among other targets, is also  present at active enhancers, however it can also be found at 
less active ones (Creyghton et al., 2010). 
Primed enhancers are regions of the genome which are ready to be activated, however are not 
exerting a specific function yet. Primed enhancers are depleted of nucleosomes and marked by 
H3K4me1(Calo and Wysocka, 2013). The priming of enhancers was observed in ESC and in 
differentiated cells (Liber et al., 2010; Xu et al., 2009). 
Inactive enhancers are unmarked regions of the genome, which act as enhancers in another cell 
type. 
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Poised enhancers 
Poised enhancers repress their target genes, are mainly described in ESCs and are marked by 
H3K27me3 (Creyghton et al., 2010; Cruz-Molina et al., 2017; Rada-Iglesias et al., 2011; Zentner 
et al., 2011), a histone modification deposited by Polycomb Repressive Complex 2 (PRC2). 
Poised enhancers have been described in mouse, humans, and drosophila (Creyghton et al., 2010; 
Koenecke et al., 2017; Rada-Iglesias et al., 2011), are repressed in ESCs and active when a 
differentiation path is taken by the cell. Neuronal target genes of poised enhancers are poorly 
transcribed in mESC, however, when cells start to differentiate to neuronal lineages, poised 
enhancers lose H3K27me3, acquire H3K27ac, and their target genes get activated (Cruz-Molina 
et al., 2017; Rada-Iglesias et al., 2011). Poised enhancers tend to be in closer proximity to 
transcription start sites (TSSs) compared to active and primed enhancers, are more enriched in 
GC, and are more evolutionary conserved than other classes of enhancers(Aran et al., 2016; 
Rada-Iglesias et al., 2011). 
Poised enhancers were also defined in mESCs as regions of the genome enriched in 5-
formylcytosin (5fC) or 5-hydroxymethylcytosine (5hmC)(Choi et al., 2014), and 
transcriptionally silent. 5hmC is also present at bivalent promoters, containing both H3K4me3 
and H3K27me3 marks (Matarese et al., 2011), which suggests a similarity between repressed 
genes and repressed enhancers.  
Recently, a study in Drosophila challenged the view of poised enhancers as Polycomb targets, 
arguing that the Polycomb signal originated from nearby genes. Therefore, acquiring the 
H3K27me3 mark would be a side-effect of the proximity effect of H3K27me3 broad 
deposition(Koenecke et al., 2017).  The biological relevance of this observation is yet to be 
understood. 
Strikingly, it was shown for a number of poised enhancers that they contact their target genes 
already in mESC, where they exert a repressive function on target genes. Fascinatingly, Cruz 
Molina et al. showed that target genes remain silenced in mESCs and are activated during 
differentiation, when poised enhancers keep the contact and switch to an active state. 
Interestingly, if contacts are disrupted in mESCs proper gene transcription upon differentiation is 
lost(Cruz-Molina et al., 2017). 
Super enhancer/ Stretched enhancers/LCR 
In 1980 a region in the β-globin locus was described to be DNAseI hypersensitive and, if 
deleted, caused a special form of thalassemia(Van der Ploeg, 1980). This region was called 
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Locus Controlled Region (LCR) and it is now understood as a region dense in enhancers(Li et 
al., 2002). More recently, clusters of enhancers were described by different groups and in various 
organism(Parker et al., 2013; Whyte et al., 2013), re-named Super Enhancers (SE)(Whyte et al., 
2013), and patented. SEs are regions of the genome that greatly enhancer target gene expression, 
bound by TFs, and highly enriched in H3K27ac, Med1 and Brd4 binding. Among their targets 
are cancer genes(Hnisz et al., 2015; Hnisz et al., 2016), cell identity genes, and developmental 
genes(Whyte et al., 2013). SE were shown to be involved in disease and cancer progression(Ko 
et al., 2017), making them biologically relevant. 
SE in the Whey Acid Protein (WAP) locus were described as a cohort of enhancers acting 
synergistically acting in a hierarchical fashion (Shin et al., 2016). However, deletion of a portion 
of SE in the beta-globin locus demonstrated that enhancers inside these regions can act 
independently(Hay et al., 2016) .  
Non-canonical enhancer 
Recently, two new histone modifications, H3K64ac and H3K122ac were characterised at 
regulatory regions and described as marks of a new and previously unknown class of enhancers, 
called non-canonical enhancers(Pradeepa et al., 2016). H3K122ac was first described to be 
present at TSSs, to co-occur with active chromatin marks such as H3K27ac, H3K4me1/3, but not 
with H3K36me3 (marking active coding regions) or H3K9me3 (marking constitutive 
heterochromatin). Failure in H3K122 acetylation impairs rapid transcriptional activation in yeast. 
H3K122 acetylation is catalysed by CBP and P300, the latter being an acetylase responsible also 
for H3K27 acetylation at enhancers. H3K122ac is found at distal regions with a potential 
enhancer activity; higher levels of H3K122ac after estrogen stimulation correlate with increased 
eRNA transcription(Tropberger et al., 2013). 
Interestingly, H3K122ac doesn’t correlate completely with H3K27ac distribution at distal 
regions(Tropberger et al., 2013). In fact, Pradeepa and colleagues(Pradeepa et al., 2016) showed 
that H3K122ac, often together with H3K64ac, can occur at regulatory region depleted of 
H3K27ac, but marked by H3K4me1. The authors called these regions “non-canonical” 
enhancers. Non-canonical enhancers were shown to be associated with genes important in stem 
cell maintenance and brain morphogenesis, to transcribe high levels of exosome-sensitive eRNA, 
and to be bound by high levels of P300. Interestingly, a subset of these non-canonical enhancers 
was enriched in H3K27me3 and associated with genes involved in development and 
differentiation. In the same work it was observed that non-canonical enhancers are more 
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enriched in protein such as CTCF and RAD21, which may point to a regulatory role involving 
chromatin loops and boundaries(Pradeepa, 2016). 
1.1.4 Transcriptionally active enhancers   
Enhancers were found to transcribe a newly identified class of RNAs, eRNAs (enhancer 
RNA)(Kim et al., 2010; Kim et al., 2015; Kaikkonen et al., 2013). Transcriptional active 
enhancers show mainly a bidirectional transcription(Andersson et al., 2014a) of short-lived 
RNAs (Andersson et al., 2014a; Pradeepa et al., 2016) and were classified as a complementary 
state to active enhancer state. eRNAs are usually not detected through polyA-RNAseq, probably 
due to a low level of poly-adenylation (estimated as ~10% by Andersson et al. 2014 (Andersson 
et al., 2014a) ) and low abundance. Some studies report eRNAs to be unspliced and not 
polyadenylated (Andersson et al., 2014a), others find eRNAs to be spliced and with a polyA tail 
(De Santa et al., 2010), making difficult to draw a general rule. They are therefore detected with 
techniques that do not rely on poly-T enrichment, such as GRO-seq, total RNA (De Santa et al., 
2010; Koch et al., 2011) and CAGE (Andersson et al., 2014a; Arner et al., 2015).  
Reports show that transcription at enhancer starts from a central point marked by a P300 peak. 
Within this region two transcription initiation events may take place, which were found to be 
separated by 180bp (Andersson et al., 2014a). This observation resemble the divergent 
transcription described at promoters of active genes (Duttke et al., 2015). Upon exosome 
knockdown, which is responsible for the degradation of not mature RNA, the relative frequency 
of eRNA detection increases (Andersson et al., 2014a), suggesting that eRNAs are fast degraded 
upon transcription and that the Exosome plays an important role in transcription regulation at 
enhancers. Interestingly, disruption of chromatin loop via Cohesin knock down was shown to not 
affect eRNA production (REF Ing-Simmons 2015 Genome Research), showing that eRNA 
transcription is not dependent on chromatin organisation. 
eRNA transcription is now a common approach to identify active enhancers (Andersson et al., 
2014a; Henriques et al., 2018). SE were also found to be robustly transcribed (Blinka et al., 
2016; Hnisz et al., 2015), possibly due to their active state coupled with high transcription 
factors occupancy and RNAPII binding (Blinka et al., 2016). 
1.1.5 Techniques to identify enhancers  
The importance of enhancers as regulatory elements makes their identification in the cell of 
interest an important field, continuously evolving. The approaches differ and vary both in 
methodology and in quality. On the one side, enhancers are identified using bioinformatics 
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approaches, usually feeding a number of datasets into a software that computes the likelihood of 
a specific region in the genome to be a regulatory element (Bu et al., 2017; Chen et al., 2012; 
Ernst and Kellis, 2012). On the other side, enhancers can be detected with the use of specific 
datasets in a more digital way: if specific marks are present, the region will be categorized as an 
enhancer. 
ChIP-seq experiments are usually performed to understand the binding pattern of TF and to 
identify putative enhancer regions. The drawback of this approach is the limited knowledge we 
have about specific TFs for cell types, especially rare and not well characterise ones. In addition, 
the specificity of transcription factors binding to identify enhancer responsive to a stimulus or a 
differentiation pathway needs prior knowledge of the specific factor involved. 
Transcription factors binding motifs (TFBM) recognised by families of TFs can be used to 
identify putative regulatory regions in various cell types. However, TFBMs can be masked either 
by a specific structure or by other marks and therefore not recognised by their TF in all cell 
types, which adds another level of gene regulation. The sole analysis of binding motifs across the 
genome, even if associated with a TF expression analysis, is therefore not sufficient in most 
cases to understand if that specific regions would be bound and active in the cell type of interest 
(Slattery et al., 2014). 
To identify SE, enhancers are firstly identified with canonical marks and then ordered by the 
enrichment for one of the specific features of SE (H3K27ac, Med1): the enhancers, which are 
highly enriched for the feature would be categorized as SE (Hnisz et al., 2013; Lovén et al., 
2013; Whyte et al., 2013). This type of approach strongly relies on the clustering methods of 
normal enhancer prior to the enrichment analysis.  
Enhancers have also been identified based on bidirectional transcription of eRNAs outside 
promoters with techniques such as GRO-seq (Core et al., 2014; Danko et al., 2015) and CAGE 
(Andersson et al., 2014a; Arner et al., 2015). Enhancers identified with these approaches are 
defined as genomic regions outside annotated promoters from which RNAs originate. The 
techniques used to detect RNAs make some assumptions on the nature of the eRNAs: CAGE 
technique, for example, detects only capped enhancers; GRO-seq has an in vitro step which can 
influence transcription at enhancers, which is less stable than the one at genes (Henriques et al., 
2018), and cannot distinguish between elongating and non-elongating RNAPII. These 
approaches aim to identify transcriptionally active enhancers, however their sensitivity is still 
debated and it is not clear whether they can identify only active enhancers, or also enhancers in 
other activation states. 
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The comparison of the number of detected enhancers in similar cell types with different 
approaches clearly shows how approaches based on different assumptions lead to the detection 
of a different number of regions (REF Fig 1.3). The variety of techniques, coupled with our 
limited knowledge of enhancer activation states, make the identification of a complete set of 
enhancers in a cell challenging. 
Figure 1.3: Number of enhancer regions identified with different approaches. Approached used in the identification on the x-axis, 
publication on top of the bar. Number shown in the graph are as indicated in the original publications.  
1.1.6 Mechanism of enhancer activity  
Enhancers have been shown enact transcriptional change via different mechanisms. One of the 
most known is the looping model, where enhancers are linearly distant from their target and are 
brought in proximity via a loop of the chromatin (Krivega and Dean, 2012). The looping 
mechanism is thought to be, at least in part, dependent on Mediator and Cohesin proteins (Kagey 
et al., 2010). Interestingly, enhancers can be in contact with their target genes prior to 
activation(Cruz-Molina et al., 2017), or with genes on other chromosomes (Markenscoff-
Papadimitriou et al., 2014). A study on the SHH locus showed with 3C technologies and DNA-
RNA FISH that contacts between enhancer and promoters are specific for the cell type and are in 
place before the target gene expression. While contacting regions can be also primed or 
repressed, expression of target gene is achieved only when contact is established (Amano et al., 
2009). 
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Despite the chromatin looping being a well-established phenomena, the functional role of the 
contact or proximity of enhancers and target genes it is not well understood. It is possible that 
enhancers create an environment rich in TFs, co-factors and RNAPII close to the gene, resulting 
in enhanced transcription frequency or robustness. Moreover, enhancers can act on the 
transcriptional burst, making the transcription event more stable and on the release of RNAPII 
from promoter proximal pausing (Chen et al., 2017; Liu et al., 2013; Schaukowitch et al., 
2014b).  
Different classes of enhancers in different tissues were proven to be in contact with their target 
genes (de Laat and Grosveld, 2003; Li et al., 2013; Sanyal et al., 2012), also prior to activation 
(Cruz-Molina et al., 2017). Moreover, it was shown that enhancer activity is confined in 
chromatin domains that, if compromised, will lead to ectopic gene expression (Lupiáñez et al., 
2015). 3C technologies, such as 4C, HiC, ChIAPet, have been recently used to understand 
enhancer-promoter contacts. This led to the interesting observation that more than one enhancer 
is in contact with the same target gene (Markenscoff-Papadimitriou et al., 2014). Recently our 
lab developed a new ligation-free technique that enables to study multiple interaction genome-
wide, Genome Architecture Mapping (GAM). GAM made possible to show that SE are highly 
enriched in contacts with multiple other super enhancers and active genes in mESC( Beagrie et 
al., 2017). 
Another proposed model of enhancer mechanism, the “tracking” model, describes enhancers as 
docks for RNAPII that can “track” chromatin in either direction until they encounter a promoter 
to start the productive transcription (Bulger and Groudine, 1999; Vernimmen and Bickmore, 
2015). In the tracking model, RNAPII binds at a regulatory region upstream the promoter, tracks 
the chromatin without producing mature transcripts and, once it reaches the promoter, starts an 
efficient mRNA transcription. It is not clear if the enhancers using the tracking model 
mechanism have different genomic or epigenetic features compared to the ones looping to the 
target, or if RNAPII is present in a unique forms at these enhancers.  
Another mechanism through which enhancers could act indirectly on target genes is via their 
transcripts. eRNAs were shown to be transcribed before their target gene(Arner et al., 2015; Li et 
al., 2015) or to correlate with target gene expression(Kim et al., 2010; Lam et al., 2013; 
Kaikkonen et al., 2013). For example, it was shown in immune cells that upon stimulus, 
enhancers are bound by the TF PU.1, start transcription and sub sequentially the target gene is 
transcribed (Kim et al., 2010). A diminished concordant expression of eRNA and mRNA was 
observed in mouse brain with Huntington disease, compared to healthy brain (Le Gras et al., 
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2017), and RNAi against eRNAs could diminish target gene transcription (Lai et al., 2013; Lam 
et al., 2013; Li et al., 2013; Melo et al., 2013), suggesting a role of coordinate transcription for 
normal target gene expression. In contrast to these results, a report showed with single molecule 
FISH that eRNA expression is not necessary for mRNA expression. eRNA and mRNA in this 
system are rarely co-expressed, and eRNA expressions happens in the allele not involved in the 
chromatin loop (Rahman et al., 2016). Another study showed that insertion of a premature 
termination cassette, which impaired eRNA expression but not transcription at enhancers, didn’t 
have any effect on target gene expression (Engreitz et al., 2016).  
Depletion of eRNAs does not seem to impact the chromatin environment of enhancers, as levels 
of H3K27ac, H3K4me1 and TFs binding remain unchanged after RNAi, suggesting that eRNAs 
do not have a role in enhancer chromatin environment maintenance (Blinka et al., 2016). Efforts 
in recent years show that some eRNAs can have roles in stabilizing the loop (Lai et al., 2013; Li 
et al., 2013), however transcription of eRNA was suggested to be not crucial for loop formation, 
which, once established, persists upon transcription inhibition (Hah et al., 2013). The exact roles 
of transcription at enhancers and eRNAs are still to be understood. 
1.1.7 Methods to study enhancer activity and find enhancer target 
genes 
Historically, an enhancer is a region of the genome that, inserted in a reporter plasmid, will 
generate a reporter signal, due to the action of the inserted tested enhancer in a vector with a 
reporter gene under a weak promoter, and is an approach that is widely used to test if a region 
acts as an enhancer. For example, in the VISTA enhancers’ atlas (Visel et al., 2007) different 
putative regulatory regions are tested for their expression patterns in embryos and organs in 
human and mouse with a reporter assay.  High-through reporter assays techniques were recently 
developed, greatly advancing progress. For example, the STARR-seq (Self Transcribing Active 
Regulatory Regions sequencing) method tests loci for enhancer activity shearing the genome and 
using RNA-seq to screen for enhancer activity (Arnold et al., 2013).  
Although reporter approaches have proven extremely valuable to understand which regions 
would function as enhancers, as well as to identify and study the minimal region (the minimal 
number of base pairs) that drives reporter expression (Milewski et al., 2004; Small et al., 1992), 
reporter assays do not take into account the effect of the 3D organisation of the chromatin. This 
is especially important as plasmids are artificial “environments” that do not resemble the original 
chromatin region.  
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Taking advantage of chromatin-contact information, such as 3C technology derived, could help 
identify regions of the genome in contact with a specific gene of interest. Contact-mapping 
methods proved useful to understand the proximity of different regions of the genome, however 
Loss of Function experiments are often needed to prove the function of regulatory regions. 
Interesting experiments using CRISPR-Cas9 methodology showed different effects of enhancer 
KO. in Blinka et al. (Blinka et al., 2016) the authors knocked-out 3 SE acting on Nanog, and 
observed diverse outcomes. One deletion had effect on both Nanog and Dppa3, a neighbouring 
gene; the second deletion did not have any effect in the locus; the third was recovered only in 
monoallelic clones with a 50% reduction in Nanog expression. CRIPR-Cas9 mediated KO was 
also used by Cruz Molina and colleagues to show that deletion of poised enhancers leads to a 
failure in activation of the target genes upon differentiation.  
A parallel approach to CRISPR-Cas9 to sample unbiasedly a region and determine target genes 
of regulatory regions is via the use of retro-transposon hopping (Anderson et al., 2014). The 
expression of genes of interest is checked while the retro- transposon occupies a diverse position: 
when a variation in gene expression is detected, the region occupied by the transposon and the 
genes of interest are matched. 
eRNAs transcription correlation with target gene expression was also used to infer target genes 
during time courses (Arner et al., 2015). This approach can estimate the target genes, however 
can only be applied to time courses with numerous time points. 
How enhancers are able to recognise their target genes in the 3D space of the nucleus, and why 
some genes are uninfluenced by close enhancer activity is still under debate. 
1.2 Transcription 
Coding DNA sequences are transcribed to RNA by the enzyme RNA Polymerase II (RNAPII). 
RNAPII is recruited to gene promoters to form the Pre-Initiation Complex (PIC) together with 
other proteins such as Mediator (Hahn and Young, 2011; Thomas and Chiang, 2006), and start 
transcription. During transcription different enzymes are responsible of the regulation of the 
process speed and frequency of RNA processing, and of chromatin remodelling another layer of 
transcriptional regulation. The recruitment of the majority these proteins and their complex 
interaction is integrated through the C-terminal domain (CTD) of RNAPII and its post-
translational modifications. 
RNAPII is a well-conserved and highly regulated enzyme and it is composed by 12 (Rbp1-12) 
subunits in mammals. The main subunit Rbp1 contains a globular domain and an unstructured 
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domain at its C-terminal domain. The CTD of RNAPII is composed of 52 tandem repetitions in 
mammals (44 repetition in Drosophila and 26-27 in Yeast) of the consensus heptapeptide 
Tyrosine1-Serine2-Proline3-Threonine4-Serine5-Proline6-Serine7 (Y1-S2-P3-T4-S5-P6-S7) 
(Chapman et al., 2008; Yang and Stiller, 2014), which can be extensively post-translationally 
modified. The post-translational modification of RNAPII-CTD determines its activation state 
and can act as a recruiter of chromatin remodellers and RNAPII maturation machinery.  
1.2.1 RNA Polymerase II states of activation: Serine phosphorylation 
Transcription at coding genes is a well-studied process characterised by different stages that 
comprise initiation and elongation. Every stage of gene transcription is associated with a specific 
form of RNAPII, which is determine by its post-translational modifications. The most known 
modifications of the RNAPII CTD are the sequential phosphorylation of the Serine residues 5 
(Ser5p), 7 (Ser7p), and 2 (Ser2p) (Akhtar and Gasser, 2007; Tietjen et al., 2010). Ser5p occurs 
first at gene promoters and recruits the capping machinery (Ghosh et al., 2011), Ser7 is 
subsequently phosphorylated, an event that is necessary for Ser2 phosphorylation, productive 
elongation, and recruitment of RNA maturation machinery (Fig 1.4) (Corden, 2013; Gu et al., 
2013; Lunde et al., 2010). The specificity of phosphorylation is reflected in their pattern along 
the gene body, with Ser5p peaking at the promoter and gradually descending, while Ser7p and 
most notably Ser2p are more enriched at the gene body and peak after the termination end side 
(TES). Among the specific enzymes responsible for the phosphorylation of the CTD residues, 
the cyclin-dependent kinase (Cdk) family is well characterized (Fisher, 2017) and responsible for 
the transitions between different stages of transcription.  
Fig 1.4: Integration of carboxy‐ terminal domain modifications with chromatin structure, RNA processing and Polycomb 
repression. Distinct modifications of the CTD assist in recruiting different chromatin modifying enzymes and RNA processing 
factors.  At active gene promoters, the phosphorylation of RNAPII at Ser 5 (Ser 5P) recruits HMTs to methylate H3K4 and the 
RNA capping machinery to add an m7G cap to nascent RNAs. Ser 2P creates an elongating polymerase that recruits the HMTs 
responsible for trimethylation of H3K36 and RNA processing factors. The mRNA, which is released after termination, is 
stabilized by its cap and poly(A) tail, thereby promoting mRNA transport and protein expression. From (Brookes and Pombo, 
2009) 
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Serine phosphorylation is recognized by protein complexes which are implicated in RNA 
maturation and chromatin remodelling (Bentley, 2014; Buratowski, 2009; Egloff and Murphy, 
2008; Hsin and Manley, 2012). For example, Ser5p recruits the RNA capping machinery 
(Fabrega et al., 2003), while Ser2 phosphorylation recruits the polyA and the splicing machinery 
(David et al., 2011; Proudfoot et al., 2002). 
1.2.2 Other RNA Polymerase II modifications 
Alongside phosphorylation of the Serine residues, RNAPII-CTD can be modified in other 
residues. For example, Thr4 residue of the CTD hepta-peptide repeats can also be 
phosphorylated, and this modification is associated with elongation at active genes(Hintermair et 
al., 2012) . Tyr1 can also be phosphorylated and its profile resembles the one of Ser2p: gradually 
increasing at the gene body, however it drops before the transcription termination site (TES), and 
inhibits the recruitment of the termination machinery (Mayer et al., 2012b). Immuno-
precipitation experiments showed the concomitant phosphorylation of Ser5 and Ser7, together 
with Tyr1, but not of Ser2, on the same CTD (Mayer et al., 2012b). Ser2p and Tyr1p could 
therefore be mutually exclusive. Tyr1p was reported at bidirectional promoters and at enhancers 
(Descostes et al., 2014; Mayer et al., 2012b). 
The distal part of the CTD can present modification of the consensus motif, which are more 
common in vertebrates (Dias et al., 2015). Non-consensus Lys7 can be acetylated and this 
modification is associated with active transcription and elongation (Schröder et al., 2013). 
Recently, our lab and others showed that Lys7 can also be mono/di/tri methylated and that these 
modifications are conserved from unicellular eukaryotes to mouse (Dias et al., 2015). Lys7me is 
linked with early stages of transcription and can co-occur with Ser5p and Ser7p, the balance 
between Lys7 methylation and acetylation levels were shown to be predictive of the 
transcriptional state of genes. Lys7mes is remarkably absent at Polycomb-repressed genes, 
suggesting a specific association with active genes and mRNA production (Dias et al., 2015). 
1.2.3 Transcription Regulators 
Transcription at genes is a tightly regulated process that involves different players and steps. 
First, RNAPII binds at the promoter, and is phosphorylated on its Ser5 residue by Cdk7 from the 
TFIIH complex. 20-60nt downstream the TSS RNAPII pauses (Adelman and Lis, 2012). This 
pausing is mediated by Nelfa and DSFI/Spt5 that are dismissed by the P-TEFb complex. The 
recruitment of the P-TEFb complex at genes is mediated by Brd4 (Jang et al., 2005): Brd4 was 
shown to be pivotal for the formation of the elongation complex (Winter et al., 2017). P-TEFb 
complex phosphorylates RNAPII and releases it from the promoter proximal pausing. P-TEFb 
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complex contains the kinase Cdk9, which phosphorylates Nelfa and DSFI/Spt5 (Adelman and 
Lis, 2012). After phosphorylation Nelfa detaches from RNAPII, while DSFI/Spt5 remain 
associated with RNAPII during elongation. Cdk9 also phosphorylates Ser7 and Ser2 (Baumli et 
al., 2008) and it is required for Thr4 phosphorylation (Hsin et al., 2011), bringing the 
transcription to its elongating phase, at the end of the process transcription can be reinitiated. 
This step is controlled by the Med12-Cdk8 complex, which negatively affects reinitiation. Cdk8 
was suggested to inhibit the Med13-mediated RNAPII recruitment and therefore to negative 
influence the re-establishment of another round of transcription (Knuesel et al., 2009). The 
Mediator complex is composed by up to 26 subunits in mammals and act as an integrator of TFs 
to present them to RNAPII (Allen and Taatjes, 2015; Conaway and Conaway, 2011). Mediator 
has shown to have wide roles, being  implicated in gene regulation, including initiation and 
elongation, and enhancer-promoter contact via chromatin looping (Allen and Taatjes, 2015). 
1.2.4 Polycomb and poised genes 
Some genes were described to be in a special chromatin state, called a bivalent state. Bivalent 
genes show marks of active and repressed chromatin, H3K4me3 and H3K27me3 respectively 
(Azuara et al., 2006; Bernstein et al., 2006b). 
Our lab showed that RNAPII phosphorylated in its Ser5 residue is present at bivalent genes 
together with the Polycomb Repressive Complex (PRC) 1 and 2 (Brookes et al., 2012; Stock et 
al., 2007). Polycomb genes bound by RNAPII are associated with rapid activation upon stimuli 
(Voigt et al., 2013). Recently, colleagues in the lab showed that RNAPII/Polycomb genes 
(poised genes) are also found during differentiation and are very interestingly associated with 
genes encoding for TFs important for trans-differentiation (Ferrai et al., 2017). Importantly 
RNAPII and Polycomb were shown to be present at the same allele, as consequential-ChIP 
experiments demonstrated (Brookes et al., 2012; Ferrai et al., 2017).  Some of the Polycomb 
repressed genes were found with Ser5p together with activating Ser7p and also producing low 
abundant RNA (Ferrai et al., 2017), however  their functions are currently unknown. 
Interestingly, Ser5 phosphorylation at Polycomb genes is mediated by the Erk2 kinase (Tee et 
al., 2014). Poised genes are also regulated by Utf1 that has the double function of preventing 
H3K27me3 spreading and of regulating the levels of unnecessary RNAs produced at poised 
genes (Jia et al., 2012). Moreover, RNAPII-CTD at poised genes is in an unknown conformation 
distinct from active genes: the 8WG16ab, which recognises the un-phosphorylated form of Ser2, 
together with Ser5p at active genes, is unable to bind poised genes, suggesting a specific 
conformation of the CTD at poised genes (Brookes and Pombo, 2012). 
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1.2.5 RNAPII at enhancers 
RNAPII is present at enhancer and transcribes eRNAs, the amount of which correlates with 
enhancer activity (Kaikkonen et al., 2013).  
Some studies analysed different forms of RNAPII at enhancers with the use of antibodies 
specific for RNAPII modifications. For example, Ser5p was found at enhancers in mESC (Cruz-
Molina et al., 2017) and in differentiated cells (De Santa et al., 2010). An interesting publication 
showed that during human endodermal differentiation RNAPII phosphorylated in Ser5, but 
absent or lowly in Ser7 co-localises with enhancers bound by LIF-1 (Estarás et al., 2015). 3D 
contact studies via ChIA-PET on RNAPII (Reeder et al., 2015) showed the presence of the 
enzyme both at genes and at regulatory regions, contacting each other. This study also showed, 
via network analysis of contacting regions in the genome (Pancaldi et al., 2016), that regions 
enriched in contacts and outside promoters have RNAPII enrichment, with remarkably high 
levels of Ser2p. 
An ongoing dispute is whether Ser2 is phosphorylated at enhancers. Some reports show its 
presence (Pancaldi et al., 2016), while other detect little to no enrichment (Koch et al., 2011). 
This discrepancy could be due to different reasons, firstly different antibodies can recognise 
different epitopes on the CTD. Secondly, the regions under examination in the different works 
may not share the same features and functions, or may even be in different activation states. 
RNAPII at SE correlates with Med1, Brd4 levels (Lovén et al., 2013), and SE activity. RNAPII 
was also found at poised enhancers when they transition to the active state (Rada-Iglesias et al., 
2011; Zentner et al., 2011). Moreover, RNAPII at enhancers is sensitive to a Cdk9 inhibitor 
(Flavopiridol) (Hah et al., 2013), which suggests that RNAPII transcription at enhancers is 
regulated at least in part via proteins known to regulate transcription at genes. Recently, 
Henriques and colleagues showed that transcription at enhancers in Drosophila is generally 
unstable compared to the one at genes and regulated by Spt5. Hence, the authors conclude that 
the elongation machinery is fundamental for transcription at enhancers (Henriques et al., 2018), 
however it remains to be determined if this finding holds true in mammalian cells. 
1.2.6 Differences and similarities between enhancers and promoters 
Some reports show that promoters and enhancers have a good degree of similarities: such as 
RNAPII and TF binding. Active promoters were believed to be enriched in H3K4me3 over 
H3K4me1 at enhancers (Heintzman et al., 2009a), however recently, this view was challenged 
by a study on transcriptionally active enhancers in Drosophila, that show active transcription 
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correlates with higher levels of H3K4me3 at enhancers (Henriques et al., 2018) Furthermore, the 
observation that active promoters can be bi-directionally transcribed (Duttke et al., 2015) and 
that bi-directionality of promoters correlate with their evolutionary age and specialisation (Jin et 
al., 2017), suggest that enhancers and promoters share more features than previously imagined. 
Tyr1p is also found at antisense promoters and actively transcribed enhancers, in human cells 
however, it is depleted at coding gene promoters (Descostes et al., 2014; Hsin et al., 2014). 
Promoters can act as enhancers of other genes in reporter assays and contact them via formation 
of chromatin loops (Dao et al., 2017), and that some enhancers can function as weak promoters 
(Mikhaylichenko et al., 2018). In particular, eRNAs share similar features with PROMoter 
uPstream Transcripts (PROMPTs). PROMTs are unstable transcripts originating from 
bidirectional promoters, which showed exosome and Flavopiridol (Flynn et al., 2011) sensitivity 
and are mainly not-polyadenylated (Andersson et al., 2014a). PROMPT regions are bound by 
RNAPII in different forms of activation, comprising also the fully elongating form RNAPIIS2p 
(Preker et al., 2011). It has been suggested that early termination sites will cause premature 
termination and RNA degradation, a mechanism that was suggested for eRNAs as well 
(Grzechnik et al., 2014). Moreover, it has even been shown that promoter upstream regions can 
act as enhancers (Dao et al., 2017; Serfling et al., 1985; Zabidi et al., 2014). 
1.2.7 Studying RNAPII  
The majority of studies dealing with RNAPII are conducted using specific antibodies that 
recognise the modified residues of the CTD, followed by pull-down and next generation 
sequencing (ChIP-seq). While this approach has proven very valuable, some aspects should be 
taken into account when analysing these data.  
An important aspect is the choice of the antibody itself. A number of commercially available 
antibodies targeting different modifications of RNAPII can be found, however not all of them 
would show the same profile at genes for the same modification. For example, among two 
different antibodies targeting Ser5p, 4H8 and E8 (Dias J, personal communication) only one 
shows RNAPIIS5p presence at gene bodies (4H8). The reason is the specificity of epitopes 
recognition of the different antibodies, specific epitopes can be marked by other close 
modification or by tertiary protein folding of the CTD. 
Interestingly, this extreme specificity of antibodies made possible to observe a yet not 
completely understood conformation of RNAPII-CTD at Polycomb genes. RNAPII, when 
present together with Polycomb at poised promoters, is recognised by antibodies binding Ser5p. 
However, these regions are not bound by 8WG16, an antibody that recognises the 
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unphosphorylated form of Ser2. 8WG16ab signal is found at active genes together with Ser5p, 
which suggests that RNAPII-Ser5p at poised genes have a specific and yet to be understood 
conformation at the CTD which impairs 8WG16ab binding (Brookes and Pombo, 2012). 
In conclusion RNAPII is heavily post-translationally modified and these modifications modulate 
protein recruitments and, as a consequence, the chromatin state of the loci to which RNAPII is 
bound and the maturation state of the RNA transcribed.  
1.3 Computational approaches  
High-throughput methods revolutionised the study of gene regulation, however, vast amounts of 
data are produced and this brings its own problems in terms of assessing quality. 
1.3.1 ChIP-seq Sequencing Quality Check 
Chromatin immune precipitation sequencing (ChIP-seq) data recapitulate the occupancy of 
proteins and histones on genomic DNA. In a typical ChIP-seq experiment, proteins and DNA are 
cross-linked, the DNA sheared, amplified, and sequenced. At this stage the information is 
completely digital, coming as a series of nucleotide sequences called reads, which have to 
undergo a series of steps. Quality checks are pivotal to assure reliability of data. A common issue 
is that some regions unbound by the protein of interest can be carried on during the purification 
process to the amplification step (Teytelman et al., 2013). 
A first quality check is performed on raw reads coming directly from the sequencer. Reads are 
tested for quality that can be used to filter out poor quality reads, which are inferred by the 
sequencer in the amplification clusters; residual adaptor sequences are also removed. Reads are 
then mapped to a genome of reference, numerous genome mappers are available, which differ in 
their mapping approach, such as Bowtie2 (Langmead et al., 2009) or Burrows-Wheeler Aligner 
(BWA (Li and Durbin, 2009)). ChIP-seq reads do not need a splicing-aware algorithm and 
regions mapping to multiple regions of the genome (multimappers) are usually not considered in 
downstream analyses. After mapping, ChIP-seq duplicated reads are preferentially removed, 
because of them being a likely product of PCR duplicates. ChiP-seq reads mapped to the 
reference genome can be loaded on a genome browser to inspect their quality and for preliminary 
analysis. 
Differential ChIP-seq analysis between datasets can be performed on peaks of enrichment or on 
raw reads and numerous methods have been developed to perform these types of comparison. 
However, it has been shown that different approaches have low levels of agreement (Steinhauser 
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et al., 2016), making it  a difficult task  to draw conclusions from direct comparison of ChIP-seq 
data. 
1.3.2 RNA sequencing data analysis TPM-FPKM-normalised counts 
RNA-seq datasets are derived from the amplification and retro-transcription of species of RNA 
in the cells of interest. RNA-seq analysis differ from ChIP-seq analysis in some aspects. RNAs 
can undergo splicing, which should be taken into account by the software which maps RNA-seq 
reads to the genome of reference. Examples of splicing-aware mappers are STAR (Dobin et al., 
2013) and TopHat (Trapnell et al., 2012b). After mapping, duplicated reads are not removed, as 
these are relative to the amount of the specific RNA species in the cell. Reads originating from 
total RNA-seq which amplify all the RNA molecules in a cell, including microRNAs, should be 
analysed for over representation of ribosomal RNA (rRNAs). Quality checks interpreting the 
percentage of rRNA presence in total RNA datasets serve to understand the quality of the rRNA 
depletion and the quality of the data. 
Reads alignments are used to quantify expression, as it was demonstrated that the abundance of a 
transcripts correlates with its expression (Trapnell et al., 2012a); expression estimates can be 
calculated on the isoform level or on the gene level. This is due to the short length of RNA-seq 
reads, which doesn’t permit to distinguish isoforms in all cases. Moreover, RNA-seq analysis 
can be performed on counted reads or reads estimates. Software using counts on the gene levels 
are of the such of HTSeq (Anders et al., 2014), while between the software that estimates 
isoform or gene expression are CuffLinks (Trapnell et al., 2012a) and RSEM (Li and Dewey, 
2011). The advantages and disadvantages of each approach are highly debated in the field. 
Different expression units exists for RNA-seq are widely used to compare datasets. The most 
used are Reads or Fragments Per Kilobase of exon per Million reads mapped (R/FPKMs), 
Transcripts Per Million (TPMs) and normalised counts. FPKMs and TMPs are length-normalised 
and are scaled for the number of reads sequenced. FPKMs are the number of reads mapping to a 
region, divided for length all multiplied by 109 scaling factor (Mortazavi et al., 2008). TPMs are 
similar to FPKMs, but are normalised so that the sum of all TPMs in a datasets equals to 1 
million. TPM was shown to be proportional to total RNA abundance (Wagner et al., 2012). 
Normalised counts do not take the length of the gene into account when calculating the 
abundance and are used by software such as DESeq2 (Love et al., 2014). DESeq2 is used to 
confront the issues of using different datasets and implements a normalisation step between 
datasets. DESeq2 calculates the “size factor”, which takes into accounts differences in 
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sequencing depth between datasets, the size factor is used to normalise counts between datasets 
to permit fair comparison. 
1.3.4 Peak finders 
Reads containing information on protein and histone occupancy can cluster in domains in the 
genome, which may be broad or narrow, depending on the nature of the data. The study of these 
regions of enrichment, called peaks, is well established in the field. Peak finders are algorithms 
that scan the genome and look for regions of enrichment for the specific mark of interest. Most 
of the peak finders use a background as reference, as some regions of the genome are likely to be 
present in a pull-down non-specifically (Teytelman et al., 2013). The use of a background allows 
the algorithm to detect a specific signal, reflective of the pull-down, over the noise of unspecific 
regions determined by the background reference. ChIP-seq performed with unspecific antibodies 
or input chromatin pull-downs are classical backgrounds. 
Factors of interest can have different binding-profiles on the DNA. TFs, for instance, tend to 
have narrow peaks, histone modifications, on the other hand, are broadly distributed. Some peak 
finders can be informed of the nature of the mark and therefore adjust their search for broad or 
narrow peaks, such as Bayesian Change-point Model (BCP, (Xing et al., 2012)) and Model-
based Analysis of ChIPSeq (MACS (Zhang et al., 2008)). Another layer of complexity arises 
with mixed peaks, such as RNAPII peakswhich have a narrow peak at the TSS or TES of genes 
and a broad distribution through the gene body. 
Peak finders are widely used and extremely powerful, however raw reads are also a source of 
information not to be discarded. While peak finders can establish the boundaries of regions of 
specific enrichments, the amount of enrichment is still defined by the raw reads. 
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2. Methods 
2.1 RNAChIP datasets generation 
RNAChIP data in 46C and OS25 mESC clones were generated by KJ Morris and RA Beagrie 
prior to when I joined the lab and the datasets are currently unpublished. KJ Morris established 
the RNAChIP protocol and published it in her thesis: “Interplay between Polycomb repression 
and RNA Polymerase II in Embryonic Stem Cells” (Morris, 2012).  OS25 cells are grown in 
serum+LIF conditions under selection for Oct4 expression, whereas 46C cells are grown in 
serum free conditions. In brief, cells are sonicated and cross-linked, immune precipitated with 
4H8ab against RNAPIIS5p and RNA is extracted. RNA was then sequenced according to 
illumina’s instruction (#1004898 Rev A). Fragment size of 200-450bp were selected.  
2.2 Total RNA-seq dataset generation 
Total RNA data in 46C mESC clone and 46C mESC differentiated cells in neuronal lineage 
according to (Ferrai et al., 2017) were generated by AM Fernandes and Carmelo Ferrai. Total 
RNA was extracted from cells using TRIzol (Invitrogen, Cat# 15596‐ 018), following 
manufacturer’s instructions. 4 ug of total RNA were further treated with 1microliter of TURBO 
DNase I (Ambion, Cat# AM1907) in a 25microliter reaction, according to manufacturer’s 
instructions. RNA quality was assessed before libraries by running all total RNA samples with 
Bioanalyser RNA 6000 Nano assay (Agilent, cat#  5067-1511) and determining the RNA 
integrity number (RIN), which was above 7.30 for all samples.  1ug of DNAse-treated total RNA 
was used for total RNA library production with TruSeq Stranded Total RNA Sample Preparation 
Kit (Illumina, Cat# RS-122-2201). Library quality was determined with Bioanalyser High 
Sensitivity DNA assay (Agilent, cat# 5067-4626). Total RNA libraries were sequenced paired-
end using using Illumina Sequencing Technology by an Illumina HiSeq2000 following the 
manufacturer's instructions. Details were gently provided by AM Fenandes. 
2.3 Flavopiridol treatment 
Flavopiridol datasets were generated by KJ Morris and are published it in her thesis: “Interplay 
between Polycomb repression and RNA Polymerase II in Embryonic Stem Cells” (Morris, 
2012). In Brief, to inhibit Cdk9 OS-25 cells were inhibited with Flavopiridol (10 uM; a kind gift 
from Sanofi-Aventis, provided by Drug Synthesis and Chemistry Branch, Developmental 
Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 
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Bethesda, MD). for 1h or DMSO for control. Flavopiridol treatment was restricted to 1h to avoid 
secondary effects on RNAPIIS5p and total RNAPII, as shown in Stock (Stock et al., 2007). 
Nascent RNA was then extracted by the cells and sequenced. 
2.4 Exosome knock down 
Exosome si KD was performed by KJ Morris (unpublished). In brief, OS25 cells were 
transfected with siRNA targeting Exosc3, a catalytic subunit of the Exosome machinery, control 
siRNA (negative control). Transfection of OS25-ESC was performed with 125 pmole siRNA per 
5x105 cells for 48h. Cells were harvested after 48h, RNA was extracted with TRIzol and treated 
with DNAseI and library were prepared for sequencing as explained on the previous paragraph 
and in accordance to manufacturer instructions. Untreated cell were also sequenced, however for 
the differential analyses negative control datasets were considered for comparison.  
2.5 RNA-seq datasets processing 
Sequenced reads that passed Illumina quality control filters were aligned to the mouse genome 
annotation (assembly mm10). 
Total RNA-seq libraries were mapped with using STAR 2.5(Dobin et al., 2013) with standard 
options. 
Total RNA-seq libraries after exosome KD, negative control and untreated cells were mapped 
with TopHat v2.0.13 (Trapnell et al., 2012b) were mapped with the options --no-novel-juncs --
library-type fr-firststrand 
RNA-ChIP-seq libraries in OS25, 46C, treated with Flavopiridol and the control DMSO were 
mapped with TopHat v2.0.13(Trapnell et al., 2012b) were mapped with the options -r -40 --
mate-std-dev 50 --library-type fr-firststrand. RNAChIP in 46C RNAChIP datasets were mapped 
by RA Beagrie with the same parameters. 
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Table 2.1: unpublished RNA-seq data mapped in this study 
RNA-seq dataset # sequenced reads # mapped reads % mapped reads 
RNAChIP (Nascent RNA) 
(OS25) 
243797996 143379774 66.5 
RNAChIP (Nascent RNA) 
(Flavopiridol) 
554339578 306774802 55.3 
RNAChIP (Nascent RNA) 
(DMSO) 
386142987 183965570 47.6 
Total RNA Day 0 163901210 154186012 94.1 
Total RNA Day 1 143712874 132245692 92 
Total RNA Day 3 154946626 146937742 93.9 
Total RNA Day 16 193519812 183247723 94.7 
Total RNA Day 30 202503600 193764526 95.7 
Total RNA 
(Exosome si) 
63292840 57889016 91.5 
Total RNA 
(Exosome untreated) 
72288287 67287013 93.1 
Total RNA 
(Exosome negative control) 
62555012 57688806 92.2 
mRNA 
(OS25) 
165227729 127030444 75.2 
 
2.6 ChIP-seq dataset handling 
Published ChIP-seq data were downloaded from the GEO repository via direct link or using the 
SRAtoolkit. 
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ChIP-seq re-mapped and processed by me for the work in the current thesis are: Nanog (Whyte 
et al., 2013), Sox2(Whyte et al., 2013), Oct4(Whyte et al., 2013), Med1(Whyte et al., 2013), 
Cdk9(Whyte et al., 2013), H3K4me1(Ferrari et al., 2014), H3K4me3(Ferrari et al., 2014), 
H3K27ac(Ferrari et al., 2014), H3K122ac(Pradeepa et al., 2016), H3K64ac(Pradeepa et al., 
2016), P300(Creyghton et al., 2010), Med12(Rahl et al., 2010), Brd4(Rahl et al., 2010), 
Nipbl(Rahl et al., 2010), Caph2(Dowen JM, 2018), Cdk8 (Young, unpublished, from 
http://younglab.wi.mit.edu/datadownload.htm), Cdk7 (Young, unpublished, from 
http://younglab.wi.mit.edu/datadownload.htm), Spt5(Rahl et al., 2010), Nelfa(Rahl et al., 2010), 
total RNAPII wt(Tee et al., 2014), RNAPIIS5p wt(Tee et al., 2014), total RNAPII Erk knock 
out(Tee et al., 2014), RNAPIIS5p Erk knock out(Tee et al., 2014), input control wt(Tee et al., 
2014). ChIP-seq and datasets re-mapped and processed by Dr Elena Torlai Triglia: 
H3K27me3(Mikkelsen et al., 2008), H3K27me3(Ferrai et al., 2017), RNAPIIS5p(Brookes et al., 
2012; Ferrai et al., 2017), RNAPIIS7p(Brookes et al., 2012; Ferrai et al., 2017), 
RNAPIIS2p(Brookes et al., 2012; Ferrai et al., 2017), RNAPIIS2u(Brookes et al., 2012), Smad1 
(Chen et al., 2008), Stat3 (Chen et al., 2008), Essrb (Chen et al., 2008), Klf4 (Chen et al., 2008), 
cMyc (Chen et al., 2008), nMyc (Chen et al., 2008), E2f1 (Chen et al., 2008), 
H3K36me3(Brookes et al., 2012; Mikkelsen et al., 2008), CTCF(Dowen JM, 2018), Dis3 (AM 
Fernandes unpublished), Erk2(Tee et al., 2014) , Utf1(Jia et al., 2012). ChIP-seq and datasets re-
mapped and processed by Dr Alexander Kukalev: H3K9ac (Consortium, 2012), H3K9me3 
(Thibodeau et al., 2017). 
 Quality control (QC) checks were performed on sequencing data (.fastq files) prior to further 
processing using FastQC software (Andrews, 2010) and trimming was performed with Flexbar 
(Roehr et al., 2018) when: adaptor sequences where found present in the sequencing data; per 
base sequence quality was below 20. Sequenced reads that passed quality check were aligned to 
the mouse genome annotation (assembly mm10/mm9) using Bowtie2(Langmead and Salzberg, 
2012) with default parameters. For each bam file generated after mapping a corresponding 
indexed .bai file and a .bed were generated with Samtools software (Li et al., 2009). Duplicate 
reads (identical reads, aligned to the same genomic location) occurring more often than a 
threshold were removed. The threshold was computed, for each dataset, as the 95th percentile of 
the frequency distribution of the reads, with an in-house script originally coded by Dr Ines de 
Santiago and modified by Dr Tiago Rito. 
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2.7 Bedgraph and bigwig generation 
To visualise and analyse RNA-seq and ChIP-seq data, datasets were further transformed. The 
bedGraph and the bigwig file formats were generated to upload and visualisation on the UCSC 
genome browser or the IGV browser. These two file formats permit to visualise continuous data 
on the genome browser to inspect coverage and density of reads. Bigwig was preferred to 
bedgraph for upload as it is of smaller size and faster to load. Bedgraphs were generateD from 
bed files through the genome coverage bed command of the BEDTools suite (Quinlan and Hall, 
2010). Bigwigs were generated from bedgraph files with the bedtobedgraph command. Data set 
were loaded on a server to create a permanent link for UCSC genome browser. Reads are 
visualised always showing the 0 and whit a smoothing window of 2. IGV desktop 
software(Robinson et al., 2011) was used with the same settings. All RNAPII datasets and 
H3K27me3_day0 tracks were loaded on the genome browser by Dr Elena Torlai Triglia. 
2.8 Expression levels calculation TPM-FPKM and data visualisation 
To calculate the transcription levels coverage of RNA-seq data at regions of interest was 
calculated with multiBamCov of the BEDTools suite v2.17.0  (Quinlan and Hall, 2010) using as 
input bam files from the RNA-seq data and bed files of the regions of interest. For exon 
expression, gene file listing all the exons were used and the total number of reads per genes was 
calculated with a custom script in python. Resulting files were loaded in R and Transcripts per 
Kilobase per Million (TPMs) and Fragments Per Kilobase Million  (FPKMs) were calculated per 
datasets. log(TPM/FPKM) + 0.001 are showed in the text for clarity. 
FPKMs were calculated as: 
# counts per region/(region length x (total counts/ 10^6)) 
TPMs were calculated as: 
((# counts per regions/region length) x 10^6)/ total # of counts 
2.9 ChIP-seq enrichment analysis 
ChIP-seq reads enrichment at regions of interest was calculated starting from bed files with 
intersecBed of the BEDTools suite v2.17.0  (Quinlan and Hall, 2010) with the –c parameter. 
Files were then imported in R and the log average reads count was calculated as follows: the 
number of reads per regions were divided for the region length. A pseudo count corresponding to 
the minimum count in the dataset higher than zero divided by ten was added to avoid log(0). 
Reads are then log transformed. 
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Formula: 
log((# reads per region/region length) + (min(#read in dataset != 0)/10)) 
Biological replicates were treated separately when present. 
2.10 Differential analysis on RNA-seq and ChIP-seq analysis 
Differential analysis of ChIP-seq and RNA-seq datasets was performed to compare datasets 
generated between different treatments or different time points. The analysis was performed with 
DESeq2 software (Love et al., 2014) in R with count bed files generated as described in 2..7 f or 
RNA-seq and 2.8 for ChIP-seq data. DESeq2 outputs consist in log2 fold change difference 
between the two datasets considered and normalised counts, which were used in the plots 
presented in the current thesis. 
2.11 Peak calling on ChIP-seq data 
Peaks for all the features presented in this thesis were called with the Bayesian Change-Point 
(BCP) software (Xing et al., 2012) with histone modification (HM) or transcription factor (TF) 
settings, depending on the dataset. TF was used for transcription factors; HM was used for 
histone modifications and RNA Polymerase II. RNAPII and H3K27me3 peaks were called by 
Dr. Elena Torlai Triglia. BCP peak caller performed poorly on Essrb dataset after visual 
inspection of both modalities and therefore the Essrb peaks were not further analysed in this 
work. However, Essrb raw reads were analysed, 
2.12 Heatmaps and average plots 
Heatmaps of feature enrichment at overlapping enhances in Fig 3.10 were generated using 
ranked normalised reads (using rank command in R) for comparison between enhancer lists. 
Hierarchical clustering was calculated based on variance (“Ward.D2” in R) on TFs and histone 
modification datasets, excluding RNAPII datasets and active transcription marks per subgroup of 
overlap. Summarised heat map for Whyte enhancers in Fig 4.12 was generated after calculating 
the average enrichment and ranked normalised per class per factor with the rank command in R.  
Positional heat maps were generated with the Deeptool software v3.0.2 (Ramírez et al., 2018) 
either starting from the center of the region or averaging the reads per regions +/- #kb of 
surroundings. Average plots were generated with Deeptools or a self-made R scripts either 
starting from the center of the region or averaging the reads per regions +/- #kb of surroundings. 
Biological replicates were treated separately when present. 
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2.13 Enhancer lists retrieval and manipulation 
Published enhancers lists used in the current thesis were downloaded from the relevant 
publications: Whyte et al. 2013 (Whyte et al., 2013), Cruz Molina et al. 2017 (Cruz-Molina et 
al., 2017), Pradeepa et al. 2016 (Pradeepa et al., 2016), Arner et al. 2015 (Arner et al., 2015), 
Chen et al. 2012 (Chen et al., 2012), Creyghton et al. 2010 (Creyghton et al., 2010), Zentner et 
al . 2011 (Zentner et al., 2011). When necessary, liftOver tool from UCSC (Karolchik et al., 
2008) was used to change the coordinates to the mouse genomic assembly mm10. The analyses 
in the current thesis were conducted in the mm10 assembly, unless otherwise specified. Enhancer 
lists were indexed and annotated for their enhancer classes with self-made bash and python 
scripts. Arner enhancers were enlarged as to be of a minimum size of 1kb with BEDTools suite 
v2.17.0  (Quinlan and Hall, 2010), as in the original paper (Arner et al., 2015). Arner enhancers 
were downloaded from the FAMTOM5 website by Dr Markus Schueler. 
2.14 PROMPTs regions generation 
PROMPT regions were defined as regions 500/1000bp upstream TSSs of active genes using the 
UCSC online portal (http://genome.ucsc.edu/cgi-bin/hgTables) selecting the table 
knownGeneOld6. This file was then filtered to contain only regions upstream active promoters 
derived from the list of promoter states in Ferrai et al. 2017 (Ferrai et alFerrai et al., 2017). Only 
results on 500bp PROMPTs are presented in this thesis. Results between 500bp and 1kb long 
PROMPTs are comparable.  
2.15 Promoter regions generation 
Promoter regions were defied as the region -1000bp, +1000bp around the TSS, as previously 
(Ferrai et alFerrai et al., 2017). The regions were recovered UCSC online portal 
(http://genome.ucsc.edu/cgi-bin/hgTables) selecting the table knownGeneOld6. Promoters were 
annotated for their state using the list of promoter states in Ferrai et al. 2017 (Ferrai et alFerrai et 
al., 2017) and a self-made python script. The states considered in the analysis are: Inactive, 
Active, Polycomb Repressed (PRC), PRC-Ser5p. 
2.16 Distribution of regions across the genome 
To show the distribution of regions across different chromosome through the genome, the R 
package GenomicFeautures package from Bioconductor (Lawrence  et al., 2018) was used. The 
Cruz Molina enhancer list is the only list defined on male cells, therefore identifying a handful of 
enhancers also on the Y chromosome. 
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2.17 Distance from the gene analysis for enhancer regions 
To calculate the distance of regions of interest promoter regions generated as in 2.15 or gene 
regions downloaded from the UCSC online portal (http://genome.ucsc.edu/cgi-bin/hgTables) 
were used. Distance from regions of interest was calculate using closestBed of the BEDTools 
suite v2.17.0 (Quinlan and Hall, 2010) with the following parameters: -d -t first.  
2.18 Combination of factors bound at regions of interest 
Regions of interested were analysed for combinatorial presence of transcription factors and 
histone modifications. The combination of factors at regions of interest was calculated as 
follows: regions of interest were annotate selected features with annotateBed of the BEDTools 
suite v2.17.0 (Quinlan and Hall, 2010) with -counts or -both parameters. As input files the BCP 
peaks of the selected features and the bed files of the regions of interest were used. The 
annotated file was then imported in R and the combination of factors plotted with the UpsetR 
package (Conway et al., 2017). If more than one peak overlapped the region it was counted as 1; 
this was done to allow compatibility with the UpsetR package, which analyses at combination of 
factors as a binary yes/no co-occurrence. 
2.19 Co-localisation analysis  
To calculate the co-localisation between regions of interest intersectBed from the BEDTools 
suite v2.17.0 (Quinlan and Hall, 2010) was used with the following parameters: -wa –u (-wb). To 
calculate the regions not co-localising intersectBed was used with the –v parameter. Regions 
generated in this way were saved as new bed files for enrichment analysis.Venn plot showing co-
localisation of regions of interest were generated in R with the venneuler package (Wilkinson, 
2012). 
2.20 TFs binding at co-localising enhancers analysis 
In Chapter 3, I analyse the number of TFs bound per region. To calculate the number of TF 
binding at regions of interest, the regions were annotate for TF BCP peaks with annotateBed 
from BEDTools suite v2.17.0 (Quinlan and Hall, 2010) with –count option. Generated files were 
imported in R for data visualisation. Regions of interest were divided in groups based on the 
number of TFs bound for further analysis. Bins were calculated as: 0 TFs, 1 TF, 2 TFs, 3 TFs, 4 
or more TFs. 
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2.21 RNAPII and CAGE tags occupancy at co-localising enhancers 
analysis 
To calculate the number of RNAPII peaks and CAGE tags binding at overlapping enhancer 
regions, regions of interest were annotated for BCP peaks of RNAPIIS5p_1, RNAPIIS5p_2, 
RNAPIIS2u, RNAPIIS7p, RNAPIIS2p, RNAPII-CTDK7me1, RNAPII-CTDK7me3 and CAGE 
tags with annotateBed of the BEDTools suite v2.17.0 (Quinlan and Hall, 2010) with the –count 
parameter. The resulting file was imported in R and converted in a binary yes: 1 or more peaks 
overlapping; no: 0 peaks overlapping files for RNAPII and CAGE tags datasets separately.  
2.22 RNAPII binding per quartile analysis 
To analyse the RNAPII binding depending on the TF enrichment, regions of interest overlapping 
with one TF bound were analysed. ChIP-seq average counts of the TF of interest per region were 
calculated and the regions divided for belonging to the quartiles: 0-25%, 25-50%, 50-75%, and 
75-100%. Quartiles were calculated with the summary function in R. RNAPII presence derived 
from files created as described in 2.21 was analysed per quartile and plotted as a fraction of 
regions covered per quartile. 
2.23 Correlation plots 
Correlations between features at regions of interest were calculated in R with the command dist 
and transformed into a matrix. Correlation plots were generate with the corrplot package in R 
with the PCA for clustering option. 
2.24 Division of enhancers in extragenic and intragenic 
Regions of interest were divided in intragenic and extragenic based on their location. Intragenic 
regions were defined as: co-localising with an annotated gen from RefSeq (O'Leary et al., 2016), 
2kb upstream of an annotated TSS, and co-localising with an RNAPII covering an annotated 
gene and extending beyond the annotated TES. Extragenic region were defined as outside 
intragenic regions previously described. The minimum overlap to define a region intragenic was 
set at 1bp.  
2.25 Division of RNAPII peaks in extragenic and intragenic 
RNAPII peaks were defined as intragenic and extragenic as defined in 2.24, with the addition of 
the use of UCSC genes (Casper et al., 2018) to define annotated regions. Regions were also 
filtered for not co-localising with the ENCODE blacklist (Consortium, 2012). 
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RNAPII peaks defined across neuronal differentiation were divided in intragenic and extragenic 
as previously, with the addition that intragenic region comprised co-localising regions with an 
RNAPII covering an annotated gene and extending beyond the termination site for all time 
points.  
2.26 Calculation of the length of RNAPII peaks protruding from 
annotated gene termination sites 
To define the length of RNAPII peaks protruding over transcription termination sites of 
annotated genes, RNAPII peaks crossing a transcription end site were selected and cut at the 
transcription end site location. The length of the peak from the cut to the end not co-localising 
annotated genes was plotted in R. Files generated for all RNAPII peaks were merged with 
mergeBed from BEDTools suite v2.17.0 (Quinlan and Hall, 2010) with standard parameters and 
used to define intragenic regions as described in 2.24 and 2.25. 
2.27 Generation of Random regions for enhancer analysis 
For every set of region of interest a matched set of random regions were generated. Random 
regions were generated randomly shuffling the original regions of interest in the genome, to 
allow fair comparison with shuffleBed from the BEDTools suite v2.17.0 (Quinlan and Hall, 
2010) with the parameters: -noOverlapping –excl <original regions of interest> to restrict their 
localisation so not to co-localise with the original regions of interest. 
Random regions matched to extragenic regions were further divided in intragenic and extragenic 
with the same procedure applied to their matched regions of interest. 
For the analysis of co-localising enhancers in chapter 3 only a set of random regions was 
produced. For the random regions generated in chapter 4 and in chapter 5 30 different 
permutations were performed and used separately to gain statistical power in calculation of 
classification cut-off and in random regions classification were used to calculate error bars. 
Random regions used to define the classification threshold and classified random regions used as 
reference were calculated separately. Random regions showed in boxplots are one representative 
random region.  
2.28 Classification of enhancer regions for RNAPII states 
To classify extragenic enhancer regions for RNAPII states different step were taken, describe 
below. 
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Enrichment of RNAPII modification  
Enrichment for every extragenic enhancer region and for matched random regions was 
calculated with intersectBed command from the BEDTools suite v2.17.0 (Quinlan and Hall, 
2010) and the option –c. Regions longer than 3kb were divided in 3kb bins and the enrichment 
was calculated per bin. The largest enrichment across all the bins was assigned to the original 
region with a sel-made python script using pandas package (McKinney, 2018). Random regions 
used in this step are not used for the annotation analysis below. 
Annotation for RNAPII peak 
Extragenic enhancer regions and matched random regions were annotated for RNAPII peak co-
localisation with annotateBed from the BEDTools suite v2.17.0 (Quinlan and Hall, 2010) with 
the –both option. Random regions annotated for RNAPII peaks are not used in the enrichment 
analysis. 
Classification as positive or negative for a RNAPII modification 
To calculate the 5% false positive threshold over random regions enrichment, the enrichment per 
region is divided by its length and a log transformation is performed. 5% top enrichment is then 
calculated in R with the quantile function. The cut-off value is then used to classify as positive or 
negative for a RNAPII modification extragenic enhancer regions: regions with a length 
normalised enrichment (log) above the threshold are considered positive, while the other are 
negative. These regions constitute the “liberal” list. Extragenic enhancer regions annotated as 
positive for the RNAPII modifications were classified as positive and negative separately and 
constitute the “conservative” list.  
Definition of RNAPII states via modification combinations 
After generation the classification for single RNAPII modifications, files were merged and 
extragenic enhancer regions are classified per RNAPII activation state. Combination of RNAPII 
modification presence at the same region generated in the previous step was analysed with a self-
made script in R and python. Classification was performed also on the random region datasets 
annotated for BCP peaks, for comparison. 
2.29 Density plots 
Density plot for enrichment of features in regions of interest are generated in R with the density 
function. Densities of subset of regions, such as BCP positive regions compared to all regions, 
are normalised for the maximum height of all regions in R in the following way: 
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d_BCP$y <- d_BCP$y x (# regions BCP+ /# total regions) 
Where: d_BCP is the density of the enrichment of the investigated feature at BCP positive 
regions, and  d_BCP$y is the height of the density curve.  
2.30 Gene Ontology analysis of extragenic Whyte enhancers 
Gene ontology analysis of Whyte extragenic enhancers positive and negative for RNAPII 
occupancy was performed with the online software GREAT (McLean et al., 2010) with the 
standard parameters and the whole genome as background, as previously (Cruz-Molina et al., 
2017). GREAT analysis on extragenic RNAPII regions failed the yield any meaningful result 
because these regions are very far from genes. These analyses were therefore no included in the 
results. 
2.31 Ranking enrichment analysis for super enhancers identification 
The analysis of ranking enrichment for super enhancer identification was performed in R as in 
(Whyte et al., 2013). In brief, enrichment of selected features was calculated at all Whyte 
enhancers and the regions were ranked for the amount of enrichment from the lowest to the 
highest. Regions were then plotted on the x-axis for their enrichment ranking and on the y-axis 
for the amount of enrichment.  
2.32 Definition of extragenic RNAPII regions 
To define extragenic RNAPII regions, RNAPIIS5p, RNAPIIS7p and RNAPIIS2u peaks from 
Brookes et al.(Brookes et al., 2012) and Ferrai et al. (Ferrai et alFerrai et al., 2017) were first 
divided in extragenic and intragenic as in 2.25. Classification was then performed similar to 2.28 
over matched random regions for RNAPIIS5p enrichment at extragenic RNAPIIS5p peaks; 
RNAPIIS7p enrichment at extragenic RNAPIIS7p peaks; RNAPIIS2u enrichment at extragenic 
RNAPIIS2u peaks. Extragenic RNAPII regions were selected among the ones with an 
enrichment above the calculated cut-off. This procedure was applied to select high confidence 
regions and filter out regions with poor enrichments. 
Extragenic RNAPIIS5p regions during neuronal differentiation were defined as described above 
per time point. Regions were then merged in a single, non-redundant file for further use. 
Merging was performed as follows: regions were concatenated in a unique file in bash using the 
cat command, sorted for chromosome and start site and merge to avoid redundancy with 
mergeBed from the BEDTools suite v2.17.0 (Quinlan and Hall, 2010) with standard parameters. 
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2.33 Classification of extragenic RNAPII regions for RNAPII states  
The classification of extragenic RNAPII regions for RNAPII enhancer state was conducted 
similarly to the extragenic enhancer classification explained in 2.28. They differ in the fact that 
extragenic RNAPII regions were classified only as in the “liberal” approach. The “liberal” 
approach considers a region positive for a RNAPII modification if the length normalised 
enrichment of the region is above the top 5% enrichment at matched random regions and it is 
also co-localising with a BCP peak of the feature of interest. RNAPII states are then defined as 
in 2.28 
Extragenic RNAPII regions during differentiation were classified for RNAPII and H3K27me3 as 
explained above. RNAPII states are then defined per time point as in 2.28. 
2.34 Comparison between extragenic RNAPII datasets 
Comparison between modifications 
To compare different extragenic RNAPII modification regions, regions were first analysed for 
their co-localisation similar to 2.19. Different overlapping groups were divided and annotated for 
TFs binding and histone modifications and plotted as in 2.20 and 2.21. 
Comparison between mESC clones 
To compare extragenic RNAPII regions derived by different mESC clones, regions were first 
analysed for their co-localisation similar to 2.19. Different overlapping groups were divided and 
annotated for TFs binding and histone modifications and plotted as in 2.20 and 2.21. Density 
were calculated and plotted as in 2.29. 
2.35 Analysis of co-regulated RNAPII extragenic regions 
Regions sensitive for transcription perturbation were analysed in R. Differential enrichment per 
regions ws calculated as in 2.10 for every feature of interest. Log2FoldChange from DESeq2 
results was used to confront sensitivity of regions for different treatments.  
2.36 Generation of heat map of waves of extragenic RNAPII states 
during neuronal differentiation 
Extragenic RNAPII regions per time point classified for different states as in 2.33 were plotted 
order for RNAPII activation state (H3K27me3, H3K27me3-RNAPIIS5p, H3K27me3-
RNAPIIS5p-S7p, RNAPIIS5p, RNAPIIS5p-S7p, RNAPIIS7p, Inactive) and time point (Day 0, 
Day 1, Day 3, Day 16, Day 30) and plotted. Waves of extragenic RNAPII states were also 
plotted in a simplified way grouping regions in more general states: Polycomb: if a region is 
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positive for Polycomb, with or whitout RNAPII; Active: if a region if positive for RNAPIIS5p 
and/or RNAPIIS7p and not Polycomb; Inactive: if the regions is negative for all the marks.  
2.37 Transition of RNAPII states during differentiation 
To calculate the percentage of transitions between days of differentiation, all transitions between 
two days were divided by the total number of regions to obtain a percentage and plotted.  
2.38 VISTA tested regions analysis 
VISTA tested regions retrieval 
VISTA tested regions were downloaded from the VISTA enhancer database (Visel et al., 2007)  
as FASTA files and transformed into a bed file with custom bash script. Only mouse enhancers 
were downloaded in mm9 forma. The VISTA tested regions were: positive in brain, positive in 
heart, positive in limb, negative. The four lists were liftOver to mm10 with the online liftOver 
software, annotated for their state on the VISTA enhancer database and a unique concatenated 
file was generated to confront with extragenic RNAPII regions. 
Overlap between VISTA regions and extragenic RNAPII regions 
The overlap between VISTA tested regions and extragenic RNAPII regions was performed with 
intersectBed command from the BEDTools suite v2.17.0 (Quinlan and Hall, 2010) with 
parameters: -wa -wb. Extragenic RNAPII regions used for the comparison were: extragenic 
RNAPII active at Day 16 and Day 30; active at Day 16 and inactive at Day 30; inactive at Day 
16 and active at Day 30; Polycomb repressed at Day 16 and at Day 30 (data not shown). The 
same analysis was performed between Day 0 and Day 1 and Day 1 and Day 3. Day 0 and Day 1 
analysis is not shown in the text of the current thesis, as the VISTA tested regions don’t cover 
enhancers active in early development and the majority of extragenic RNAPII regions were 
negative at both time points. 
2.39 Custom scripts and plot generation 
All the plots showed in the current thesis were generated in R with R plotting functions or 
ggplot2 package (Wickham, 2009), unless otherwise specified. All plotting scripts were custom 
made, unless specified. 
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3. Understanding enhancer classifications 
3.1 Introduction 
Transcription factor (TF) binding at regulatory regions is associated with enhancer activity 
(Palstra and Grosveld, 2012): specific TFs bind a consensus region on the genome and regulate 
enhancers. The regulation can be towards activation, but also towards repression. Interestingly, 
combinations of TFs can form complexes known as enhanceosomes, composed of different TFs 
and can achieve different regulatory outcomes (Merika and Thanos, 2001). Therefore, the 
combination of TFs bound at a specific enhancer can be informative of their state. However, our 
current understanding of TF binding and its relation with enhancer activation states is lacking. 
Enhancers exist in different states (active, poised, primed, etc) (Calo and Wysocka, 2013). The 
study of these different states has helped understand how, for example, poised enhancers keep 
genes in a repressed state in stem cells and ready for activation during neuronal differentiation 
(Cruz-Molina et al., 2017; Rada-Iglesias et al., 2011). However, single studies concentrate on 
particular classes of interest, lacking a global comparison between different classes of enhancers. 
Recently, Benton and colleagues compared active enhancers defined with different strategies. 
The authors showed that regions identified as enhancers by multiple approaches were not more 
likely to act as regulatory regions than those identified by a single approach; the former were not 
more often found to be active in transgene assays or in the VISTA enhancer database (Visel et 
al., 2007) than putative enhancers uniquely found by one approach (Benton et al., 2017). 
The combinatorial nature of TF binding to enhancers, the different activation states, and the 
differences between the approaches used to find enhancers leave open the question on how all 
these features relate with each other. What kinds of regions are identified when choosing one 
approach over another? Do they have similar or different properties? 
3.2 Aim of the chapter 
The aim of the current chapter is to understand differences and similarities between regulatory 
regions identified through different enhancer classification strategies and definitions, and to 
investigate their characteristics in general, but especially with respect to TF binding (Scheme of 
the chapter Fig 3.1). 
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Fig 3.1: Overview of Chapter 3. Enhancers classified with different strategies were analysed for feature enrichment and 
Transcription Factors binding. We find that RNAPII binding co-occurs with Transcription Factor binding at regulatory regions. 
 
I started by analysing three different published lists of enhancers that define five different classes 
of enhancers in mouse embryonic stem cells (mESC): super enhancers, normal/active/canonical 
enhancers, primed enhancers, poised enhancers, and non-canonical enhancers (Fig 3.2).  
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Fig 3.2: Overview of the enhancer classes analysed in this chapter and their described function. In bold the main class explored in 
the original publication. To enhance clarity, the schematic doesn’t reflect the exact proportions and position of protein and 
histone modifications. 
The work presented in the current thesis describes to what extent different enhancer 
identification approaches find different regulatory regions characterized by diverse sets of 
features. Combinations of TF binding at candidate enhancers co-occurs with RNAPII occupancy, 
suggesting RNAPII as a possible new feature to define enhancers at extragenic regions, and their 
activation state. 
3.3 Contribution disclosure  
Elena Torlai Triglia processed and calculated the peaks for all the RNAPII modifications 
datasets presented in the current chapter. Elena Torlai Triglia and Alexander Kukalev processed 
some of the datasets used in the current chapter, when specified. Markus Schueler downloaded 
published CAGE tags regions and converted them from mm9 to mm10. 
3.4 Results 
3.4.1 Choice of published enhancer lists  
To understand how different classes of enhancers compare to each other, I obtained three 
published lists of enhancers (Whyte et al. 2013 (Whyte et al., 2013), Pradeepa et al. 2016 
(Pradeepa et al., 2016), Cruz Molina et al. 2017 (Cruz-Molina et al., 2017)), classified in mouse 
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embryonic stem cells (mESCs) based on the presence different markers; these lists will be 
referred throughout as Whyte, Cruz Molina and Pradeepa. The three lists cover the five main 
classes of enhancers described in the literature: super enhancers, normal/active/canonical 
enhancers, primed enhancers, poised enhancers, and non-canonical enhancers. Whyte, Cruz-
Molina and Pradeepa classifications are based on the presence of different features to identify 
candidate enhancers outside promoter regions: presence of histone modifications (HM) and 
transcription factor (TF) binding (Table 3.1). The Whyte list catalogues regulatory regions as 
normal enhancers if bound simultaneously by Nanog, Sox2 and Oct4 and clustered within 
12.5kb, and as super enhancers (SE), the regions among normal enhancers that are highly 
enriched for Med1 (Whyte et al., 2013). The Cruz Molina list uses an approach based on histone-
modification enrichment to classify: active enhancers, when enriched for H3K27ac and 
H3K4me1; primed enhancers when enriched only for H3K4me1; and poised enhancers when 
enriched for H3K27me3 and H3K4me1. Finally, the Pradeepa list also uses a histone-
modification based approach: canonical enhancers are marked by H3K27ac and H3K4me1, 
while non-canonical enhancers are marked by H3K4me1, H3K122ac, but not by H3K27ac. 
Canonical active enhancers of the Pradeepa list can also be occupied by H3K122ac (Pradeepa et 
al., 2016). 
Table 3.1:  List of enhancer lists considered in this chapter divided by enhancer class. Publication, number of enhancers, mESC 
clone and marks used for the classification are indicated. 
 
The choice of these three lists enabled me to investigate classes of enhancers in different states, 
from the less active (primed enhancers), to the active enhancers and the super enhancers, but also 
the poised and the non-canonical enhancers. More enhancer lists were published on mESC 
during the course of this PhD project: in the next chapter some analysis on the Chen et al. 2012 
(Chen et al., 2012) and Arner et al. 2015 (Arner et al., 2015) lists are presented. However a 
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profound analysis on these lists or other recently published ones have not been considered here 
for time constrain reasons. 
3.4.2 Features used to characterise enhancer classes 
To study the features associated with the different enhancer classes considered, ChIP-seq 
datasets were downloaded as raw data and re-processed for consistent analysis (Table 3.2). 
Available occupancy sites were avoided for a number of reasons: first, I wanted to process the 
datasets in the same, reproducible way and with the same quality standards; second, not all the 
features analysed provided occupancy sites; third, available occupancy sites differed in their 
processing between publications. Some datasets, such as CTCF and Nanog from ENCODE, 
where found of poor quality due to high noise and not considered in the analyses presented here. 
After data re-processing, peaks were called for all datasets using the BCP software (Xing et al., 
2012). BCP software performs well on narrow and broad peaks and especially well in mixed 
peaks such as RNAPII peaks (Harmanci et al., 2014; Thomas et al., 2017). Of note, BCP 
software, as well as MACS2 software (Zhang et al., 2008), performed badly with the Essrb 
datasets (data not shown) and therefore peaks of Essrb were not used in the analysis, whereas 
Essrb ChIP-seq raw reads were used. 
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Table 3.2: Published ChIP-seq datasets used in this work. * Re-mapped and processes by Elena Torlai Triglia; † Re-mapped and 
processed by Alexander Kukalev. All peaks of the datasets in this list were computed by Giulia Caglio, except H3K27me3 day0 
and RNAPII datasets, computed by Elena Torlai Triglia.
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Briefly, I have analysed the classifier marks used to define the different enhancers (Nanog, Sox2, 
Oct4, H3K4me1, H3K27ac, H3K27me3, H3K122ac, H3K64ac), known TFs (Smad1, Stat3, 
Essrb, Klf4, cMyc, nMyc, E2f1), histone modifications that mark active chromatin (H3K9ac), 
inactive chromatin (H3K9me3), promoters (H3K4me3), transcribed regions (H3K36me3), 
RNAPII modifications (Unphosphorylated Ser2 (8WG16ab), RNAPII Ser5p, Ser7p, Ser2p, 
CTDK7me1, CTDK7me2), co-factors (P300, Med12, Brd4), and proteins involved in genome 
architecture (CTCF, Nipbl, Caph2, Med1). I have also analysed Mock IP controls. In some cases, 
I considered more than one dataset per feature (e.g. H3K27me3). Taken together, the features 
considered here define different states of chromatin: heterochromatin, promoters, transcribed 
coding regions, putative enhancers, and insulators or looping domains.  
3.4.3 Enhancer classes distribution across the genome 
To find the similarities and differences across enhancer classes and lists, I started by mapping the 
position of the different enhancers onto their chromosome coordinates. The distribution of 
enhancers across the genome is quite uniform between datasets and enhancer classes (Fig 3.3 
whole genome a – chromosome 2 zoom-in b).  
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Fig 3.3: Enhancers identified in different lists are widespread across the genome. a) Location of Whyte’s, Cruz Molina’s, and 
Pradeepa’s enhancers across the genome. Chromosomes are ordered by number (specified on the left). Lists and classes of 
enhancers are color-coded. Whyte enhancers: normal – light blue, super – dark blue; Cruz Molina enhancers: active – brown, 
poised – orange, primed – gold; Pradeepa enhancers: canonical – light green; non-canonical – dark green. b) Location of Whyte, 
Cruz Molina, and Pradeepa enhancers and Refseq genes across chromosome 2. Blue lines indicate Whyte enhancers, golden lines 
indicate Cruz Molina enhancers, green lines indicate Pradeepa enhancers, and black line indicate Refseq Genes. Image generated 
with the IGV software.   
However, closer inspection of specific gene loci shows a complex scenario Fig 3.4a). For 
example, SEs can overlap with canonical, non-canonical, active, and primed enhancers (see 
Nanog locus). Interestingly, poised enhancers, which contact repressed target genes in mESC, 
can reside in SE regions (see Tbx3 locus). Additional examples of enhancer distributions at 
specific genomic regions can be found for loci Sox2, Foxd3, Gm5607 and Lif, in Appendix Fig 
3.A1. Taken together, these examples clearly show that enhancer lists are ambiguous, with 
different genomic regions being classified in varied ways depending on the subset of features 
considered.  
 
Fig 3 4: Regulatory landscape at gene loci. a) Enhancer classes locations at 3 gene loci. Whyte, Cruz Molina,Pradeepa enhancers 
and RefSeq genes are shown as coloured boxes. Classes of enhancers are indicated below the enhancers. Whyte enhancers: 
normal – light blue, super – dark blue; Cruz Molina enhancers: active – brown, poised – orange, primed – gold; Pradeepa 
enhancers: canonical – light green; non-canonical – dark green. Nanog locus was chosen because of its relevance in mESC. Klf4 
locus was investigate as SE targets in previous publications 8. Tbx3 locus was investigated as non-canonical enhancer’s targets 9. 
Images generated via the IGV software. 
3.4.4 Enhancer features differ between classification lists 
To explore whether candidate regulatory regions identified in each list have different properties, 
I first examined their length and distance to the most proximal gene. These two measures could 
be informative of enhancer function and mechanism: distal enhancers could be involved in 
chromatin looping, or long enhancers could act as TF docks.  
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SEs tend to be longer than normal enhancers in the Whyte list, with medians 8667bp and 703bp, 
respectively (Fig 3.5a). Pradeepa’s canonical and non-canonical enhancers are in general longer 
(median 4000bp and 3000bp, respectively), while the Cruz Molina enhancers are shorter (median 
431bp, 353bp and 1265bp, for active, poised, and primed enhancers). These differences can 
influence the TF binding and histone modification occupancy across different lists of enhancers. 
 
Fig 3 5: General features of enhancer classes. a) Distribution of length of enhancers. Whyte, Cruz Molina and Pradeepa 
enhancers are shown, divided in enhancer classes. The box on the bottom specifies the marks used for each class definition: green 
– mark present; red – mark absent.  b) Distribution of enhancer classes’ distance from nearest annotate TSS-TES in  bp. 
Intragenic: the enhancer region is inside an annotated gene. Whyte, Cruz Molina and Pradeepa enhancers are shown, divided in 
enhancer classes. The box on the bottom specifies the marks used for each class definition: green – mark present; red – mark 
absent.   
Next, I measured the distance of enhancers to most proximal gene (Fig 3.5b) to understand 
whether different classes of enhancers have preferential positions. For all lists, half of the 
candidate enhancer regions are contained inside a coding region and 10-20% are located at a 
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distance between 0 to 10kb from the closest transcription start site (TSS) or transcription 
termination site (TES). For all lists, 10 to 20% of the enhancers lie at more than 50kb of the most 
proximal gene, with noticeably some at more than 100kb; the Whyte list captures the largest 
proportion of enhancers in this category (855/8794, ~10%).  
In conclusion, these results show that the different approaches to define enhancers are consistent 
in their genomic location in respect to genes, with ~50% residing inside them, however they also 
show differences in the features associated with each region. Some enhancers tend to be 
significantly shorter than others, potentially influencing features occupancy, and this effect is 
mainly dependent on the approach used to define enhancers.  
3.4.5 Binding of transcription factors and structural proteins differ 
between classes of enhancers 
Transcription factors have a fundamental role in enhancer activation and in keeping cell identity: 
binding of different combinations of these proteins together with transcription co-factors, and 
chromatin re-modellers can inform about the potential activity of enhancer regions. To explore 
whether enhancer classes vary in their protein binding and whether any differences are connected 
to activation states, I analysed the binding of transcription factor, transcription co-factors, and 
chromatin re-modellers.  
In the Whyte list, most regions are bound by Nanog, Oct4, and Sox2 (6748 /8794, 77%), or 
combinations of at least two of these three factors (93%; Fig 3.6a, for other combinations see 
Appendix Fig. 3.A2). The few enhancers not classified here as positive for either Nanog, Sox2, 
or Oct4 (1.2%) are probably due to slight differences in peak calling between the current thesis 
and the original Whyte paper. Interestingly, Nanog, Sox2, and Oct4 binding is associated with 
the concomitant binding of proteins involved in chromatin looping, such as Nipbl (cohesin 
loading factor), at normal enhancers, but especially at SEs, possibly because they are involved in 
chromatin loops (Hnisz et al., 2013; Whyte et al., 2013) (~30 and ~90% respectively). Other TFs 
expressed in mESCs, such as nMyc and cMyc, together with Smad1, are not found frequently at 
Whyte enhancers. 
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Fig 3.6: Different classes of enhancers have diverse TFs and structural proteins binding. a) Plot showing the binding of different 
proteins at Whyte enhancers. On the box below: combination of factors. On the y-axes the number of enhancers bound by the 
combination indicated. On the x axis on the left: total number of enhancers with that specific protein bound. b) Plot showing the 
binding of different proteins at Cruz Molina enhancers. On the box below: combination of factors. On the y-axes the number of 
enhancers bound by the combination indicated. On the x axis on the left: total number of enhancers with that specific protein 
bound.  
In the Cruz Molina list, the most represented TFs remain Nanog, Oct4, and/or Sox2 (at least one: 
~56% of active, ~40% of poised, ~25% of primed). The most represented combination of TFs at 
active and poised enhancers is Nanog, Oct4, and Sox2 (25%, 17% respectively), while at primed 
enhancers Oct4 is mainly found alone (~20%) (Fig 3.6b). CTCF, a transcription factor thought to 
be important in insulation and chromatin looping, is not preferentially found at active enhancers, 
and only in a small subset of primed enhancers (7%). Only a small subset of Cruz Molina 
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enhancers are bound by CTCF (>7%), while Cohesin is bound to Cruz Molina enhancers the 
more they are in an active state (5% of primed, 13% of poised, 24% of active). Other TFs 
expressed in mESCs are not highly represented at Cruz Molina enhancers, as it was seen in 
Whyte enhancers. 
In the Pradeepa list, Nanog, Sox2, and Oct4 are abundant at both classes of enhancers (at least 
one: 46% of canonical, 26% of non-canonical), however often the three TFs are not bound 
together (~19% canonical, ~7% non-canonical) (Fig 3.7). CTCF is bound preferentially at non-
canonical Pradeepa enhancers (~30%) than at canonical ones (~18%), which are in contrast 
bound by Cohesin (~16% of canonical enhancers, 9% of non-canonical enhancers). Cohesin and 
CTCF are rarely bound concomitantly at Pradeepa enhancers (~5%). CTCF binding at non-
canonical regions was shown in the original Pradeepa et al. paper (Pradeepa et al., 2016). As for 
the other lists, other mESC TFs are not especially enriched at Pradeepa regions. 
 
 
 
 
 
Fig 3..7: Combination of TFs and structural proteins binding at Pradeepa enhancers. a) Plot showing the binding of different 
proteins at Pradeepa enhancers. On the box below: combination of factors. On the y-axes the number of enhancers bound by the 
combination indicated. On the x axis on the left: total number of enhancers with that specific protein bound. 
  
64 
When I compare the classes of enhancers across lists, I found that active enhancers (normal, 
super and active) share binding for Oct4, Sox2, and Nanog, together with an enrichment for 
Cohesin. Poised enhancers share similarities with active enhancers, such as Nanog, Sox2, and 
Oct4 binding, whilst primed enhancers show binding mainly for single transcription factors. 
Pradeepa enhancers, however, show remarkable differences with the other classifications, with a 
preference for CTCF also at canonical enhancers. Pradeepa enhancers are very long and this 
could influence the analysis, however this effect is not seen at SEs, which are also longer than 
Cruz Molina’s and normal enhancers. 
Taken together, the combinations of protein binding at enhancer lists shows a central role for 
Nanog, Sox2, and Oct4 at all mESC enhancers considered. These three TFs are preferentially 
found at active enhancers across lists, while Oct4 alone is mainly found at less active, or 
repressed, enhancers.  
3.4.6 Differently classified enhancers show enrichment for factors 
used in other lists 
The previous analysis of TF binding at different enhancer classes showed similarities between 
classes of enhancers, together with some striking differences. To understand how chromatin 
marks and other features relate with classes of enhancers across lists, I also measured the 
enrichment of other features used as classifiers for the three lists: Nanog, Sox2, Oct4, Med1, 
H3K27ac, H3K27me3, H3K4me1, H3K122ac, H3K64ac (Fig 3.8). 
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Fig 3.8: Enhancer classes enrichment of classifiers features. a) Boxplots showing the enrichment at enhancer classes for marks 
used in the enhancer classification. Log of average counts (normalised per length) are represented. A pseudo-count of the 
minimum count per dataset divided by 10 was added to all counts, to avoid log function of 0. Grey transparent box represents 
enrichment of the feature at random regions (25%-75% range). Random regions represent randomly shuffled enhancer regions 
across the genome. 
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Active enhancers (normal, super, and active) show an enrichment for active enhancer marks: 
H3K27ac, Nanog, Sox2, Oct4, Med1, and H3K122ac. Notably, SE are the most enriched for 
H3K27ac and Med1, which are two marks used in the literature to differentiate SE from normal 
enhancers (Hnisz et al., 2013; Whyte et al., 2013). Poised enhancers are enriched in H3K27me3 
and depleted of H3K27ac, while concomitantly being enriched for TF. Primed enhancers show a 
lower enrichment for all the marks considered, but still above random. H3K4me1 is enriched 
ubiquitously above random at all classes of enhancers. The Pradeepa lists shows a lower 
enrichment for all the features compared to the other lists, more similar to the enrichment at 
primed enhancers for both canonical and non-canonical regions. Canonical enhancers are more 
enriched for H3K122ac than non-canonical ones; this is in agreement with the original findings 
in the Pradeepa et al. 2016 (Pradeepa et al., 2016). For density distribution of this marks across 
the two different classes please refer to the Appendix Fig 3.A3. Non-canonical enhancers show a 
slight enrichment for H3K27me3, which could suggest that a subset of non-canonical enhancers 
are poised, in line with an observation made in the original paper. The proportion of repressed 
enhancers among the non-canonical ones was never investigated. 
Taken together, the results show that active, SE, and normal enhancers share similar chromatin 
state together with similar TF binding properties, poised enhancers have a specific chromatin 
mark, H3K27me3, primed enhancers are in an intermediate or premature state, with less protein 
binding and feature enrichment that active or poised enhancers. On the other side, Pradeepa’s 
canonical and non-canonical enhancers show mixed characteristics: canonical enhancers show 
similarities to active enhancers, however with some noticeable differences such as CTCF 
binding, and non-canonical enhancers show characteristic comparable to primed enhancers. 
3.4.7 Enhancer lists identify both unique and shared regions 
The analysis performed until now showed that enhancers classified similarly show similar 
features, however noticeable differences can be found. This prompted me to ask to what extent 
enhancer regions were identified by multiple approaches. Moreover, it was important to 
investigate the properties of enhancer regions specific to a given enhancer list. I analysed the 
enhancer lists co-localization across the genome (Fig 3.9a), considering as co-localisation 1bp of 
overlap minimum. Many Whyte enhancers (6559/8794, 75%) and Cruz Molina enhancers 
(21067/32880, 64%) are detected also with other approaches, while many Pradeepa enhancers 
(16625/32489, 51%) tend to be unique, irrespectively of their longer length. This is in line with 
the unique properties of Pradeepa enhancers described above, and the shared properties of Whyte 
and Cruz Molina enhancers, especially for the active class. 
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To understand whether enhancer regions that co-localise share similar classifications (e.g. 
normal-active), I analysed the fraction of different classes of enhancers per overlapping group 
(Fig 3.9b). Indeed, normal, active, canonical enhancers are found to co-localise (in total 1884 
overlapping regions out 3391 regions seen in all lists); however, primed and non-canonical 
enhancers also co-localise with the Whyte list. Poised enhancers, canonical, and non-canonical 
enhancers are found in different combinations across all the overlapping groups. For the 
distribution of each class per group of overlap please refer to Appendix Fig 3.A4. 
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Fig 3.9: Co-localisation of enhancer lists. a) Overlap between Whyte’s, Cruz Molina’s  and Pradeepa’s enhancers’ location in the 
genome. An overlap is considered positive if at least 1bp is shared between regions. b) Combination of classes of enhancers per 
group of overlap. Fraction of group of overlap occupied by each combination of enhancer’s classes is shown. On the left, 
rectangles represent the presence of the specific enhancer class. On the right, schematic of the overlap between different enhancer 
lists: in colour the group of overlap shown on the graph. W = Whyte, C M = Cruz Molina, P = Pradeepa.  
This study shows how complex is the relation between regulatory regions defined with different 
approaches. Regions classified in different states co-localise in the genome, making difficult to 
estimate which approach or classification defines and classify enhancers more reliably. 
3.4.8 Candidate enhancer regions identified by different criteria 
have heterogeneous features 
Enhancers identified in different lists co-localise in the genome. One possibility would be that 
overlapping enhancer regions could share chromatin features, while uniquely found regions 
could have specific ones. I therefore investigated the different groups of enhancer regions 
according to whether they were unique or common to different enhancer lists, and explored their 
occupancy features. The overlapping enhancer regions were merged and compared for their 
relative normalised ChIP-seq enrichment of different marks (Fig 3.10a). The absolute ChIP-seq 
enrichment for selected features at all overlapping regions can be found in Appendix Fig 3.A5 .  
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Fig 3.10 : Overlapping enhancer regions show diverse features enrichment. a) Percentile of enrichment of ChiP-seq normalised 
(ranked) reads of different group of features at overlapping groups of enhancers. Overlapping groups are schematised on the left 
of the graph. W = Whyte, C M = Cruz Molina, P = Pradeepa. Datasets are divided in broad categorised specified above the graph. 
Darker colour means stronger relative enrichment, lighter colour means lower relative enrichment in all the overlapping regions. 
b) Heatmap showing the genomic location of overlapping regions. Extragenic regions: outside +/- 2kb from TSS-TES of 
annotated genes, in orange; intragenic active gene: +/- 2kb from TSS-TES of annotated active genes (TPM >1), in blue; 
intragenic inactive gene: +/- 2kb from TSS-TES of annotated inactive genes (TPM <1), in white. TPM calculation where taken 
from published tables on mESCs from Ferrai et al. 2017 17. c) Heatmap showing the number of TF peaks at overlapping 
enhancer regions. TF binding where binned in: 0 TF peaks (white), 1 TF peak (light pink), 2 TF peaks (pink), 3 TF peaks (violet), 
>=4 TF peaks (dark purple). d) Heatmap showing the presence of RNAPII peaks peaks at overlapping enhancer regions. In dark 
blue: overlap with a RNAPII peak, in white, no overlap with a RNAPII peak. e) Heatmap showing the presence of CAGE tags 
outside promoters at overlapping enhancer regions. In black: overlap with a CAGE tags, in white, no overlap with a CAGE tags. 
CAGE-tags were downloaded from the FANTOM5 website ) http://fantom.gsc.riken.jp/ ) by Markus Schueler. Every row in all 
the heatmaps represents an overlapping enhancer region.    
All subgroups of overlapping or unique enhancer regions show heterogeneous enrichment for 
classification features. For example, regions common to all three enhancer lists have a high 
enrichment for Nanog, Sox2, and Oct4, but show variable H3K27ac, while others contain 
H3K27me3. In general, regions overlapping Whyte enhancers have the strongest normalised 
ChIP-seq enrichment signal for Nanog, Sox2 and Oct4, but similar strength of enrichment for the 
same three TFs can be seen in the Cruz Molina-only regions. Regions uniquely identified by 
each of the three approaches also show heterogeneity: Pradeepa unique regions have low 
enrichment for Nanog, Sox2 and Oct4, can be high or low in H3K122ac, and are enriched in 
CTCF, which was expected from the original Pradeepa analyses. 
Another example of the heterogeneity is for example in the regions shared by Cruz Molina and 
Pradeepa, which show in general lower enrichment for all the marks considered, but can be 
associated with features of active genic regions, such as H3K36me3 and RNAPII-S2p. To 
understand whether the presence of this latter signature results from active transcription at 
coding regions, I took advantage of published gene expression levels in mESC obtained by 
RNA-seq (Ferrai et alFerrai et al., 2017) and categorized all the regions as: extragenic, if outside 
+/- 2kb annotated TSSs and TESs; intragenic active, if inside +/- 2kb annotated TSSs and TESs 
of an active gene (TPM >=1); intragenic inactive, if inside +/- 2kb annotated TSSs and TESs of 
an inactive gene (TPM <1). Indeed, active transcribing chromatin mark H3K36me3 appears in 
regions inside active genes (Fig 3.10b). Raw read enrichment of RNAPII is visible at extragenic 
regions (Fig 3.11). 
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Fig 3.11: Single gene examples of RNAPII coverage. Images generated with IGV software. 
The picture that emerges from this enrichment analysis is extremely complex. Therefore, to 
investigate whether TF binding could help prioritise specific enhancer groups, I measured the 
number of TF found to occupy each enhancer region and whether this binding could be related 
with specific chromatin features, I counted the number of TF bound at least once per region. I 
first calculated the distribution of binding events inside the whole dataset of overlapping regions 
to define optimal binning (Appendix Fig 3.A6); regions were then categorized into 0, 1, 2, 3 or 
≥4 TFs bound (Fig. 3.10c). Unexpectedly, a great number of common enhancer regions are not 
bound by any of the TFs studied (25558/46945, 54%). Candidate enhancer regions inside active 
genes have fewer TF binding events than extragenic regions (~50% in extragenic regions, ~40% 
in active gene regions, 46% in inactive gene regions).  
3.4.9 RNAPII occupies regions bound by one or more transcription 
factor 
The association of RNAPII at enhancers has previously been shown (Cruz-Molina et al., 2017; 
De Santa et al., 2010;  Kaikkonen et al., 2013). To explore whether RNAPII binding could help 
characterize the different enhancer regions, especially those occupied by TFs, I quantified the 
presence of RNAPII and of CAGE tags at these regions (Fig 3.10d-e). CAGE tags were 
previously used to identify enhancers, as an orthogonal approach to chromatin marks based on 
eRNA transcription and mark active transcription outside promoters (Arner et al., 2015). 
RNAPII is present at 50% of all enhancer regions considered here, of which 42% are extragenic. 
The regions where at least 1 TF are present have 50% change of being occupied by RNAPII, 
whereas most (87%) of regions occupied by more than 4 TF have RNAPII, even when only 
extragenic regions are considered (Fig 3.12a). The CAGE tags dataset is not numerous (2604), 
however CAGE tags are preferentially found in regions with >3 TFs (1283/2604, ~50%) (Fig 
3.10e), and at these region RNAPII is bound 98% of the time. Therefore, when numerous TFs 
are present at a regulatory region, RNAPII is also bound. The transcriptional activity of 
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extragenic RNAPII occupancy at candidate enhancer regions will be investigated in more detail 
later in this thesis. 
To assess whether the presence of RNAPII might relate with TF abundance, I took all the 
extragenic overlapping enhancer regions (outside +/- 2kb from annotated TSSs and TESs) with 
one TF bound, divided the read distribution in quartiles and quantified the fraction of region 
bound by RNAPII per quartile (Fig3.12b, 6 TFs analysed are shown). A trend is visible where 
the more a TF is enriched (higher quartile) the more RNAPII occupies that region (higher 
fraction). Interestingly, Smad1 shows a different behaviour of anti-correlation between the 
quantity of TF bound and the presence of RNAPII, which could suggest a repressive activity of 
Smad1 at enhancers. Other Smad proteins, such as Smad4, where shown to have a repressive 
function (Vincent et al., 2009; Wotton et al., 1999). 
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Fig 3.12: RNAPII binding at overlapping enhancer regions co-occurs with high TF binding. a) RNAPII binds at overlapping 
regulatory regions when >=1 TF is present. In blue: regions overlapping with a RNAPII peak; in white, regions not overlapping 
with a RNAPII peak. Regions are divided for their genomic location: extragenic region are +/-2kb from TSS-TES of annotated 
genes; active genes inside SS-TES of annotated active genes (>1 TPM). TPM calculation where taken from published tables on 
mESCs from Ferrai et al. 2017. b) RNAPII preferentially binds at overlapping enhancer regions with high TF enrichment. 
Barplot showing the percentage of RNAPII positive enhancer overlapping regions per quantile of enrichment of Sox2, Oct4, 
Nanog, E2f1, Stat3, Smad1. Only extragenic regions are shown: +/-2kb from TSS-TES of annotated genes. 
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3.4.10 RNAPII is present in different activation states at regulatory 
regions 
Post-translational modifications of the CTD of RNAPII are informative of its state of activation. 
To explore whether RNAPII is present at enhancers in different activation states and whether the 
activation correlates with enhancer features, namely TFs, I analysed the co-occupancy of 
different RNAPII modifications and TFs at regions characterized by binding of 1, 2, 3 or 4 TFs. 
To avoid confounding effects, only extragenic regions were considered in this analysis (outside 
+/- 2kb from annotated TSSs and TESs). All the different forms of RNAPII considered in this 
analysis were found present at regulatory regions to different extents, including RNAPIIS5p 
(characteristic of active and poised gene promoters), RNAPIIS7p (of active promoters) and 
RNAPII-S2p (of elongation; Fig 3.13a). The extent of occupancy of RNAPII modifications at 
extragenic enhancer regions reflects the RNAPII activation state, with less active RNAPII found 
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more often than fully elongating one at these regions (~46% RNAPIIS2u (8WG16ab), ~37% 
RNAPIIS5p, ~30% RNAPIIS7p, ~25% RNAPIIS2p).  
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Fig 3.13: Most represented combination of TFs binding and RNAPII modifications at extragenic overlapping enhancers. a) 
Combinations of TFs and RNAPII modifications peaks at extragenic overlapping enhancers, showed by number of TFs bound 
per region: 0 TF peaks, 1 TF peak, 2 TF peaks, 3 TF peaks, >= 4 TF peaks. Only extragenic regions are shown: +/-2kb from TSS-
TES of annotated genes. Blue transparent box around features represents TF datasets; pink transparent box around the analysed 
features represents RNAPII datasets. 
To understand whether the extent of TF binding positively correlated with RNAPII recruitment 
and activation state, I correlated the ChIP-seq reads of different RNAPII modifications and TFs 
at extragenic overlapping regulatory regions (Fig 3.14). RNAPII modifications are highly 
correlated with themselves, as expected (e.g. Dias et al. 2015 (Dias et al., 2015)), with E2f1 and 
partially with Klf4. Nanog, Sox2 and Oct4 mostly correlate with themselves. This result, 
connected with the finding that 1969 regions show a unique biding of Nanog, Sox2 and Oct4 
without any RNAPII (Fig 3.12a), suggests that RNAPII regulation is not directly linked to Oct4, 
Nanog and Sox2 binding, but could be recruited after TF binding specifically at some enhancer 
regions, to participate in specific aspects of enhancer activity. Interestingly, similar correlation 
was found at promoters (+/- 2kb from TSSs) of active genes (Fig 3.14b) suggesting that 
promoters and enhancers share common features. Interestingly, the correlation between Sox2, 
Nanog and Oct4 at TSS is lower than the one at enhancers. Correlation over all promoter regions 
can be found in Appendix Fig 3.A7. 
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Fig 3.14: RNAPII modifications correlate with TFs at extragenic overlapping enhancers a) at extragenic enhancers and b) at 
active TSSs. Correlation plot showing pearson correlation between RNAPII modifications and TFs. Plot made with the corrplot 
package in R, and hierarchical clustering option.  
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3.5 Discussion 
After their first discovery (Banerji et al., 1981), enhancers were extensively investigated and 
described in different states of activation. These states can be defined with different 
combinations of chromatin occupancy features and are thought to describe the level of activity 
and diverse functions of enhancers (Calo and Wysocka, 2013). In parallel, studies have clarified 
the important role of transcription factors in target gene activation (Spitz and Furlong, 2012), and 
the role of proteins such as CTCF and Cohesin in mediating chromatin loops; loops create a 
preferred region of interaction where enhancers might act (Rao et al., 2014). However, the 
enhancer field lacks a clear comparison between the different classes and states of activation of 
enhancers. Some studies have tackled these questions both regarding methodologies of enhancer 
identification (Kleftogiannis et al., 2014) and basic enhancer features (Benton et al., 2017), 
however they focused only on active enhancers leaving out the comparisons of different classes 
of enhancers defined with different approaches or associated with poised states.  
In this chapter, I show that enhancer classes identified by different approaches are found at 
distinct genomic locations. Regions more enriched for typical enhancer marks, therefore more 
likely to act as enhancers in vivo, are more enriched in TFs. When one or more TF is bound to a 
regulatory region, 50-90% of the time RNAPII would be bound. RNAPII is therefore an 
interesting candidate to investigate regulatory regions. 
3.5.1 Enhancers lists identify regions with different features  
To understand how different enhancer classification approaches relate with each other, I 
compared lists and classes of enhancers in mESCs from three publication: Whyte et al. (Whyte et 
al., 2013), Cruz Molina et al. (Cruz-Molina et al., 2017), Pradeepa et al. (Pradeepa et al., 2016). 
The three lists I analysed classify enhancers in five different states: active/normal/canonical, 
super, poised, primed and non-canonical. These different classes were described in the literature 
to have distinct functions and characteristics: normal (Whyte list)/active (Cruz Molina 
list)/canonical (Pradeepa list) enhancers enhance target gene expression, possibly through 
chromatin looping, and are marked by H3K4me1 and H3K27ac, or bound by specific TFs, such 
as Nanog, Sox2 and Oct4  (Calo and Wysocka, 2013; Zentner et al., 2011). Super enhancers 
(Whyte list) are clusters of enhancers or stretched enhancers that can act synergistically; they 
cover a large distance in the genome and greatly enhance target gene expression. Super 
enhancers are marked by high levels of Med1 or H3K27ac and bound by specific TFs (Hnisz et 
al., 2013; Whyte et al., 2013). Poised enhancers (Cruz Molina list), on the other hand, repress 
their target genes in mESC via direct chromatin contact and activate them during differentiation, 
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when they lose the repressive mark H3K27me3 and acquire the active mark H3K27ac (Cruz-
Molina et al., 2017; Rada-Iglesias et al., 2011). Primed enhancer (Cruz Molina list) are not yet 
active and marked by H3K4me1 and pioneer transcription factors (Calo and Wysocka, 2013). 
Finally, non-canonical enhancers (Pradeepa list) were recently found to enhance target gene 
expression similarly to active enhancers, without being marked by the canonical enhancer mark 
H3K27ac and instead being marked by H3K122ac. In the original paper was observed that a 
subgroup of non-canonical enhancers is marked by H3K27me3, which is coherent with some of 
the results in the current chapter (Fig 3.8). 
These different enhancers are widespread through the genome, however their distribution at gene 
loci shows discrepancy between the classifications: very active enhancers, such as super 
enhancers, could be located at the same regions were primed enhancers, or even poised 
enhancers are located. Partially, this could be due to the size differences between enhancer 
classifications: super enhancers tend to be longer, as close TF peaks used to defined enhancers 
were merged in larger regions in the original paper (Whyte et al., 2013). Cruz Molina’s regions 
on the other hand are the shortest, while Pradeepa’s enhancers are intermediately long. The fact 
that SE can be found to contain enhancers in different states could suggest that these regions 
contains numerous enhancers that potentially don’t share the same activation state and could 
have different functions or respond to different stimuli which should act in concert, possibly in a 
big chromatin domain together with co-regulated genes. 
Different classes of enhancers show diverse TFs binding and histone modification enrichment: 
active/normal/super enhancers have simultaneous binding of Nanog, Sox2 and Oct4. These three 
TFs are frequently bound to the enhancers examined in this study and represent pivotal TFs in 
mESC that regulate cell stemness (Kashyap et al., 2009). Interestingly, less active classes of 
enhancers are bound more often by Oct4 alone. Oct4 was shown to be a pioneer TF (King and 
Klose, 2017), in accordance with his presence at primed enhancers. Preadeepa enhancers are the 
least enriched for enhancer marks across all the enhancers considered, also when the non-
canonical mark H3K122ac is analysed. Moreover, Pradeepa’s regions show a preference for 
CTCF, which is shared to some degree with primed enhancer, but not found at active enhancers. 
In particular, canonical enhancers were defined as active and, even if they were classified with 
the same logic of active enhancers in the Cruz Molina list, substantially differ from the other 
active enhancers also regarding length. These differences can be attributed to technical reasons, 
such as threshold choice, or peak calling softwares used. However, this observation raises 
concerns on the robustness of enhancer identification approaches and their reproducibility. 
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Differences in features between enhancer classes could be indicative of diverse functions; 
regulatory regions might act through different mechanisms, while still regulating target gene 
expression. Specific mechanisms were shown for poised enhancers, that repress their target 
genes (Cruz-Molina et al., 2017), or for active genes contacting the target gene via chromatin 
looping(Ferrai and Pombo, 2009) or via RNAPII tracking from the enhancer to the promoter 
(Wang et al., 2005). Some of the regulatory regions investigated in this chapter could be mainly 
involved in looping of chromatin and therefore show a higher occupancy for proteins such 
Cohesin, while other regions could act as dock for transcription factors and co-factors or might 
be involved in chromatin structure, if for example bound by CTCF. The different scenarios can 
co-exist, where regulatory regions in close proximity to a gene create a highly dense TFs hub and 
a preferred region of interaction.  
3.5.2 Enhancer lists co-localisation is complex 
To understand the relationship between the different enhancer lists I look at their co-localisation 
and analysed the resulting overlapping groups. The enhancer regions identified in the 3 different 
publications are not completely recovered in any other list. Every approach identifies unique 
regions, which are however not only the unique class of that particular list. For example, the 
majority of Whyte enhancers are found also in either Cruz Molina or Pradeepa lists, however the 
regions unique to the Whyte lit are not only super enhancers. This may be surprising, as super 
enhancers can be categorised as active enhancers or canonical enhancers in the other two lists. 
The regions unique to Cruz Molina are not solely poised and primed, and surprisingly poised 
enhancers where also found in different lists that where not considering this repressed state. The 
internal differences in groups can be attributed to different classes of enhancers that co-localise 
between lists and are therefore assigned to the same group. All lists considered in this study have 
classes not considered in other studies, which makes it all more surprising that one region 
classified as active with one approach could be classified as primed or poised with another. 
Surprisingly, numerous enhancers showed no TFs binding, which is known to be important for 
enhancer activation. It is possible that these regions are bound by other TFs not considered in 
this study. However, another intriguing possibility is that these regions show a diverse function, 
may be bound by structural protein such as CTCF and contribute to genome architecture and are 
less involved in direct gene regulation. 
The results highlight how heterogeneous the landscape of enhancers in mESC is. Different 
approaches not only define different regions with different characteristics, but also classify them 
in different states of activation. The heterogeneity is preserved even if co-localising regions are 
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grouped; groups have diverse characteristic and features within themselves. Interestingly, 
regions identified by more than one approach do not appear in general terms more enriched for 
enhancer marks, compared with regions unique to one study. This is in accordance with the study 
from Benton and colleagues (Benton et al., 2017) where active enhancers identified with 
different approaches where shown to be not more active than enhancers identified by single 
approaches. 
Enhancer identification and classification remains a challenge in the field; further studies should 
aim to clarify what kind of regions every approach identifies, what is the power of the 
approaches and how different types of enhancers act and are regulated. 
3.5.3 Transcription Factor binding co-occurs with different forms of 
RNAPII 
RNAPII transcription at enhancers was indirectly shown to be important for their activity: 
eRNAs produced at enhancers correlate with mRNA produced at target genes (Kim et al., 2010;  
Kaikkonen et al., 2013). To investigate RNAPII at enhancers I analysed its binding in relation 
with TFs. Enhancers were showed to act as recruitment sites for TFs (Spitz and Furlong, 2012), 
increasing their abundance near target genes in the 3d space of the nucleus; a similar mechanism 
was suggested for RNAPII creating a hub of co-regulated genes. Although only a limited number 
of TFs were analysed in the current chapter, RNAPII binds at regulatory regions together with 
transcription factors in at least 50% of the regions considered. RNAPII binding is influenced by 
the abundance of TF at the regulatory region: more TF occupies a regulatory region more likely 
it is that RNAPII would be bound as well. RNAPII binds at regulatory regions when different 
TFs are present in different forms, here analysed via its post-translational modifications of its 
CTD. TFs could bind at regulatory regions and act as recruiter for RNAPII, similarly to what 
happens at genes (Brookes and Pombo, 2009). RNAPII recruited at enhancers could be post-
transnationally modified and transcribe eRNAs. Active RNAPII states are found at regulatory 
regions, especially concomitantly with 4 or more TFs bound, which suggest a link between 
RNAPII state and enhancer state. TFs can bind in combinations, which in turn can influence the 
state of the regulatory region (Merika and Thanos, 2001). This phenomena, added to the 
observation that RNAPII can be found in different states at enhancers, amplify the regulatory 
landscape of enhancers: combinations of TFs and RNAPII states can finely tune enhancer 
activity and consequently target gene expression.  
However, RNAPII doesn’t bind all regions bound by a TF. Smad1 has little to no co-binding 
together with RNAPII at regulatory regions. RNAPII and Smad1 could be mutually exclusive 
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and potentially Smad1 could negatively regulate enhancer regions. It would be interesting to 
further understand the relation between this TF and RNAPII at regulatory regions and to 
understand if other TFs behave in the same way and what are their characteristics, how is this 
repressive process regulated, and what are the target genes. 
Interestingly, a high correlation between RNAPII and E2f1 was found. E2f1 is a master 
regulatory transcription factor involved in cell cycle and up regulated in cancer. Its targets were 
shown to be down regulated after Brd4 inhibition that affected specifically SE in cancer cells 
(Chapuy et al., 2013), and it was suggested that it is involved indirectly in RNAPII-CTD 
phosphorylation (Ma et al., 2003). A more detailed exploration of the relation between E2f1 and 
RNAPII at extragenic candidate enhancers would be of great interest however was beyond the 
aims of this thesis.  
The fact that RNAPII is present at enhancer, possibly in different states of activation, could 
suggests that genes and enhancers share RNAPII and TFs, possibly in specialised chromatin 
hubs. The TFs combination and the RNAPII states can be regulated concomitantly in the hub, 
leading to a coordinate gene regulation. However, no study dealt yet with the activation state of 
RNAPII at enhancers and the implication on enhancer state and their activity on gene regulation. 
The study of RNAPII regulation could be beneficial for understanding the state of enhancers, 
clarify their mechanism of activation and identify enhancers in the genome. 
In the next chapters, I investigate if RNAPII is present in different states at enhancers, if these 
states resemble the ones at genes, and if extragenic RNAPII can be used as a tool to find 
enhancers and their state. 
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3.6 Figures Appendix 
 
Fig 3. A1: Examples of gene loci regulatory landscape. a) Enhancer classes locations at 3 gene loci. Whyte, Cruz Molina and 
Pradeepa enhancers and RefSeq genes are shown. Classes of enhancers are indicated below the enhancers and color-coded: 
Whyte enhancers: normal – light blue, super – dark blue; Cruz Molina enhancers: active – brown, poised – orange, primed – 
gold; Pradeepa enhancers: canonical: light green; non-canonical – dark green. Images generated via the IGV software. 
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Fig 3.A2: All combinations of different TFs and structural protein at enhancers. Plot showing the binding of different proteins at 
enhancer lists. On the box below: combination of factors. On the y-axes the number of enhancers bound by the combination 
indicated. On the x axis on the left: total number of enhancers with that specific protein bound. 
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Fig 3.A3: Density of enrichment of non-canonical marks at Pradeepa enhancers. Black line: density of enrichment at all Pradeepa 
enhancers; dark green: density of enrichment at non-canonical enhancers; light Green: density of enrichment at canonical 
enhancers. Density calculated with the density function in R. 
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Fig 3.A4: Distribution of enhancer classes per group of overlap. a) Plot showing the fraction of different classes of enhancer 
present in the overlapping group. Legend of colours representing groups is on the right of the plot, together with a schematic 
representing the overlapping group. W = Whyte enhancers, CM = Cruz Molina enhancers, P = Pradeepa enhancers. 
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Fig 3.A5: Enrichment of different features at overlapping groups of enhancers. a) Violin plots showing the distribution of 
absolute enrichment of feature per overlapping groups. Log of average counts (normalised per length) are represented. A pseudo-
count of the minimum count per dataset divided by 10 was added to all counts, to avoid log function of 0. Grey transparent box 
represents enrichment of the feature at random regions (25%-75% range). Whyte = Whyte enhancers unique regions; W CM = 
Whyte - Cruz Molina overlapping regions; W P = Whyte -Pradeepa overlapping regions; W CM P = Whyte - Cruz Molina - 
Pradeepa overlapping regions; Cruz Molina = Cruz Molina unique regions; Pradeepa = Pradeepa unique regions; P CM = 
Pradeepa – Cruz Molina overlapping regions. Random Regions = randomly shuffled overlapping regions. 
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Fig 3.A6: Analysis of TF binding to define binning. Number of overlapping enhancer regions overlapping with 0 or more TFs 
peaks. 
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4. RNAPII activation states at enhancer 
regions mirror their activation  
4.1 Introduction 
In the previous chapter, I showed that RNAPII is present at enhancer regions, especially 
concurrently with TFs. RNAPII was previously described to be present at enhancer regions (De 
Santa et al., 2010) and to transcribe enhancer RNAs (eRNAs) (Andersson et al., 2014a; Arner et 
al., 2015; Kim et al., 2010; Kaikkonen et al., 2013). eRNAs are currently investigated in the field 
for their possible role in the regulation of target gene expression. For example, it has been shown 
that knockout of eRNA with interference techniques can decrease the expression of the target 
genes (Li et al., 2013;Kaikkonen et al., 2013; Wang et al., 2011). eRNAs may also be involved 
in chromatin looping (Plank and Dean, 2014), and in promoter proximal pausing release 
(Schaukowitch et al., 2014a). However, eRNA depletion techniques used in these studies have 
often interfered with transcription at regulatory regions (Kaikkonen et al., 2013; Plank and Dean, 
2014), making it difficult to decouple the effects of transcription from direct effects of the 
eRNAs. In this regard, it was found that the premature arrest of transcription via insertion of a 
polyA-cassette at enhancers influenced eRNA production but not transcription itself. This 
experiment elegantly showed that inhibition of eRNA expression does not have a direct effect on 
target gene expression (Engreitz et al., 2016). Therefore, more attention has recently been given 
to the mechanism of transcription at enhancers. Some studies have dealt with RNAPII 
characterization at regulatory regions, showing for example that RNAPII can bind enhancer 
regions after their activation through stimuli in macrophages (De Santa et al., 2010) or enhancer 
activation (Cruz-Molina et al., 2017). It was also shown that extremely active enhancers – super 
enhancers – are enriched in RNAPII binding (Hnisz et al., 2013). However, the field lacks a 
detailed investigation of the states of activation of RNAPII at regulatory regions and how these 
states relate with enhancer states.  
Enhancers have also been shown to exist in different state of activation which are linked with 
their chromatin environment. For example, H3K27ac enrichment correlates with enhancer 
activity (Creyghton et al., 2010) at active enhancers. Levels of H3K27ac enrichment are used to 
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distinguish between normal enhancers and super enhancers, which are greatly enriched for 
H3K27ac and Brd4(Hnisz et al., 2013; Lovén et al., 2013; Whyte et al., 2013). Other marks 
highlight further differences between classes of enhancers, such as P300, that can distinguish 
between primed enhancers and enhancers transitioning to activation (Zentner et al., 2011), or 
H3K4me1, which is not indicative of enhancer state and are ubiquitously present at regulatory 
regions, from poised, to primed to active. Therefore, different chromatin occupancy features may 
be indicative of enhancer state, and potentially help distinguish the degree of activation of 
enhancers and their target genes.  
4.1.1 RNAPII modifications and gene states 
RNAPII states of activation are deeply characterized at coding genes. RNAPII can be post-
translationally modified on its C-terminal domain (CTD) and these modifications act as 
recruitment platform for chromatin remodellers and RNA maturation machineries. These in turn 
shape the chromatin environment and the state of maturation of RNA at each transcription event. 
RNAPII is recruited at promoters by TFs. It binds in an unphosphorylated form and it is sub-
sequentially modified in its Serine residues. First, the phosphorylation of Serine-5 residues (S5p) 
causes the transition to transcription initiation. At this stage, RNAPII pauses and it is released 
from the promoter only after the phosphorylation in Serine-7 and Serine-2 to starts transcription 
elongation (Brookes and Pombo, 2009). Therefore, RNAPII can be found in different activation 
states at genes, which are linked to the state of the gene. 
Genes can be in different states, such as inactive, when RNAPII is not bound and no mRNA is 
expressed, or active, when RNAPII is bound and elongating and fully mature RNA is 
transcribed. However other gene states exist, such as the Polycomb-repressed state, where 
RNAPII phosphorylated in Ser5 is present at the gene promoter together with Polycomb 
repressive complexes. Most Polycomb repressed genes in ESCs exist in a poised state, are lowly 
to not express and are linked with development and signalling (Brookes et al., 2012; Stock et al., 
2007) and often encode for TFs important in other lineages in differentiated cells (Ferrai et al., 
2017). RNAPII at Polycomb-repressed genes is not recognized by an antibody that binds 
unpshophorylated S2 (RNAPIIS2u, 8WG16ab), which recognizes RNAPII at promoter of active 
gene simultaneously recognized by RNAPII-S5p antibody. This suggests that poised RNAPII at 
Polycomb-repressed genes is in a special configuration and/or with a new, yet to identify 
modifications that could interfere with the binding of 8WG16 antibody to unmodified S2 
residues (Brookes and Pombo, 2012).  
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Although eRNA transcription has been used to identify regulatory regions (Andersson et al., 
2014a; Arner et al., 2015; Henriques et al., 2018; Mikhaylichenko et al., 2018), the state of 
activation of RNAPII has not yet been investigated at enhancers. It remains to be understood 
how many regulatory regions are bound by RNAPII, whether RNAPII exists in a different states 
of activation at enhancers and if enhancers bound by RNAPII have different functions compared 
to regions not bound by RNAPII.  
4.2 Aim of the chapter 
The presence of RNAPII at regulatory regions and the reported correlation between transcription 
at enhancer and at genes raises some interesting questions. Is RNAPII present in different states 
of activation at enhancers? Do RNAPII activations states inform about enhancer states? To 
answer these questions, I explored the state of RNAPII at published enhancers and the relation 
with enhancer activation state. Transcription and its regulation at extragenic regions will be 
investigated in Chapter 5.  
In the current chapter, I consider the previously characterized RNAPII activation states at coding 
regions, and investigate their presence at enhancer regions previously defined in Whyte et al. 
2013 (Whyte et al., 2013) (Scheme of the chapter Fig 4.1). Furthermore, I sub classified the 
Whyte enhancers according to RNAPII state and analyse their chromatin marks. Together, the 
results in the current chapter show that RNAPII exists in different activation states at regulatory 
regions, which reflect enhancer activation states and suggest that RNAPII occupancy at 
extragenic regions can be used as a feature to identify enhancers and infer their state. 
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Fig 4.1: Scheme representing the open questions on RNAPII state at transcriptionally active and inactive enhancers compared to 
active and Polycomb-repressed genes. On the right are represented genes in two states: active and polycomb repressed. Below the 
bars represent the enrichment of RNAPII modifications and the Polycomb marks H3K27me3 along the gene body. On the left are 
represented enhancer regions in an active transcribing state and in a not transcribing state. Curved arrows represent chromatin 
loops. Question marks depict open questions in the field. 
4.3 Contribution disclosure  
Elena Torlai Triglia processed all the RNAPII datasets and calculated the peaks of occupancy 
presented in this chapter. Elena Torlai Triglia and Alexander Kukalev processed other additional 
datasets used in the current chapter, when specified.  
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4.4 Results 
4.4.1 Choice of enhancer lists 
In the previous chapter, I showed how heterogeneous is the landscape of enhancers in mESC. I 
also showed enhancer regions are not only characterized by the presence of specific enhancer 
marks and TFs, but also often co-occupied by RNAPII. Different RNAPII modifications were 
present at regulatory regions, which prompted me to explore the state of activation of RNAPII at 
enhancers. To explore the activation state and role of RNAPII at enhancers, I focused on the 
Whyte list, where enhancers were defined as co-bound regions of Nanog, Sox2, and Oct4 
(Whyte et al., 2013). TFs are understood as the core mediators of enhancer function and known 
to directly or indirectly recruit RNAPII to chromatin. 
Other enhancer lists which were partially analysed were obtained from: Arner et al. 2015 (Arner 
et al., 2015), Chen et al. 2012 (Chen et al., 2012), Creyghton et al. 2010 (Creyghton et al., 2010), 
Zetner et al. 2011 (Zentner et al., 2011). The results were in general concordant, with some 
exceptions acknowledged in the text and in the discussion. Cruz Molina and Pradeepa lists are 
not presented in this chapter, as they were published after the work presented here had been 
conducted, and not repeated due to time constraints. 
4.4.2 RNAPII datasets used in the current chapter 
To investigate the presence and state of activation of RNAPII at enhancer regions, I investigated 
RNAPII best-known post-translational modifications, namely phosphorylation of Serine residues 
2, 5 and 7 present in RNAPII’s CTD (abbreviated here as S2p, S5p and S7p). Post-translational 
phosphorylation of RNAPII’s CTD has been previously studied in detail and characterize 
RNAPII’s state of activation during initiation, pausing and productive elongation at coding 
regions (Brookes et al., 2012; Ferrai et al., 2017). I analysed S5p, mark of transcription initiation, 
S7p, mark of transition from initiation to productive elongation, and Ser2p, mark of fully 
elongating RNAPII. S5p is also found at poised genes together with the Polycomb marks 
H3K27me3 and H2AK119ub1 (Brookes et al., 2012; Ferrai et al., 2017; Stock et al., 2007). I 
also analysed the presence of RNAPII complexes recognised by the 8WG16 antibody, which has 
a preference for unphosphorylated Serine 2 residues (called here RNAPIIS2u) (Fig 4.2a). The 
8WG16 antibody identifies RNAPII present at the promoters of active genes, and it does not 
bind to the poised RNAPII complexes found at Polycomb repressed genes (Brookes et al., 2012; 
Ferrai et al., 2017; Stock et al., 2007). These four RNAPII datasets for different post-
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translational modification states enable the identification of different states of RNAPII activation 
at regulatory regions: from poised, to initiating, to fully elongating RNAPII. 
 
Fig 4.2: RNAPII datasets used in the current chapter. Scheme representing RNAPII-CTD phosphorylation and the antibody used 
in the current chapter. RBP1 subunit is depicted together with the CTD, composed of heptapeptides repeats. Circles with P 
represent phosphorilations. Ab clones are specified in the drawing. 
Table 4.1 summarizes the RNAPII ChIP-seq datasets used here. Data was downloaded from 
GEO, remapped for consistency and duplicated reads were removed. To identify the genomic 
regions positively occupied by each RNAPII modification, datasets were analysed with Bayesian 
Change-Point (BCP) peak finder (Xing et al., 2012), using Mock IP dataset as control, in histone 
mark (HM) mode. Processed datasets and lists of positive windows (peaks) were available at the 
onset of this project, and previously processed by Elena Torlai Triglia. BCP is one of the 
preferred peak finders currently available as it performs well with both narrow and broad 
chromatin occupancy (Harmanci et al., 2014; Thomas et al., 2017). 
 
Table 4 1: RNAPII datasets used in the current chapter. List of the RNAPII modifications used in the current chapter. RNAPII 
peaks were calculated by Dr Elena Torlai Triglia. 
 
4.4.3 Strategy to classify extra-genic enhancers according to RNAPII 
occupancy 
To eliminate the confounding effects of RNAPII roles in genic transcription, I subclassified the 
Whyte enhancer list in intragenic and extragenic regions. Intragenic regions were defined as the 
regions inside annotated genes (RefSeq genes (O'Leary et al., 2016)), the 2kb region upstream 
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from annotated transcription start sites (TSSs) and any RNAPII peaks that contiguously extended 
beyond annotated coding regions, ie beyond the polyA site, or transcript end site (TES) 
(Schematic in Fig 4.3a). Regions beyond the TES are excluded to consider the imprecise 
termination of genic transcription which extends beyond the polyadenylation site (Proudfoot, 
2016). In mESCs, I found that RNAPII can readthrough beyond the TES for up to 11kb (For an 
analysis on how long the RNAPII peaks can extrude the TES please refer to Appendix Fig 4.A1). 
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Fig 4.3: Strategy to classify RNAPII modifications at enhancers. a) Scheme representing the strategy to define extragenic 
enhancers. Enhancer overlapping a gene, in a 2kb window upstream a TSS or overlapping a RNAPII peak transcribing a gene are 
considered intragenic and are filtered out in this study. Black box: gene, the arrow indicates the TSS and the direction of 
transcription; grey box: RNAPII peak; blue box: Whyte enhancers. X on top of a blue box signifies that the enhancers is 
considered intragenic and was not analysed further. Dark shaded regions: intragenic regions. Light shaded regions: extragenic 
regions. b) Example of long enhancer regions with RNAPII local peaks. ChIP-seq read counts per RNAPII modification are 
shown. Transparent blue boxes highlight regions inside the enhancer with an RNAPII peak. Image generated with the IGV 
software. c) Scheme of the classification pipeline. On the left: schematic of the approach used to calculate the extragenic 
enhancers positive regions. Green line represent the maximal enrichment of ChIP-seq reads at extragenic regions; red line 
represents the maximal enrichment of ChIP-seq reads at extragenic regions positive for a called peak for the modification; grey 
dashed line represent maximal enrichment of ChIP-seq reads at 30 randomly permutated extragenic regions. Black vertical 
dashed line represents the 5% false positive cut-off used to define positive regions. Transparent blue box represent the regions 
positive for the modification. On the right: steps to classify every regions for each RNAPII modification considered. 
The remaining genomic regions were considered as extragenic enhancers, which were therefore 
confidently annotated for the presence of the RNAPII modification of interest, without the 
confounding effect of transcription from annotated genes. Of note, annotated lncRNA regions 
were not used as exclusion regions in this analysis, because some annotated lincRNAs regions 
were shown to have enhancer function (Orom et al., 2010; Paralkar et al., 2016). 
To classify extragenic Whyte enhancers according to the presence of the RNAPII modifications 
considered here, I calculated the enrichment for each specific modification at the enhancer 
regions. A visual investigation of Whyte regions on the UCSC genome browser showed that 
RNAPII peaks overlapping the Whyte enhancers can cover broad regions with non-homogenous 
RNAPII coverage (Fig 4.3b), which was taken into account in the classification strategy.  
The classification strategy of RNAPII occupancy at enhancers was performed separately for each 
RNAPII modification as follows (Scheme of the classification approach can be found in Fig 
4.3c). First, Whyte enhancers in extragenic regions were identified. Second, extragenic regions 
were classified as positive or negative for overlap with RNAPII peaks. Third, the enrichment of 
reads in extragenic enhancer region was calculated. Extragenic enhancer regions longer than 
3000bp were divided in bins of 3000bp, and the RNAPII enrichment was calculated per bin and 
the maximum enrichment was used in the following steps. Fifth, the enrichment for each 
RNAPII modification was also calculated at randomly shuffled extragenic regions with the same 
length as the Whyte enhancer regions; shuffling was repeated 30 times. Sixth, the length-
normalized region enrichment (total number of reads of the largest enrichment divided by the 
length of the region) is plotted as a density at both enhancer regions and the random regions. The 
densities of all random regions are calculated singularly and merged for plotting to improve the 
statistical power of the random shuffling. Seventh, a 5% False Positive cut-off is calculated 
considering the top 5% random regions enrichment. All enhancer regions with length-normalized 
enrichment above the threshold were defined as positive for the specific modification. Steps 
from 3 to 6 were applied both to all extragenic enhancer regions and to extragenic enhancer 
regions positive for overlap with RNAPII peaks calculated in the second step. Different cut-off 
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settings were tested and 5% False Positive cut-off was chosen as it yielded a reasonable number 
of RNAPII-positive enhancers, while maintaining a low number of positive random regions. 
After these steps, the extragenic Whyte enhancer regions were classified as positive for each 
RNAPII modification in two different ways: a “conservative” classification, where extragenic 
enhancer regions are considered positive for a RNAPII modification if they overlap with a BCP 
peak for that RNAPII modification with enrichment over the 5% cut-off; and, a “liberal” 
classification where extragenic enhancer regions are considered positive for a RNAPII 
modification if they are enriched over the 5% cut-off, irrespectively of an overlap with a BCP 
peak. 
4.4.4 Classification of Whyte enhancers with RNAPII datasets 
Using the approach explained in the previous paragraph, I classified the extragenic Whyte 
enhancers for RNAPIIS5p, RNAPIIS2u, RNAPIIS7p and RNAPIIS2p datasets (Fig 4.4a). Most 
enhancer regions (60%) were found to be positive for RNAPIIS5p or RNAPIIS2u, and fewer 
were positive for Ser7p (37%) and Ser2p (23%). 20% of the time extragenic Whyte enhancers 
overlapped with an RNAPII BCP peak, however the enrichment was below the 5% threshold 
calculated (Table with all the numbers per region and modification in Fig 4.4b). 
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Fig 4.4: Classification of Whyte enhancer. a) Profiles used for the classification of Whyte enhancers for the four RNAPII 
modifications considered. The blue line represents the maximum ChIP-seq enrichment at all extragenic Whyte enhancer regions. 
The red line represents the maximum ChIP-seq enrichment at Whyte extragenic enhancer regions positive for the consider mark. 
The grey dotted line represent the maximum ChIP-seq enrichment at 30 randomly permuted extragenic regions. The vertical 
dotted line represent the 5% false positive cut-off used to define positive regions. Transparent blue box represent the regions 
positive for the modification. b) Table with numbers of regions above and below the computed cut-off, for all enhancers and peak 
finder (BCP) positive enhancers. In green: highlighted the regions above cut-off among all extragenic Whyte enhancer regions. In 
red: highlighted the regions above the cut-off among extragenic Whyte enhancer positive for the RNAPII peak. 
Before exploring the different state of activation of RNAPII at extragenic enhancers, I wanted to 
understand in what way the two classifications differed and with which one to proceed further in 
the analysis. 
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4.4.5 Differences between liberal and conservative classification 
approach 
To understand the differences between the liberal and the conservative classification approaches, 
I analysed the regions classified differently on a genome browser (Fig 4.5a). For example (Fig. 
4.5a left), the liberal approach detected an enrichment on S2p in an enhancer region, which was 
missed by the peak caller. This kind of discrepancy is probably due to the fact that the BCP peak 
caller used on the RNAPII datasets takes the local background into consideration, calculated in 
this case over the control MockIP dataset. Liberal classification, on the other hand, takes into 
consideration only the background of random regions in the genome. In another example (Fig 
4.5a, right), RNAPII enrichment region can lie outside the enhancer region, while the tail 
protrudes inside it. In this case, the conservative approach would see the region positive for the 
mark, while the liberal approach would miss it. 
 
 
Fig 4.5: Example of discrepancy between liberal and conservative classification. The snapshots show single enhancer regions on 
the genome browser. On top the classification resulting from the two approaches is specified. In colour: modification present in 
one classification and not in the other. The star indicates the feature classified differently between the approaches: red star – 
positive region for that modification in liberal classification and negative in conservative classification; blue star - positive region 
for that feature in the conservative and negative in the liberal classification. Black bars underneath reads are peaks of the specific 
feature. Images obtain with UCSC genome browser. 
After a thorough investigation of numerous regions with discrepancies between the two 
classifications, I decided to proceed with the conservative lists. This choice influences the 
number of positive regions and the statistical power, but gives us confidence on the classification 
of RNAPII states and the following results. All the analyses presented in the following chapter 
were also performed on the liberal list and were in general in accordance with the conservative 
Figure 4.5
Examples of discrepancies between conservative and liberal classification
Enhancers
RNAPII S2u
peak
peak
peak
peak
RNAPII S5p
RNAPII S7p
RNAPII S2p
Conservative
Liberal RNAPII S2u-S5p
RNAPII S2u-S5p-S7p
RNAPII S2u-S5p-S7p-S2p
RNAPII S2u-S5p-S7p
*
*
  
102 
list. In conclusion, I developed a strategy to categorise enhancer lists into extragenic or 
intragenic and to classify them for RNAPII modifications. 
4.4.6 Whyte enhancers through the RNAPII classification pipeline 
The proportion of extragenic enhancers in the Whyte list is 30% of the total (Fig 4.6a), which is 
consistent with analysis on other lists, such as Chen et al. 2012 (Chen et al., 2012)and Arner et 
al. 2015 (Arner et al., 2015)(data not shown). Of the 2628 extragenic Whyte enhancers, 840 
(32%) are co-occupied by at least one form of RNAPII, while 1788 (68%) are not bound by any 
of the RNAPII marks considered here. 
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Fig 4.6:  Whyte enhancers through the classification pipeline. a) Graph showing the number of Whyte enhancers per step of the 
pipeline. Whyte enhancers are first subdivided in intragenic and extragenic regions and extragenic regions are classified as 
positive of negative for RNAII presence. Blue arrows indicate the path to the regions selected to be further investigated in this 
study. b) Percentage of each RNAPII modification at Whyte extragenic enhancers. On the x-axis: RNAPII modification. On the 
y-axis: percentage of extragenic Whyte enhancers positive for that modification. Blue bars represent Whyte enhancers. Grey bars 
represent extragenic permutated regions. Error bars are computed on randomly permuted regions classification and indicate 
standard deviation.  
All RNAPI modifications were from present at extragenic Whyte enhancers above random. The 
most represented RNAPII dataset at extragenic Whyte enhancers is RNAPIIS2u (28% of 
extragenic enhancers), followed by (20% of extragenic enhancers), RNAPIIS7p (11% of 
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extragenic enhancers) and RNAPIIS2p (7% of extragenic enhancers) (Fig 4.6b). Similar 
proportions were found at extragenic Whyte enhancers classified with the liberal approach 
(Appendix Fig 4.A2a). After classifying all extragenic Whyte enhancer regions for the presence 
or absence of RNAPII modifications, I moved forward to classify the different states of RNAPII 
at extragenic Whyte enhancers. 
4.4.7 RNAPII is found in different activation states at extragenic 
Whyte enhancers 
To understand the states of RNAPII at regulatory regions, I proceeded analysing the different 
combinations of RNAPII modifications found at extragenic Whyte enhancers. I found different 
RNAPII states, among which the most represented states of RNAPII are: Only RNAPIIS2u 
(258), RNAPIIS2u-S5p-S7p (198), RNAPIIS2u-S5p (168), Only RNAPIIS5p (96), RNAPIIS2u-
S5p-S7p-S2p (83) (Fig 4.7a). Other less abundant categories were not considered further, as they 
comprise 5% of the total RNAPII-bound extragenic Whyte enhancers. I also briefly explored 
regions positive for RNAPIIS2u-S7p (20) in the genome browser to understand if they could be 
added to one of the above mentioned classes, in case they fell just below the 5% FP threshold of 
RNAPIIS5p detection. However, these regions were very mixed and were therefore not 
considered further. 
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Fig 4.7: RNAPII is present in different states at extragenic Whyte enhancers. a) Plot showing all the combinations of RNAPII 
modifications at extragenic Whyte enhancers. On the y-axis: RNAPII combinations. On the x-axis: percentage of extragenic 
Whyte enhancers. Blue bars represent Whyte enhancers. Grey bars represent extragenic permutated regions. Error bars are 
computed on randomly permuted regions classification and indicate standard deviation. b) Enhancer classes selected for further 
study. On the x-axis: state of RNAPII. On the y-axis: number of regions. Blue bars represent extragenic Whyte enhancers bound 
by RNAPII.  Green bar represent extragenic Whyte enhancers not bound by RNAPII. Grey bars represent extragenic permutated 
regions. Error bars are computed on randomly permuted regions classification and indicate standard deviation. c) Enrichment of 
unphosphorylated Ser2 at RNAPII-bound enhancers, divided by RNAPII state. Average count: number of ChIP-seq reads per 
region divided by the region length. Log values are shown for clarity. A pseudo count equivalent to the minimum value not equal 
to 0, divided by 10 was added, to avoid log of 0. Random regions are randomly permuted extragenic regions. d) Enrichment of 
MockIP at RNAPII-bound enhancers, divided by RNAPII state. Average count: number of ChIP-seq reads per region divided by 
the region length. Log values are shown for clarity. A pseudo count equivalent to the minimum value not equal to 0, divided by 
10 was added, to avoid log of 0. Random regions are randomly permuted extragenic regions.  
The RNAPII states selected at extragenic enhancers are similar to the ones described at genes: 
from RNAPIIS5p, associated with poised genes, to the fully elongating state with RNAPIIS2u-
S5p-S7p-S2p. Noticeably, I find also regions marked by RNAPIIS2u alone (Fig 4.7b), which is 
not a common RNAPII state at genes where only 38/18860 gene promoters were marked by 
RNAPIIS2u along (Brookes et al., 2012). This result is consistent across different published 
enhancer lists (Appendix Fig 4.A2b). As a side note, while the classes recovered at other lists are 
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the same, the proportion between them varies. This is most probably a reflection of the states of 
the enhancers in each list: Arner enhancers, which are mainly co-occupied by elongation 
RNAPII or RNAPII transitioning to elongation (Appendix Fig 4.A2b), are defined as transcribed 
regions outside promoters identified by CAGE tags. These differences between proportions of 
classes linked with the specificity of the enhancer lists could suggest a relationship between the 
enhancer state and the RNAPII state. 
To understand whether the state of activation of RNAPII is also linked with increased RNAPII 
recruitment at extragenic enhancer regions, I analysed the enrichment of RNAPIIS2u. RNAPII-
bound enhancers are progressively more enriched for RNAPIIS2u, the more active is the state of 
RNAPII (Fig 4.7c). Importantly, this gradual increase in RNAPIIS2u occupancy is not reflected 
in the Mock-IP datasets, suggesting that it is not a secondary effect of open chromatin (Fig 4.7d), 
but connected with the state of RNAPII at extragenic enhancers. 
Taken together, the results show that RNAPII binds in different states of activation to a subset of 
extragenic enhancers, and these states resemble the ones previously descried at genes, suggesting 
that RNAPII transcription at enhancers may be controlled by similar regulatory mechanisms as at 
genes. Moreover, RNAPII binds enhancers at increasing levels concordant with RNAPII 
activation state. 
4.4.8 RNAPII-bound enhancers are associated with early 
development genes and negative regulators of differentiation 
To investigate differences between extragenic Whyte enhancers bound or not bound by RNAPII, 
I first analysed their putative target genes. As a first approximation, I used the GREAT software 
(McLean et al., 2010), which performs Gene Ontology (GO) analysis based on the closest genes 
to the enhancers of reference. This is an approximation, as enhancer targets can be found very far 
away from their target genes with other genes occurring between them (Arner et al., 2015; 
Lettice et al., 2018). Interestingly, enhancers bound by RNAPII and enhancers not bound by 
RNAPII show a different enrichment in biological process’ GO terms. Enhancers bound by 
RNAPII have more terms of related to stem cells maintenance and negative regulators of 
differentiation, while enhancers without RNAPII are more associated with genes related with 
positive regulation of differentiation, and therefore with genes that might be primed for 
activation but not yet active (Fig 4.8a). 
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Fig 4.8: RNAPII bound enhancers are associated more with genes involved in stem cell maintenance. GO analysis at RNAPII-
bound and RNAPII not-bound enhancers. On top in blue: enhancers bound by RNAPII. On bottom in green: enhancers not bound 
by RNAPII. Analysis performed with the GREAT software with standard parameters and whole genome as background. Yellow 
circles: highlighted terms that refer to stem cells and negative regulator of differentiation.  
This analysis highlights differences wbetween enhancers bound by RNAPII and enhancers not 
bound by RNAPII which are likely to have biological relevance, and which may allow more 
robust categorization of functional enhancers in a give cell type or differentiation stage. It 
suggests that enhancers bound by RNAPII could be more active in mESC than the ones not 
bound by RNAPII, but still occupied by Sox2, Nanog, and Oct4.  
4.4.9 RNAPII-bound enhancers have diverse features related with 
RNAPII state 
To explore whether specific classes of RNAPII-bound enhancers might show different 
properties, I first inspected single enhancer regions in the genome browser (Fig 4.9a). Extragenic 
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Whyte enhancers are bound by TFs, as expected, and show a broad enrichment for H3K4me1, 
which marks all classes of enhancers. Other accepted enhancer marks are present to different 
extents. For example, the more RNAPII is active (i.e. marked not only by S5p but also S7p and 
S2p), the more H3K27ac, Med1, and P300 occupancy increases.  
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Fig 4.9: RNAPII-bound enhancers show diverse features. a) UCSC tracks of single Whyte extragenic enhancers classified for 
RNAPII state. Enhancer classes are order from enhancers not bound by RNAPII to enhancers bound by the most active RNAPII. 
Combinations of the RNAPII states are indicated on the top. On the left: name of the mark of the track. Black boxes on the 
bottom are enhancer regions. b) Average depth per nucleotide of RNAPII modification enrichment at different classes of 
RNAPII-bound enhancers and their surroundings. On top of each graph: ChIP-seq dataset analysed. Every line represents the 
average read count per class of enhancer. 
To quantify the enrichment of each RNAPII modification at each group of enhancer classified 
according to the presence or absence of different RNAPII modifications, I next calculated the 
average enrichment after normalizing enhancer length. Enrichment of RNAPII per region was 
calculated at the nucleotide levels and averaged among the classes. Interestingly, RNAPII levels 
of occupancy vary across classes, and RNAPII is increasingly found to expand beyond the 
Whyte enhancer coordinates the more active its state is (Fig 4.9b). For example, enhancers 
marked by all RNAPII marks studied here, also show higher enrichment in S5p and S2p across 
all classes, and S2p clearly expands beyond the coordinates of the Whyte enhancers, possibly 
indicating a transcribing RNAPII.  This trend is especially evident for RNAPIIS5p and 
RNAPIIS2u, but also holds true for RNAPIIS7p and RNAPIIS2p. Next, I investigated the length 
of enhancers marked by RNAPII modifications increasingly associated with productive 
transcription (Fig 4.10a), and found that RNAPII-bound enhancers tend to be longer than 
unbound ones, and interestingly that Whyte enhancers associated with fully activated RNAPII 
(S2p and/or S7p) tend to be the longest. To test whether these differences in RNAPII activation 
and enhancer window length were also reflected in the genomic location of extragenic enhancer 
classes relative to candidate target genes, I analysed their distance to the closest gene.  I found 
that enhancers are located both upstream and downstream the closest genes with no noticeable 
differences per class (not shown), with the majority separated by around 10-50kb from the 
nearest gene (333/803) (Fig 4.10b). There is a 2-5kb tendency for enhancers associated with 
elongating forms of RNAPII to be closer to their target genes. Interestingly, enhancers can be 
located up to 100kb from the closest gene and this feature is common for all the differently 
classified enhancers (173/803). On the genomic level, different classes of enhancers do not show 
any obvious position difference (Appendix Fig 4.A3). 
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Fig 4.10: Features of RNAPII-bound extragenic Whyte enhancers. a) Length distribution of extragenic Whyte enhancers divided 
by RNAPII class. On x-axis: combinations of RNAPII modification at enhancers specified. On the y-axis: length, expressed in 
kilo bases. p-value calculated with Wilcoxon test. b) Gene distance distribution of extragenic Whyte enhancers. On bottom 
enhancer classes are specified. Distances are binned in: 2-5kb from the closest gene; 5-10kb from the closest gene; 10-50kb from 
the closest gene; 50-100kb from the closest gene; >100 kb from the closest gene. On the y-axis: fraction of enhancers in bin. 
Taken together, these results show that subdividing enhancers according to RNAPII activation 
state provides further hints of their biological roles, that these classes have specific 
characteristics, in terms of enhancer length and occupancy. The observation that RNAPII-bound 
enhancers tend to be longer with increased RNAPII activation state with higher RNAPII 
enrichment suggest that these longer enhancer regions may build a specific chromatin 
environment. 
4.4.10 RNAPII activation state at enhancers reflects their activation 
states defined by TF and histone marks 
To test whether RNAPII-bound enhancers have diverse enrichment for enhancer features and 
whether these differences are associated with specific RNAPII activation states, I first analysed 
the presence of features commonly accepted to mark enhancer regions. I considered: Nanog, 
Sox2 and Oct4, which are the mESC TFs used in defining enhancers in the Whyte list; 
H3K4me1, which marks enhancers irrespectively of activation state (primed, poised and active); 
P300, which is the enzyme responsible for H3K27 acetylation and marks primed enhancers 
converting to active and; H3K27ac, whose levels are positively associated with enhancer activity 
(Creyghton et al., 2010; Hnisz et al., 2013). Heatmap representation of TF, H3K4me1, p300 and 
H3K27ac ChIP-seq occupancy centred on length normalized extragenic Whyte enhancer regions 
(Fig 4.11a) show that transcription factors are enriched at all extragenic Whyte enhancer regions, 
independently of RNAPII presence, with a slight preference for RNAPII-bound enhancer regions 
(Fig 4.11b) TF binding is detected preferentially inside the defined enhancer regions, as expected 
from their original definition (Whyte et al., 2013). Interestingly, RNAPIIS2u has the lowest 
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enrichment for Nanog and Oct4 among the RNAPII-bound classes, while comparable levels of 
Oct4. This difference may be due to Oct4 binding before the other factors to prime the region 
and could suggest that these enhancers are less active compared to other RNAPII-bound 
enhancers. In contrast, H3K4me1 spreads over the enhancer region, and is enriched at their 
boundaries, with lowest overall enrichment at enhancers not bound by RNAPII and increased 
enrichment with RNAPII activation state. These observations suggest that RNAPII presence may 
help distinguish enhancer activation states. P300 and H3K27ac, on the other hand, show a 
preferential enrichment for RNAPII-bound enhancers (Fig 4.11a,c). RNAPII states associated 
with productive transcription at active genes (RNAPIIS2u-S5p, RNAPIIS2u-S5p-S7p, 
RNAPIIS2u-S5p-S7p-S2p) are significantly more often enriched for P300 than less active 
configurations of RNAPII (RNAPIIS2u or RNAPIIS5p alone).  
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Fig 4 .11: RNAPII state at extragenic enhancers reflect their activation state. a) Positional heatmaps of TFs and enhancer marks 
at different classes of RNAPII-bound enhancers and +/- 2kb. Darkblue: stronger enrichment, white: lower enrichment. Heatmap 
generated with deeptools. b) Absolute enrichment of TFs at enhancer regions divided by RNAPII state. Average count: number 
of ChIP-seq reads per region divided by the region length. On the x-axis: RNAPII modification combiantions. On the y-axis: 
average count of ChIP-seq reads. Log values are shown for clarity. A pseudo count equivalent to the minimum value not equal to 
0, divided by 10 was added, to avoid log of 0. Random regions are randomly permuted extragenic regions. p-value calculated 
with Wilcoxon test. c) Absolute enrichment of enhancer features at enhancer regions divided by RNAPII state. Average count: 
number of ChIP-seq reads per region divided by the region length. On the x-axis: RNAPII modification combinations. On the y-
axis: average count of ChIP-seq reads. Log values are shown for clarity. A pseudo count equivalent to the minimum value not 
equal to 0, divided by 10 was added, to avoid log of 0. Random regions are randomly permuted extragenic regions. p-value 
calculated with Wilcoxon test. 
Taken together these results show how RNAPII-bound enhancers have specific properties, which 
are linked with enhancer states. The incremental occupancy of H3K27ac and the differential 
enrichment of P300 strongly suggest that the state of activation of RNAPII mirrors the state of 
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activation of enhancers. TF binding alone would not be enough to clearly distinguish these 
properties that are captured by RNAPII states. Enhancers bound by RNAPII show typical 
enhancers marks. Importantly, marks associated with enhancer activation states are differentially 
enriched at enhancers with more active RNAPII, suggesting that not only the presence of 
RNAPII, but also its state of activation, is linked with the enhancer activation state. 
4.4.11 RNAPII-bound enhancers show diverse feature enrichment for 
RNAPII state 
In the previous section, I found that RNAPII states at enhancers are linked with enhancer state, 
based on well-established enhancer chromatin marks. To understand whether RNAPII state at 
extragenic Whyte enhancers is linked with other features, I analysed different factors and histone 
marks. RNAPII-bound enhancers have higher enrichments for marks linked with active 
chromatin, such as H3K9ac and TFs, compared to unbound enhancers (Fig 4.12a). However, 
other features are similarly enriched at Whyte enhancers irrespectively of RNAPII occupancy 
and activation state; for example CTCF, H3K36me3, and repressive marks such as H3K9me3 
and H3K27me3, are not specifically enriched. Smad1, instead, shows an interesting trend, being 
more enriched at regions marked by RNAPIIS5p alone, but not the other RNAPII marks 
associated with productive transcript. 
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Fig 4.12: RNAPII-bound regions show diverse feature enrichment. Heatmap showing relative average enrichment (percentile of 
enrichment) per class of RNAPII-bound enhancers of HMs, TFs, and structural proteins at RNAPII bound enhancers. Relative 
average enrichment was calculated as the mean of the normalised enrichment per class, for comparison purposes. Red: higher 
relative enrichment; light blue: lower relative enrichment. Classes of enhancers are specified at the bottom of the graph.  
Active RNAPII states at extragenic enhancers are associated with increase TF occupancy, such 
as E2f1 and Klf4. Interestingly, factors connected with chromatin architecture, Med1, Caph2, 
Nipbl, are also increasingly enriched at extragenic Whyte enhancers with increased RNAPII 
activation state. This could be indicative of an involvement of these regions in chromatin 
contacts. Interestingly, CTCF is depleted at these regions.  
It is also noteworthy that the enhancers marked only by RNAPIIS2u and RNAPIIS5p classes 
show different behaviours from the enhancer regions associated with increasing states of 
RNAPII activation. Not only P300 is differently enriched between RNAPIIS2u and 
RNAPPIIS5p compared to the other RNAPII-bound classes of extragenic enhancers, but also 
other factors show this behaviour, such as Brd4 and Caph2. This suggests again the existence of 
differences between enhancers bound by primed or active RNAPII configurations. 
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In conclusion, these analyses show that RNAPII is present at different states of activation at 
enhancers, which mirror the enhancer activation state. Moreover, the state of the RNAPII 
modification dissects the chromatin state of enhancer activation, a distinction missed by Nanog, 
Sox2, and Oct4 occupancy. 
4.4.12 Active states of RNAPII are found at super enhancer regions 
The Whyte enhancer list contains normal enhancers and super-enhancers (SE), which were 
shown to be the most active among all the enhancers in a cell type (Hnisz et al., 2013; Whyte et 
al., 2013). SE comprise only a small proportion of the extragenic enhancer regions selected 
(40/2628). To understand whether SE have a preferential RNAPII state, I investigated them 
separately. First, I have classified them for RNAPII state, and I have analysed the enrichment for 
enhancer marks at these regions. 
SEs are associated with active states of RNAPII, with 77% (31/40) of the SE regions bound by 
RNAPII either in fully elongating, RNAPIIS2p form, or transitioning to elongating, and marked 
by RNAPIIS7p (Fig 4.13a). Only 2 of the extragenic SEs are not bound by RNAPII. 
Interestingly, RNAPIIS5p alone is not found at SEs, which may imply that SEs are not in a 
poised or repressed state.  Additionally, SE are enriched in RNAPII and enhancer marks (Fig 
4.13b), which is in accordance with the previous results in the current chapter, were regions with 
active RNAPII are more enriched for active chromatin marks. 
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Fig 4.13: Super enhancers are bound by active RNAPII. a) Pie chart showing the proportion of extragenic SE classified with 
different forms of RNAPII. Numbers of extragenic SE per class are indicated. b) Absolute enrichment RNAPIIS2u, H3K4me1, 
H3K27ac at enhancer regions divided by RNAPII state and SE. Average count: number of ChIP-seq reads per region divided by 
the region length. On the x-axis: RNAPII modification combinations. On the y-axis: average count of ChIP-seq reads. Log values 
are shown for clarity. A pseudo count equivalent to the minimum value not equal to 0, divided by 10 was added, to avoid log of 
0. Random regions are randomly permuted extragenic regions. p-value calculated with Wilcoxon test. 
4.4.13 RNAPII occupancy distinguishes enhancers and super 
enhancers 
Whyte et al. 2013 (Whyte et al., 2013) and Hnisz et al. 2013 (Hnisz et al., 2013) showed that 
Med1 and H3K27ac are more enriched at SEs compared to normal enhancers and their 
enrichment can be used as a proxy to identify SEs. To test whether RNAPII occupancy alone can 
distinguish SEs from normal enhancers, I compared ChIP-seq enrichment of all RNAPII forms 
considered, as well as RNAPIIK7me1 and RNAPIIK7me2, in all the enhancer regions ranked 
according to the same enrichment. RNAPIIK7me1 and RNAPIIK7me2 were recently described 
in the lab to mark transcription initiation (Dias et al., 2015).  
Interestingly, I found that RNAPII modifications show a similar trend to that of Med1 and 
H3K27ac (Fig 4.14a). Direct comparison with the position of the original Whyte SE list show 
that RNAPII occupancy performs as well as Med1 and H3K27ac (Fig 4.14b, red dots indicate 
originally identified SE). This analysis was conducted over the total set of Whyte enhancers, 
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including both extragenic and intragenic. It is remarkable that even in this case, RNAPII datasets 
show good performance; this was especially true for RNAPII-K7me1 and me2 (not shown and 
Fig. 4.14b, respectively). For comparison, Fig. 4.14b also shows Med1, used in Whyte et al. 
2013 (Whyte et al., 2013) to define super enhancers and H3K27ac, which shows similar ranking 
but does not exactly recapitulate Med1. 
This finding confirms that RNAPII states are linked with enhancer states and suggests that 
RNAPII modifications can be used to differentiate between normal and SEs.  
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Fig.4.14: RNAPII performs good distinguishing normal and super enhancers. a) Ranking analysis over all Whyte enhancers for 
SE factors and RNAPII modifications. Enhancers were ranked from less to more enriched for each modification. Zoom in shows 
the enrichment turning point used to distinguish normal enhancers and super enhancers. b) Ranking plot of enrichment for Med1, 
H3K27ac, RNAPIIS5p, RNAPIIK7me2. Enrichment was calculated per Whyte enhancer region and regions were ordered for 
least to most enriched, as in the original Whyte paper. In black: enhancers; in red: super enhancers defined in Whyte et al. 2013. 
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4.5 Discussion 
RNA polymerase II is responsible for the transcription of all protein-coding genes, lincRNAs, 
small RNAs and enhancer RNAs. Although its presence at regulatory regions had been observed 
before, a deep investigation of RNAPII activation states and the relationship with enhancer 
activation state was not previously conducted. 
4.5.1 RNAPII exists in different states of activation at enhancers 
In the current chapter, I investigated the state of RNAPII at enhancer regions previously defined 
based on Nanog, Sox2, and Oct4 co-occupancy (Whyte et al., 2013), and I focused on active 
enhancers. I only analysed extragenic regions to avoid confounding effects of detecting initiating 
or elongating RNAPII at promoter, coding and termination regions of genes. Interestingly, more 
than 50% of enhancer regions identified using histone marks, TFs or chromatin factors map to 
intragenic regions (data not shown), irrespectively of the list of enhancers analysed (Arner et al., 
2015; Chen et al., 2012; Creyghton et al., 2010; Zentner et al., 2011).  
To achieve highest confidence on the RNAPII presence at enhancer regions, I took into account 
that the RNAPII occupancy outside coding regions is low (De Santa et al., 2010). To this end I 
developed a classification strategy that considers the noise occupancy across the genome, with 
random permutated region and calculation of a 5% False Positive cut-off. Combined with the use 
of BCP to detect positive windows (Xing et al., 2012), the classification also considers local 
noise intrinsic of ChIP-seq experiments. BCP models the enrichment of the feature of interest 
over the enrichment of a matched control immunoprecipitation (mock immunoprecipitations, in 
the present study). The chosen approach aims to give high confidence on the classification of 
RNAPII presence, at the expense of the number of positive regions.  
RNAPII classification at extragenic enhancers showed that RNAPII is present in different states, 
from initiating RNAPIIS5p to a fully elongating one, with RNAPIIS7p and RNAPIIS2p. These 
modifications encompass the states described at genes. Interestingly, RNAPII at enhancers can 
also be found in an unphosphorylated form, RNAPIIS2u, which is uncommon at genes (Brookes 
et al., 2012).  
The same analyses presented here were also conducted using other published enhancer lists 
(Arner et al., 2015; Chen et al., 2012; Creyghton et al., 2010; Zentner et al., 2011), reaching 
similar conclusions about RNAPII presence and activation at enhancers regardless of the initial 
approach used to define enhancers. Most interestingly, the nature of features used to define each 
enhancer list influences the proportion of RNAPII-bound enhancers recovered. For example, the 
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Arner list (Arner et al., 2015) defined enhancers as regions of the genome marked by CAGE tags 
outside gene promoters, such that by definition the Arner’s enhancers are transcribed and the 
transcripts produced are at least capped. As eRNA transcription is linked with active enhancers 
(Kim et al., 2010;Kaikkonen et al., 2013), most of the Arner enhancers are bound by RNAPII 
and in an elongating form. In contrast, the Whyte enhancer list is composed of enhancers bound 
by TFs: the enhancers contained in this list are also defined as active. While the Whyte list does 
not include poised enhancers, they nevertheless present different levels of activation based on 
RNAPII states or chromatin marks. Interestingly, SEs are associated with active RNAPII state, 
which suggests a role of RNAPII state in enhancer activation. The fact that Whyte enhancers do 
not show enrichment of repressive marks is intriguing. Based on results from the previous 
chapter, it appears that TF binding differs at active and Polycomb repressed enhancers: when 
Nanog, Sox2, and Oct4 are found together, such in the case of Whyte enhancers, enhancers are 
in active state, while if only one or two are bound, enhancers are more likely to be repressed. It 
would be interesting to understand if other factors are involved in this difference and if they 
recruit chromatin remodellers. Finally, the analysis of the Chen enhancer list (Chen et al., 2012) 
showed that enrichment of H3K27me3, a mark of Polycomb repression, occurs at RNAPIIS5p 
classes of enhancers (data not shown), in line to what we know at genes (Brookes et al., 2012; 
Ferrai et al., 2017; Stock et al., 2007; Tee et al., 2014). This topic will be further investigated in 
the next chapters. 
4.5.2 RNAPII is associated with enhancers in different activation 
states 
The enhancers in the Whyte list are identified by the co-binding of Nanog, Sox2 and Oct4. By 
definition these regions are considered to be all similar and have an active state, but through the 
analyses of RNAPII, histone modifications and transcription factors occupancy, I find that not all 
enhancers in the Whyte list are the same, as they have different properties and features. 
Noticeably, RNAPII-bound Whyte enhancers are longer than unbound ones and have broader 
RNAPII peaks. Interestingly, Nanog, Sox2 and Oct4 do not have a strong differential enrichment 
at these regions, while other TFs such as E2f1 or Klf4 preferentially bind enhancers with active 
states of RNAPII and Smad1 with primed RNAPIIS5p. These differences would indicate that 
among the Whyte enhancer regions, some are more activated than the others. Based on the 
current literature, enhancer regions enriched for factors such as P300 and H3K27ac would be 
more likely to be the most active (Creyghton et al., 2010), which suggests that active RNAPII 
states mark the most active enhancers. In mESCs, enhancers bound by RNAPII are associated 
with genes related to stem cell maintenance and negative regulators of differentiation, while 
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enhancer regions not bound by RNAPII are associated with gene terms more related with early 
differentiation and exit from pluripotency. Possibly, RNAPII-bound enhancers keep the mESC 
state, while enhancers not bound by RNAPII are less active, or fluctuating within the ESC 
population, ready to differentiate. This observation suggests that enhancers in an active state can 
be further dissected in more subtle and possibly biologically meaningful subgroups. 
To understand whether different states of RNAPII can more finely dissect enhancer activation 
state, I analysed different features. H3K27ac is gradually enriched in concordance with RNAPII 
activation state and increased RNAPII occupancy levels. In 2010, Creyghton and colleagues 
(Creyghton et al., 2010) showed that enhancers are increasingly active the more H3K27ac marks 
is enriched, and in 2013 Whyte et al. 2013 (Whyte et al., 2013) showed that stretches of 
enhancers highly active have a higher enrichment for marks such as H3K27ac and Med1, with 
similar TFs binding. These results suggest that RNAPII state is indicative of enhancer activation 
state. The more RNAPII is found in an active state the more regulatory regions are occupied by 
marks associated with their activity. Active enhancers can therefore be divided in more and less 
active, according to RNAPII occupancy. Interestingly, the results of this chapter show 
differences between enhancers bound with RNAPII configurations typical of productive 
transcription at active genes (RNAPIIS2u-S5p, RNAPIIS2u-S5p-S7p, RNAPIIS2u-S5p-S7p-
S2p) and also with regions associated with paused (RNAPIIS2u) or Polycomb-poised states 
(RNAPIIS5p alone). Concordant with this observation, RNAPIIS2u and RNAPIIS5p classes of 
enhancers show an intermediate enrichment for active chromatin marks, which hints at different 
transcriptional states and potentially enhancer activity, which will be partially analysed in the 
following chapters. 
Activity at enhancers is always difficult to define: it could be the strength or the stability of 
target gene enhanced expression. It will be interesting to analyse whether different forms of 
RNAPII contribute to these effects with different mechanisms or to different degrees. 
The finding that RNAPII is present at different state of enhancers that mirror enhancer activation 
state offers a new layer in understanding enhancer activation. TF binding at enhancers is the first 
step, however it is not indicative of the state of activity of an enhancer: chromatin marks, and 
now RNAPII state, can give a deeper of understanding of enhancer activation state. 
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4.6 Figures Appendix 
 
Fig 4.A1: Distribution of RNAPII peaks length overhanging TESs in mESC. Coloured numbers represent the length below which 
75%, 80%, 85%, 90% of all RNAPII peaks are found, respectively.  Datasets of RNAPII modifications from Brookes et al. 2012. 
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Fig 4.A2: Classification of extragenic enhancers. a) Percentage of each RNAPII modification at Whyte extragenic enhancers 
classified with the liberal approach. On the x-axis: RNAPII modification. On the y-axis: percentage of extragenic Whyte 
enhancers positive for that modification. Blue bars represent Whyte enhancers. Grey bars represent extragenic permutated 
regions. Error bars are computed on randomly permuted regions classification and indicate standard deviation. b) Classification 
of enhancers from Chen et al. 2012 and Arner et al. 2015 ordered by RNAPII activation. On the x-axis: state of RNAPII. On the 
y-axis: number of regions. Purple bars represent extragenic Chen 2012 extragenic. Light red bar represent extragenic Arner 2015 
extragenic enhancers. Grey bars represent extragenic permutated regions (30 times). Error bars are computed on randomly 
permuted regions classification and indicate standard deviation. 
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Fig 4.A3: Genomic distribution of extragenic Whyte enhancers. Distribution of RNAPII-bound and not bound extragenic Whyte 
enhancers in different chromosomes. White spaces are gene dense regions with no extragenic enhancers, based on our 
classification. Each vertical line represent an enhancer location, color-coded for the enhancer class with the maximum divergent 
colours to enhance readability  
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5. Extragenic RNAPII states identify 
enhancers in different activation states 
5.1 Introduction 
In the previous chapter I studied the presence and state of activation of RNAPII at published lists 
of enhancers and found that RNAPII occupies known extragenic enhancers with different 
activation states. In the current chapter, I will identify extragenic RNAPII peaks independently 
of previous enhancer lists, and investigate their association with enhancer features, and candidate 
roles as enhancers. 
5.1.1 Approaches to identify regulatory regions 
One major challenge in the enhancer field remains the identification of putative regulatory 
regions. Numerous approaches and advances were made in recent years, and each approach 
identifies and categorises different regions (Chapter 3 for more details). On the one hand, TF 
binding is a reliable and powerful approach to identify candidate enhancer regions, with the 
requirement to produce or have access to numerous ChIP-seq datasets for several transcription 
factors important for each cell type and upon response to stimuli, including the availability of 
antibodies. However, TF binding fails to recapitulate the different states of activation of 
enhancers (Fig 4.11, see also (Hnisz et al., 2013; Whyte et al., 2013)), which in turn can be 
distinguished through the levels of occupancy of other chromatin marks, such as H3K27ac 
(Creyghton et al., 2010). Chromatin marks, on the other hand, mark very broad regions and can 
be unspecific to point the precise enhancer location (Calo and Wysocka, 2013).  
I was interested in exploring the possibility of defining enhancers and their activation state using 
a minimal number of datasets, which themselves in addition directly inform of the state of gene 
promoters and coding regions. Towards defining novel ways of identifying candidate enhancer 
regions, I explored the use of RNAPII and Polycomb datasets to dissect the state of extragenic 
regulatory regions. 
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5.1.2 Transcription regulation at genes 
RNAPII activation states are highly regulated at genes. RNAPII is post-translationally modified 
during the transcription cycle and these modifications act as recruiters for chromatin remodelers 
and RNA maturation machineries which act co-transcriptionally (Brookes and Pombo, 2009; 
Egloff and Murphy, 2008). Therefore, the state of RNAPII and its regulation influence the 
chromatin environment and the RNA products from a given gene. 
Interestingly, RNAPII phosphorylation on Ser5 at Polycomb-repressed genes is carried out by 
Erk2 kinase, instead of Cdk7 (Tee et al., 2014). Polycomb repressed genes are also regulated by 
Utf1, that on the one hand prevent the excessive spreading of PRC2 mark H3K27me3 and on the 
other recruits the de-capping machinery that regulates unnecessary RNA production from 
repressed genes (Jia et al., 2012) (Scheme of regulation at genes in Fig 5.1). It is unknown if 
these proteins are active at extragenic poised regions. 
 
Fig 5.1: Regulation of transcription at coding genes.  Scheme representing regulation of transcription at active genes (on top), and 
Polycomb Repressed genes (PRC) on bottom.  
Another interesting phenomenon is the transcription of short and unstable RNAs upstream of 
active genes  (Almada et al., 2013; Core et al., 2014; Preker et al., 2011). Even if it is still 
debated whether all active promoters are bidirectionally transcribed or only a subset, some 
interesting features were described. Transcripts produced upstream of promoters (PROMPTs) are 
usually very unstable and sensitive to exosome degradation (Preker et al., 2008), not 
polyadenylated and not spliced (Fig 5.2). These similarities of eRNAs and PROMPTs are 
currently explored in the field. 
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Fig 5.2: Antisense transcription at active genes. Scheme representing sense and antisense transcription at active promoters. 
Antisense transcripts, here defined as PROMPTs, are exosome sensitive.  
It is unknown to what degree transcription of extragenic RNAPII (RNAPII not transcribing genic 
regions) is regulated. Previous studies have shown that eRNA levels decrease after Cdk9 
inhibition through Flavopiridol, without effect on enhancer-promoter looping (Hah et al., 2013), 
and that eRNAs are sensitive to Exosome degradation (Andersson et al., 2014b).  
5.2 Aim of the chapter 
In the current chapter, I have defined extragenic RNAPII regions independently of previous 
enhancer classifications and analysed their chromatin and transcriptional state to understand to 
what extent they help to identify extragenic enhancers. The results of the current chapter show 
that extragenic RNAPII recognises new candidate regulatory regions. These regions are 
regulated at the transcriptional and the post-transcriptional levels, responding to similar 
regulators as RNAPII at genes and at other described enhancers. RNAPII is therefore a powerful 
approach to identify putative enhancers in a cell type of interest, and without further work to 
inform of enhancer activation states.  
5.3 Contribution disclosure  
Elena Torlai Triglia mapped the RNAPII and H3K27me3 datasets and calculated their peaks, 
and re-mapped Brd4, CTCF, Utf1 and Erk2 ChIP-seq datasets. Some of the datasets in the 
current chapter are unpublished, as follows: Nascent RNA-ChIP-seq in control and Flavopiridol-
treated mESCs, Total RNA after Exosome knockdown. These datasets were produced by Kelly 
J. Morris and Robert A. Beagrie. 46C Nascent RNA-ChIP untreated was mapped by Robert A. 
Beagrie. The remaining datasets were mapped by me. Exosome Dis3 ChIP-seq dataset was 
produced by Ana Miguel Fernades and analysed by Elena Torlai Triglia. Total RNA-seq datasets 
were produced by Ana Miguel Fernandes and Carmelo Ferrai and mapped by me. 
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5.4 Results 
5.4.1 Strategy to define extragenic RNAPII regions 
Inspection of ChIP-seq tracks reveals the presence of RNAPII at extragenic regions not 
previously classified as enhancers (Fig. 5.3). 
 
Fig 5.3: Extragenic RNAPII mark putative regulatory regions missed by other approaches. UCSC screenshot of extragenic 
regions. Black rectangles represent enhancers identified in Whyte et al. 2013 1, Arner et al. 2015 29, Chen et al. 2012 19. Tracks 
always show the 0 to the maximum high indicated, with a smoothing window of 2. Coloured boxes under RNAPII tracks 
represent BCP peaks for that dataset. Empty black box highlight extragenic regions marked by RNAPII and enhancer marks. 
Image generated with UCSC genome browser. 
To define extragenic RNAPII regions, I used an approach similar to the one used in Chapter 4 
and considered as extragenic all the RNAPII peaks that do not overlap with a gene or 2kb 
upstream the TSS annotated in the RefSeq list (O'Leary et al., 2016) or in the UCSC gene list 
(Casper et al., 2018) and any RNAPII peaks that do not contiguously extend beyond annotated 
coding region (Fig. 5.4a). With this approach, some intragenic regions which could potentially 
function as enhancers are not considered, but being conservative enables to explore RNAPII as 
an enhancer marker minimizing the confounding effects of non-annotated alternative 
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transcription start sites upstream of gene promoters. All regions overlapping with the ENCODE 
blacklist were also excluded from the present analysis, to remove genomic regions with 
“anomalous, unstructured, high signal/read counts in next gen sequencing experiments 
independent of cell line and type of experiment” (Consortium, 2012). 
 
Fig 5.4: Extragenic RNAPII peaks definition. Scheme of extragenic definition of RNAPII peaks in the current chapter. Black 
rectangles represent genes, grey rectangles represent RNAPII peaks overlapping coding genes. Purple rectangles represent 
RNAPII peaks to be divided in extragenic and intragenic. X represents a intragenic peak and therefore not analysed in the 
following paragraphs. Transparent light grey boxes define extragenic regions; transparent dark grey boxes define intragenic 
regions. 
5.4.2 Strategy to classify extragenic RNAPII regions 
To identify RNAPII extragenic regions and to investigate to what extent they coincide with 
previously described enhancer regions, I first choose the RNAPII datasets that could be most 
informative for this work. First, I compared different RNAPII modifications to understand 
whether they co-localise at extragenic regions and to analyse their chromatin features occupancy. 
RNAPII dataset from Brookes et al. 2012 (Brookes et al., 2012), namely RNAPIIS5p, 
RNAPIIS7p, RNAPIIS2u (RNAPIIS2 unpshopshorylated), were classified at extragenic or 
intragenic (Fig. 5.5a), as described previously in chapter 4 (4.4.3). RNAPIIS2p was not 
considered in these analyses because of the low number of extragenic RNAPIIS2p peaks (737) 
and the results from the previous analysis in Chapter 4 (4.4.7) that showed the co-occurrence of 
RNAPIIS2p with RNAPIIS7p; RNAPIIS2p therefore would not be able to discover new regions. 
Next, the enrichment in each RNAPII modification was determined at extragenic peaks and 
random (shuffled) regions with similar properties as the identified peaks. Finally, a 5% cut-off 
was calculated based on the random region enrichment. This procedure identified 5319 
RNAPIIS2u extragenic regions (96% were above threshold), 3699 RNAPIIS5p regions (84%) 
and 2273 RNAPIIS7p regions (96%) (Fig 5.5b).  
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Fig 5.5: Definition of extragenic RNAPII Brookes datasets. a) Strategy to define RNAPII extragenic regions.  b) Classification of 
RNAPIIS2u, RNAPIIS5p, RNAPIIS7p extragenic regions. Coloured thick lines represent enrichment of RNAPII modification at 
RNAPII extragenic regions. Grey lines represent enrichment at random extragenic regions. Dotted vertical line represent 5% FP 
cut-off.  
In conclusion, I generated three extragenic RNAPII lists of regions with different RNAPII 
modifications to then investigate whether they identify the same regions and which properties 
these regions have.  
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5.4.3 Comparison of RNAPII modifications at extragenic regions 
To understand how the different extragenic RNAPII regions relate with each other. I first 
analysed their co-localisation in the genome. Most RNAPII extragenic regions are marked by 
both RNAPIIS2u and/or RNAPIIS5p (4335 regions), with 1814 regions are found with the three 
RNAPII datasets. Only 130 regions are identified by RNAPIIS7p alone (Fig 5.6a), in line with 
the results of the previous chapter and with RNAPII modification at coding genes, where 
RNAPIIS7p occurs downstream of RNAPIIS5p on polymerases also marked by RNAPIIS2u. 
RNAPIIS5p and RNAPIIS2u alone also identify unique regions: 2152 (40%) and 728 (20%), 
respectively.  
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Fig 5.6: Extragenic RNAPII modifications identify similar regions in the genome. a) Venn diagram showing the co-localisation 
of extragenic RNAPII peaks for three different datasets from Brookes et al: RNAPIIS2u, RNAPIIS5p, RNAPIIS7p. The numbers 
indicate the number of region per group. b) Occupancy of histone modifications and co-factors at regions identified solely by 
RNAPIIS5p (right on top, in dark pink) c) identified by RNAPIIS2u, RNAPIIS5p and RNAPIIS7p (right center, in pink) d) 
identified solely by RNAPIIS2u datasets (left bottom, in purple). 
To explore the candidate enhancer roles and regulation of the extragenic RNAPII regions, I 
measured their overlap with H3K4me1, p300, H3K122ac, H3K27ac, H3K4me3, and 
H3K27me3. Regions marked by all three RNAPII modifications are most often co-occupied by 
all tested enhancer marks, and only a small number is bound by H3K27me3, as expected from 
the lack of co-association between Polycomb marks and elongating RNAPII at active genes 
(Brookes et al., 2012). The regions uniquely found with RNAPIIS2u and RNAPIIS7p differ 
slightly in the proportion of occupancy of important enhancer features. RNAPIIS2u regions are 
mainly occupied by H3K4me1, in combination with marks of non-canonical enhancers 
(H3K122ac) and H3K4me3, a mark of open promoters. RNAPIIS5p unique regions are more 
occupied by non-canonical enhance marks and proportionally more occupied by H3K27me3 (Fig 
5.6b, c, d).  
To investigate the potential of extragenic RNAPII occupancy to define enhancers, I compared 
how many of the RNAPII peaks identified overlapped with previously identified enhancers using 
the Chen et al. 2012 (Chen et al., 2012), Whyte et al. 2013 (Whyte et al., 2013), Cruz Molina et 
al. 2017 (Cruz-Molina et al., 2017) lists. I found that 30%, 22% ,and 22% of the S2u, S5p and 
S7p peaks coincided with an enhancer region previously identified (data not shown), confirming 
their partial redundancy with alternative criteria to detect candidate enhancers, but also the 
potential of using RNAPII peaks to discover new candidate regions and their activation states. 
This topic will be explored in more detail in the following chapter (chapter 6). 
From these analyses, it was clear that both RNAPIIS2u and RNAPIIS5p identify candidate 
extragenic enhancers. The following analyses presented in this chapter focus on studying the 
new candidate enhancers only on RNAPIIS5p and not RNAPIIS2u for two reasons: first, 
RNAPIIS5p is present at repressed genes together with Polycomb and a poised enhancers, while 
RNAPIIS2u would miss these regions; second, genome-wide mapping of RNAPIIS5p but not 
RNAPIIS2u is available in a time-course neuronal differentiation (Ferrai et al., 2017) which 
allows not only the exploration of extragenic RNAPIIS5p regions in ESCs, but also the 
opportunity to follow dynamics of candidate RNAPII-marked enhancers during differentiation. 
A brief inspection of the 2152 RNAPIIS2u extragenic regions show that 60% do not overlap 
with known enhancers (Whyte et al. 2013 (Whyte et al., 2013), Cruz Molina et al. 2017 (Cruz-
Molina et al., 2017)), and that ~50% coincide with TF binding sites (data not show); these 
regions will be explored in future analyses. 
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5.4.4 Classification of extragenic RNAPIIS5p regions in the mESC 
46C clone 
Ferrai et al. 2017 (Ferrai et al., 2017) have produced ChIP-seq datasets for RNAPII-S5p, S7p, 
S2p, H3K27me3 and mRNA-seq during a differentiation time line that starts in ESCs using clone 
46C (day 0), covers the early exit from pluripotency (days 1 and 3) and ends with immature and 
mature dopaminergic neurons (days 16 and 30, respectively). In this chapter, I study the ESC 
datasets (Table 5.1), and in the following chapter I will explore datasets for all time points. 
Another publication from the lab, Fraser et al. 2015 (Fraser et al., 2015), describes Hi-C and 
CAGE data produced from ESCs (day 0) and immature neurons (day 16). Other important 
unpublished data was available in the laboratory from the same ESC clone and timeline, namely 
nascent and total RNA. Therefore, to leverage on these resources which are matched for the 
same ESC clone and differentiation timeline, I decided at this stage to transfer my analyses of 
RNAPII extragenic enhancers from the Brookes datasets analysed (which included more 
RNAPII marks) to the published datasets from Ferrai et al. 2017 (Ferrai et al., 2017). To this 
end, I repeated the identification of extragenic RNAPII-S5p peaks using published RNAPIIS5p 
produced in mESC 46C datasets as previously described for Brookes RNAPII datasets.  
Table 5.1: RNAPII datasets from Ferrai et al. 2017 Table describing RNAPII dataset used in the following analysis. Datasets 
mapped and processed by Elena Torlai Triglia.  
 
In brief, I divided previously calculated RNAPIIS5p peaks by Elena Torlai Triglia in extragenic 
and intragenic and excluded regions overlapping with the ENCODE blacklist. I then calculated 
the enrichment for RNAPIIS5p from the ESC (Day 0) dataset and classified them as positive if 
they were enriched over a 5% false positive cut-off calculated on matched extragenic random 
regions (Fig 5.7a). More than 83% (4432) of RNAPIIS5p Day 0 peaks were above the 
enrichment cut-off, which is comparable with the RNAPIIS5p Brookes dataset.  
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Fig 5.7: Extragenic RNAPIIS5p day0  definition. a) Classification of RNAPIIS5p extragenic regions. Purple thick lines 
represents enrichment of RNAPIIS5p at RNAPIIS5p extragenic regions. Grey lines represent enrichment at random extragenic 
regions. Dotted vertical line represent 5% FP cut-off. 
5.4.6 Comparison of RNAPIIS5p extragenic regions in two ESC lines 
To compare extragenic regions occupied by RNAPIIS5p in ESC clones OS25 (Brookes et al. 
2012 (Brookes et al., 2012)) and 46C (Ferrai et al. 2017 (Ferrai et al., 2017)), I first analysed 
their length distribution, also against published enhancer previously analysed. The two 
RNAPIIS5p datasets were produced with the same antibody clone against RNAPII-S5p (clone 
CTD-4H8), using the same chromatin preparation and similar ChIP and sequencing strategies. 
Importantly, the two ESC lines are grown in different conditions: OS25 cells are grown in 
serum+LIF conditions under selection for Oct4 expression, whereas 46C cells are grown in 
serum free conditions. Both conditions preserve the repression of Polycomb-repressed 
developmental genes, but show noticeable differences in the expression of some signalling genes 
(Elena Torlai Triglia, personal communication), as expected from the different growth 
conditions.  
Extragenic RNAPIIS5p regions from Brookes and Ferrai datasets had comparable lengths, and 
both tended to be longer than the published Whyte enhancers defined with TF binding (Fig 5.8a), 
irrespectively of whether the full extragenic Whyte list was considered or only the extragenic 
Whyte enhancers occupied by RNAPIIS5p. Comparisons between the two RNAPIIS5p datasets 
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showed that ~2500 extragenic RNAPIIS5p regions are common to the two cell lines, with ~4000 
RNAPII extragenic regions identified exclusively in each dataset (Fig 5.8b). These observations 
highlight the importance of matching datasets for enhancer regions on the same cell line and 
growth conditions, as it is expected from comparisons between different cell types that enhancer 
marking varies more than expressed gene cohorts (Anderson and Hill, 2014). 
 
Fig 5.8: Comparison between Ser5p datasets from Brookes and Ferrai (Day0) datasets. a) Comparison of length distribution 
between RNAPIIS5p extragenic peaks from Brookes dataset, Ferrai day0 datasets, extragenic Whyte enhancers, and extragenic 
Whyte enhancers with RNAPIIS5p. b) Venn diagram of the overlap of Brooked and Day0 RNAPIIS5p datasets at extragenic 
regions. c) On the left: density distribution of RNAPII5p day0 reads at extragenic RNAPII5p regions from Day0 (dark pink) and 
Brookes (light pink). Solid lines represent regions overlapping between datasets, dotted lines represent regions not overlapping 
within datasets. On the right: density distribution of RNAPII5p Brookes reads at extragenic RNAPII5p regions from Day0 (dark 
pink) and Brookes (light pink). Solid lines represent regions overlapping between datasets, dotted lines represent regions not 
overlapping within datasets. 
To understand whether regions shared by the two datasets were more strongly associated with 
RNAPIIS5p, I examined its enrichment in the common and unique regions. Regions overlapping 
between the two datasets are the most enriched for RNAPIIS5p (Fig 5.8c). In contrast, regions 
not overlapping show a lesser degree of enrichment. It is interesting to notice that regions 
specific for the Ferrai dataset (46C) have a higher enrichment for RNAPIS5p from Ferrai (46C) 
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compared to the ones of the Brookes dataset (OS25), and vice versa. This suggests that the 
differences in extragenic RNAPII highlight biological differences and are not easily explained by 
different sequencing depths of the two datasets or by technical noise in the detection of 
RNAPIIS5p extragenic regions. Similar analysis for RNAPIIS7p, RNAPIIS2p, and H3K27me3 
enrichment can be found in Appendix Fig 5.A1. It is possible that highly enriched and shared 
regions are more stably bound by RNAPII, while the specific regions of each dataset can be 
more related to biological differences between the mESC clones in their signalling and metabolic 
pathways.  
5.4.7 Comparison between extragenic RNAPIIS5p regions and 
published enhancer regions 
To understand whether extragenic RNAPIIS5p regions mark putative enhancers, I compared the 
extragenic RNAPIIS5p regions with published enhancer datasets and analysed their chromatin 
marks.  Only ~30% of extagenic RNAPIIS5p regions co-localise with either Whyte or Cruz 
Molina enhancers (Fig 5.9a), which is however in line with the low co-localisation of different 
published enhancer lists shown in chapter 3 of the current thesis and in previous publication 
(Benton et al., 2017). However, most (94%) of the regions that do not overlap Whyte or Cruz 
Molina enhancer lists, overlap with known enhancer marks; H3K27ac, P300, H3K4me1 and the 
non-canonical H3K122ac (Fig 5.9b). Regions co-localising with published enhancers show the 
same pattern, with a preference for co-localising with all the enhancer marks considered, 
whereas the same was true for only the minority of extragenic RNAPIIS5p regions not 
overlapping with one of the two enhancer lists. Similar comparisons at enhancer regions 
precedently identified not overlapping with RNAPII reveal a similar pattern of co-association 
with all considered marks (Appendix Fig 5.A2).  
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Fig 5.9: Extragenic RNAPII regions identify regions with enhancer marks. a) Overlap between extragenic RNAPIIS5p regions 
and Whyte and Cruz Molina extragenic enhancers. b) Combinations of enhancer marks at extragenic RNAPII5p regions co-
localising with Whyte and Cruz Molina extragenic enhancers (on the left, in light purple) and not co-localising with Whyte and 
Cruz Molina extragenic enhancers (on the right, in pink). c) Enrichment of selected enhancer marks at Whyte and Cruz Molina 
enhancers (in blue), extragenic RNAPIIS5p regions co-localising with Whyte and Cruz Molina extragenic enhancers (in light 
purple), and extragenic RNAPIIS5p regions not co-localising Whyte and Cruz Molina extragenic enhancers (in pink). Extragenic 
random regions are shown as reference (in grey).  
To better dissect differences and similarities between the two types of RNAPII extragenic region 
and understand their chromatin state, I calculated their enrichment for different enhancer markers 
(H3K4me1, P300, H3K27ac, Oct4, Med1 and H3K27me3). In general, RNAPIIS5p extragenic 
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regions have a comparable enrichment for enhancer features to published enhancers, which are 
above enrichment at random regions, without noticeable differences whether they co-localise 
(labelled S5p) or not with published enhancer lists (Fig 5.9c). H3K4me1 is slightly reduced at 
RNAPIIS5p extragenic regions, especially the regions not co-localising with published 
enhancers. The reason could lay in the fact that these regions could be transcribing and therefore 
enriched in H3K4me3 over H3K4me1. Interestingly, RNAPIIS5p extragenic regions tend to 
have higher enrichment for H3K27ac, a mark of active enhancers, higher Oct4 and H3K27me3 
enrichment, compared Whyte and Cruz Molina enhancer regions. 
Taken together these results demonstrate that extragenic RNAPIIS5p regions are enriched for 
known active and poised enhancer marks, and the enrichment of these marks is not dependent on 
whether these regions are identified by other approaches. 
5.4.8 Classification of RNAPII states at extragenic regions 
To study the activation state of extragenic RNAPIIS5p regions, I classified them according to 
their co-occupancy in RNAPIIS7p, RNAPIIS2p, and H3K27me3. The classification strategy 
applied was the same performed for extragenic Whyte enhancers (in Chapter 4, section 4.4.3). 
Briefly, the enrichment for each mark was calculated in the extragenic RNAPIIS5p regions. A 
5% false positive cut-off was calculated over the random enrichments and used to classify as 
positive or negative for the feature of interest at the extragenic RNAPIIS5p regions. Positive 
regions were enriched above the cut-off and overlap with a BCP peak of the classifying feature 
(Fig 5.10a). 
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Fig 5.10: Classification of RNAPII states extragenic RNAPIIS5p regions from Day0 dataset. a) Classification of H3K27me3, 
RNAPIIS7p and RNAPIIS2p at RNAPIIS5p extragenic regions. Thin purple lines: enrichment of the considered feature at all 
extragenic RNAPIIS5p regions; thick purple lines: enrichment of the considered feature at extragenic RNAPIIS5p region 
overlapping a peak of the featured considered; grey dotted curved line: enrichment at extragenic random regions. Vertical dotted 
line: 5% FP cut-off. b) Number of RNAPII classes recovered. 
To investigate the coincidence of the four markers considered, I overlapped their coordinates, 
and found that the most represented configuration of the extragenic RNAPIIS5p regions is 
RNAPIIS5p alone (2461), followed by RNAPIIS5p-S7p (1593), RNAPIIS5p-S7p-S2p (165) and 
H3K27me3-RNAPIIS5p (158) (Fig 5.10b). A small number (35) of regions had other minor 
combinations of markers and were not considered in the following analyses.  
In conclusion, RNAPII is found in different activations states at extragenic regions, from poised 
together with Polycomb to fully elongating, similarly to the results on published enhancer lists 
presented in chapter 4. 
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5.4.9 RNAPII is more enriched at more active extragenic regions 
To investigate the distribution and level of occupancy of RNAPII and Polycomb mark 
H3K27me3 at RNAPIIS5p extragenic regions, I analysed their pattern of enrichment. RNAPII 
modifications are enriched in the peak area concordantly with their classification (Fig 5.11a). 
H3K27me3 spreads over the RNAPII extragenic region and its surroundings, potentially 
generating a wide repressive area, as is known for its occupancy at Polycomb repressed genes 
(Bernstein et al., 2006a).  Interestingly, RNAPIIS5p is enriched at the same level at regions with 
or without Polycomb. In contrast with H3K27me3 and RNAPIIS5p, RNAPIIS7p and 
RNAPIIS2p show a major peak of enrichment in the center of the extragenic RNAPIIS5p region. 
Importantly, no detectable enrichment is found at the extragenic RNAPIIS5p regions considered 
in a control ChIP experiment performed in the absence of primary antibody (Mock IP control).  
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Fig 5.11: RNAPII modifications are enriched at extragenic RNAPII regions concordantly with their classification. a) Average 
enrichment of feature used in the classification per classes of extragenic RNAPII regions. Colorcoded are the classes of 
extragenic RNAPII regions. The average enrichment inside the regions +/- 5kb is shown. Regions shorter than 1kb were not 
included in the averaging. 
5.4.10 Extragenic RNAPII regions marked by Polycomb are closer to 
repressed genes 
Next, I explored the proximity of each class of extragenic RNAPIIS5p region to genes, and the 
promoter state of these genes. For example, H3K27me3-RNAPIIS5p regions could be located 
closer to Polycomb repressed genes, than extragenic regions containing S7p and S2p, to build a 
repressive chromatin environment, as was previously suggested for poised enhancers (Koenecke 
et al., 2017; Rada-Iglesias et al., 2011). Most extragenic RNAPII regions were found located at 
more than 10kb from the closest annotated gene >75% of the times, with most at more than 50kb 
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(>30% per class; Fig 5.12a). Interestingly, H3K27me3-RNAPIIS5p regions are the closest to 
genes with distances of <10kb ~20% of the time.  
 
Fig 5.12: Extragenic H3K27me3 positive regions are closer to Polycomb repressed genes. :  a) Gene distance of extragenic 
RNAPIIS5p regions from the closest gene, divided in bins. b) Scheme of states of promoters considered in this analysis. 
Promoters states were define in Ferrai et al.  2017  .c) State of the closest gene per class of extragenic RNAPII. d) Distance per 
class of closest gene, divided per class of enhancer and gene states.  
To understand whether H3K27me3-RNAPIIS5p reside closer to Polycomb repressed genes, I 
took advantage of a published list of promoter states derived from the same datasets (Ferrai et 
al., 2017). In this list, active promoters were defined as positive for RNAPIIS5p, RNAPIIS7p 
and expressing mRNA; PRC-RNAPIIS5p promoters were defined as positive for H3K27me3 
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and RNAPIIS5p and negative for the other features considered; PRC promoters were defined as 
positive for H3K27me3 and negative for the other features considered; Inactive promoters were 
defined as negative for all the features considered (Fig 5.12b). I decided to consider both PRC 
and PRC-RNAPIIS5p regions to investigate whether a difference could be found in respect to 
extragenic RNAPII position, which could be indicative of different regulatory mechanisms. 
Interestingly, I find that the state of the closest gene to H3K27me3-RNAPIIS5p regions is often 
Polycomb repressed (38% of closest genes) (Fig 5.12c), with a preference for H3K27me3-
RNAPIIS5p compared to other extragenic RNAPII regions. Moreover, H3K27me3-RNAPIIS5p 
regions are found between 2-50kb closer to Polycomb-repressed genes than to active genes (2-
50kb 28% Polycomb-repressed, 14% active; 2-10kb 11%, 2%). This result raises the possibility 
that H3K27me3-RNAPIIS5p extragenic regions reside close to repressed genes to help keep or 
promote a repressive environment. This analysis also shows that a clear picture of enhancer and 
promoter state correlation is challenging when only linear distance is taken into account.  
5.4.11 Extragenic RNAPII regions co-associate with active histone 
modifications and transcription factors 
To investigate whether different state of RNAPII at extragenic regions associate with specific 
enrichments of histone modifications and TFs linked with enhancer activity, I analysed the 
enrichment of selected modifications and TFs in each region according to the class of extragenic 
RNAPIIS5p regions (Fig 5.13). H3K4me1 spreads in the surroundings of extragenic RNAPII 
regions of all classes, while marks related with activity, such as H3K27ac and P300 are more 
enriched the more active is the state of RNAPII, and are more centered in their distribution. 
Interestingly, TFs such as Nanog, Sox2, and Oct4 are enriched to different degrees inside the 
extragenic RNAPII classes. This could reflect the partial co-localisation between extragenic 
RNAPII regions and Whyte enhancers (Fig 5.9a), and show that some regions occupied by 
RNAPII are not bound by these specific TFs. Nevertheless, it is important to notice that Brd4 
and Med1 are present at extragenic RNAPII regions. Interestingly, proteins involved in 
chromatin looping, such as Caph2 and Nipbl are also present at all the classes, while CTCF is 
depleted in all regions. (For a quantification of the enrichment levels of H3K27me3, H3K27ac, 
H3K4me1, H3K122ac, Klf4, Nanog, Sox2, Oct4, Smad1, Caph2, CTCF, Nipbl, Med1 please 
refer to Appendix Fig 5.A3). 
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Fig 5.13: Extragenic RNAPII classes show diverse enrichment for chromatin marks. Positional heatmaps showing the positional 
enrichment of selected marks at RNAPII regions. Regions +/- 4kb from the middle point of the extragenic RNAPII region are 
shown. On the bottom scale per feature are specified. 
Altogether, the results show how extragenic RNAPII can capture different chromatin states. 
Extragenic RNAPII regions are enriched in enhancer marks and also in chromatin looping 
associated proteins, which would suggest a role in 3D gene regulation.  
5.4.12 Datasets used to study transcriptional activity at extragenic 
RNAPIIS5p regions 
To study the regulation of transcription at extragenic RNAPII regions, I explored both RNA-seq 
and ChIP-seq datasets, published and unpublished (a list of the datasets used in the following 
paragraphs can be found in Tables 5.2 and 5.3, for RNA-seq and ChIP-seq datasets, 
respectively).  
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Table 5.2: RNA-seq datasets used in the current chapter. RNA-seq datasets used in the current chapter. *Processed by Elena 
Torlai Triglia. § Processed by Robert A Beagrie. 
 
Table 5.3: ChIP-seq datasets used for the transcriptional analysis. ChIP-seq datasets of regulators of transcription or perturbation 
of transcription used in the current chapter. 
 
RNA-seq datasets cover different maturation states of RNA (Total RNA-seq, Nascent RNA-seq, 
PolyA RNA-seq), perturbation of transcription (Nascent RNA-seq after Cdk9 inhibition with 
Flavopiridol), and RNA maturation surveillance (Total RNA-seq after Exosome KD). ChIP-seq 
datasets include mapping of kinases involved in RNAPII regulation (Cdk9, Erk2), pausing 
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factors (Nelfa, Spt5), Exosome (Exosome catalytic subunit Dis3), co-factors involved in 
Polycomb repression (Utf1) and RNAPII modification in WT and after Erk2 inhibition (total 
RNAPII and RNAPIIS5p ChIP-seq). 
5.4.13 RNAPII at extragenic regions transcribe differently mature 
RNAs 
Different states of RNAPII are associated with different stages of the transcription cycle. 
RNAPII marked by S5p, S7p and S2p is associated with productive elongation that leads to fully 
mature mRNA (Brookes and Pombo, 2009), while poised RNAPIIS5p, in the absence of S7p and 
S2p, leads to abortive transcription (Jia et al., 2012). eRNAs, on the other hand, were shown to 
be unstable and not polyadenylated (Andersson et al., 2014a; Arner et al., 2015; Flynn et al., 
2011), although they are capped, but it is not clear which phosphorylation state of RNAPII is 
most associated with eRNA production. Moreover, promoters can have divergent transcription 
which produces PROMoter uPstream Transcripts (PROMPTs), which are differently regulated 
from RNA originating from genes (Almada et al., 2013; Flynn et al., 2011), and resemble 
eRNAs. For example, PROMPTs and eRNAs were shown to be under exosome surveillance 
(Andersson et al., 2014b; Flynn et al., 2011). 
To investigate whether extragenic RNAPII regions produce differently mature RNAs based on 
their RNAPII state, I analysed different RNA-seq datasets. Total RNA-seq captures all the RNA 
species in a cell, except for the rRNAs that were depleted prior to sequencing. Nascent RNA-seq 
(RNAChIP) captures RNA associated with RNAPIIS5p bound to chromatin, and are enriched for 
nascent RNAs (Kelly J. Morris, personal communication). PolyA RNA-seq is the pool of mature 
RNAs, with a polyA tail. I compared the amount of RNA produced at the extragenic RNAPIIS5p 
regions with the expression at active genes (on exons) and also with the signal at upstream 
regions of active genes (PROMPTs).  
Differently classified RNAPII extragenic regions transcribe different amounts of total RNA, 
from mostly not detectable at H3K27me3-RNAPIIS5p to levels higher than at PROMPTs at 
RNAPIIS5p-S7p-S2p regions. Specifically, total RNA is detected at regions with RNAPIIS5p 
alone to almost similar levels to PROMPTs, however when RNAPIIS2p is present the 
transcription is higher than 1 TPM in 62% of the regions (Fig. 5.14a). Strikingly, levels of 
Nascent RNA at RNAPIIS5p-S7p-S2p are comparable to active genes (Fig 5.14b), however this 
is not the case for polyA-RNA (Fig 5.14c), where the levels are significantly lower at extragenic 
regions compared to active coding regions. Similar data were obtained analysing RNA-seq 
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datasets originating from OS25 cells (Appendix Fig 5.A4, Methods Table 2.1 for details on the 
OS25 datasets). 
 
 
Fig 5 .14: Extragenic RNAPII regions transcribe differently mature RNAs depending on their activation state. a) total RNA. b) 
Nascent RNA (RNAChIP). c) polyA-RNA. Log10 TPM + pseudo count are shown for clarity. Active genes (exon coverage) and 
PROMPTs regions (500bp) are shown as reference. 
These results show that RNAPII at extragenic regions transcribes RNAs with different degrees of 
maturation and transcription levels, which reflect RNAPII activation states. Interestingly, nascent 
RNA levels at active extragenic region are comparable to RNA levels at active genes and 
significantly higher than PROMPTs, while fully mature RNA is lowly expressed. This confirms 
that bonafide detection of RNAPII at extragenic regions and shows that transcription occurs at 
extragenic regions, leading to RNA molecules that are not processed to full maturation and/or 
degraded. 
5.4.14 Extragenic RNAPII transcripts are under exosome surveillance 
To test whether transcripts are actively degraded at extragenic RNAPII regions, I analysed 
Exosome occupancy at these regions. Exosome was described to be present at enhancer regions 
and degrade eRNAs (Andersson et al., 2014b; Flynn et al., 2011). Interestingly, H3K27me3-
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RNAPIIS5p regions are the most enriched for Dis3, a catalytic subunit of the Exosome 
machinery (Fig 5.15a), with comparable levels of occupancy at Polycomb promoter regions. 
Exosome is known to be active to prevent PROMPTs accumulation at transcribed upstream 
regions of active genes (Flynn et al., 2011), but it is unclear whether Exosome activity at active 
genes coincides with chromatin association that could be detected by ChIP.  
 
Fig 5.15: Extragenic RNAPII regions are under exosome surveillance. a) Average count enrichment of exosome catalytic subunit 
Dis3 at extragenic RNAPII regions and at TSS of differently active promoters. Log10 of normalised reads per length + 
pseudocount are shown for clarity. b) Foldchange (on the left) and normalised reads (on the right) of total RNA levels after 
Exosome KD. Ctrl: cells treated with a control Si. Si: cell treated with Si against exosome. Active genes (exon coverage) and 
PROMPTs regions (500bp) are shown as reference.  
To understand whether Exosome is actively involved in the degradation of transcripts produced 
from extragenic RNAPII regions, I took advantage of a total RNA-seq dataset previously 
produced in the lab (KJ Morris et al., in preparation). The total RNA-seq was performed in 
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control and after Exosome knockdown using siRNAs. The depletion of Exosome leads to an 
increase in the levels of total RNA detected at extragenic RNAPII regions and a low effect on 
PROMPTs (Fig 5.15b).  
In conclusion, RNAs produced at extragenic RNAPII regions are under Exosome surveillance. 
5.4.15 Regulators of transcription at coding regions are also enriched 
at extragenic RNAPII regions 
To investigate whether the transcriptional activity of extragenic RNAPII is regulated similarly to 
what happens at genes, I analysed the occupancy of known transcriptional regulators at 
extragenic RNAPIIs5p regions (Fig. 5.16a,b), including: Spt5 and Nelfa, involved in the 
promoter proximal pausing; Cdk9 and Erk2, two kinases that phosphorylate CTD at active and 
Polycomb genes, respectively; and Utf1, a co-factor that regulates Polycomb repressed genes. 
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Fig 5.16: Transcription regulators are differentially enriched at extragenic RNAPII classes. a) Positional enrichment of selected 
transcriptional regulators at extragenic RNAPII regions. Extragenic RNAPII regions +/- 2kb are shown. On the bottom scale per 
feature are specified. b) Absolute enrichment of selected features at extragenic RNAPII region and differently active TSSs. 
Spt5 and Nelfa are more enriched at extragenic RNAPIIS5p regions with increased activation of 
RNAPII, and these two factors do not spread in the surrounding chromatin, but are confined to 
the RNAPII peak (Fig 5.16a). Spt5 has similar enrichment at RNAPIIS5p-S7p and RNAPIIS5p-
S7p-S2p extragenic regions, while Nelfa is more enriched at RNAPIIS5p-S7p than at 
RNAPIIS5p-S7p-S2p regions. These observations are in accordance with the promoter proximal 
pause release mechanism described at genes, where Nelfa and Spt5 bind and cause RNAPII 
pausing. After phosphorylation by Cdk9, Nelfa dissociates releasing paused RNAPII, while Spt5 
remains associated to elongating RNAPII throughout the gene body (Adelman and Lis, 2012). 
As expected from Erk2 roles at Polycomb-repressed promoters (Tee et al., 2014), Erk2 shows its 
highest enrichment at H3K27me3 positive regions, although barely detectable. In contrast, Cdk9 
and Utf1 are present at all RNAPIIS5p extragenic regions considered. A comparison between the 
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enrichment levels at extragenic regions and TSSs shows lower occupancy of Nelfa, Spt5 and 
Cdk9 at extragenic regions compared to coding regions (Fig 5.16b).  
In conclusion, extragenic RNAPII regions are bound by known transcriptional regulators. Erk2, a 
regulator of RNAPII posing which are specific for Polycomb genes is more enriched at 
H3K27me3 positive regions. Taken together, these results suggest that transcription at extragenic 
regions is regulated similarly to genes.  
5.4.16 RNAPII transcription is sensitive to Cdk9 inhibition 
To investigate Cdk9 presence at extragenic RNAPIIS5p regions in more detail, I analysed 
Nascent RNA dataset from control cells and matched cells treated with Flavopiridol (1h; 10 uM), 
which inhibits Cdk9. Cdk9 phosphorylates the RNAPII-CTD, Nelfa pausing factor and Spt5 
positive elongation factor and regulates the transition between initiation to elongation stages of 
RNAPII transcription at coding genes. Inhibition of Cdk9 with Flavopiridol blocks the transition 
between initiation to elongation and results in transcription inhibition. 
Flavopiridol treatment results in decrease in nascent RNA levels at all extragenic RNAPII 
regions considered, with a stronger effect for RNAPIIS5p-S7p and RNAPIIS5p-S7p-S2p (Fig 
5.17a), which are the more transcribed extragenic RNAPII regions. A somehow unexpected 
result is the increase in nascent RNA from the coding regions of active genes which is probably 
due to RNAPII stalling at TESs for inefficient termination (Jonkers et al., 2014). These results 
show that RNAPII transcription at extragenic regions is under Cdk9 control.  
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To understand whether regions under Cdk9 control are also under Exosome surveillance, I 
compared the fold change in the two different treatments at all the extragenic regions. 
Interestingly, regions bound by more active RNAPII are under Exosome and/or Cdk9 
surveillance (Fig 5.17c, a plot showing the definition of sensitivity to Exosome or Flavopiridol  
can be found in Appendix Fig 5.A6 ). RNAPIIS5p-S7p is predominantly regulated by Cdk9 
Fig 5.17: Extragenic RNAPII regions are sensitive to Cdk9 inhibition. a) Foldchange (on the left) and normalised reads (on the 
right) of nascent RNA levels after Flavopiridol treatment. Ctrl: untreated cells. Si: cell treated with Flavopiridol (1h; 10 uM). 
Active genes (exon coverage) and PROMPTs regions (500bp) are shown as reference. b) Sensitivity of extragenic RNAPII 
regions to Flavopiridol treatment and Exosome KD. Dotplot showing all the extragenic RNAPII regions and their sensitivity to 
Flavopiridol (x-axis)  and Exosome KD (y-axis). Log2 of normalised reads is shown. c) Sensitivity to Flavopiridol, Exosome KD 
or both per class. Fraction of regions per class is shown. 
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alone, while RNAPIIS5p-S7p-S2p is almost equally regulated through Cdk9 and Exosome 
together. Possibly, Exosome complex plays a more prominent role at more actively transcribed 
regions, where it is important to avoid accumulation of unnecessary RNAs. 
This analysis hints at the possibility that transcription at enhancers is regulated through CTD 
modifications and pausing release, as well as through active degradation of the resulting non-
coding transcripts. Similar results were obtain at the RNAPII-bound extragenic Whyte enhancers 
and partially presented in Appendix Fig 5.A6. 
5.4.17 Erk2 knock out influences RNAPII binding at extragenic 
regions 
Polycomb repressed genes are regulated by Erk2 which phosphorylates poised RNAPIIS5p 
complexes at developmental genes in ESCs (Tee et al., 2014). To understand whether Erk2 
regulates extragenic transcription at poised H3K27me3-RNAPIIS5p extragenic regions, I 
analysed Erk2 enrichment at extragenic RNAPIIS5p regions and I also investigated RNAPII 
occupancy at extragenic RNAPIIS5p regions and at active, Polycomb-repressed, and inactive 
genes after Erk knock out (KO) in mESCs .  
Erk2 is preferentially enriched at extragenic regions bound by Polycomb, and at coding genes 
(Fig 5.18a) and to a lesser extent at other extragenic RNAPII regions. While the levels of Erk 
and H3K27me3 vary between H3K27me3 positive and negative regions, as expected, the levels 
of RNAPIIS5p enrichment are comparable (Fig 5.18b), also as expected from the identification 
of similar levels of S5p at active and Polycomb repressed genes.  
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Fig 5.18: Erk2 is enriched at extragenic RNAPII regions. a) Heatmap showing the enrichment of H3K27me3 and Polycomb at 
extragenic RNAPII region with or without H3K27me3 and at Polycomb repressed genes, Active genes and Inactive genes, as 
reference. b) Absolute enrichment of H3K27me3, Erk2, RNAPIIS5p at extragenic RNAPII region with or without H3K27me3 
and at Polycomb repressed genes, Active genes and Inactive genes, as reference. Log of average counts (normalised per length) + 
pseudo count are shown for better visualisation. 
To test whether Erk2 regulates RNAPII occupancy at extragenic regions, I compared the 
enrichment of RNAPIIS5p and total RNAPII before and after Erk KO in mESCs. As previously 
observed at Polycomb-repressed genes marked by Erk2 (Tee et al., 2014), Erk KO decreases the 
occupancy of RNAPIIS5p and total RNAPII also at Polycomb-RNAPIIS5p extragenic regions 
(Fig 5.19a). As shown previously (Tee et al., 2014), active genes are not occupied by Erk2 and 
not influenced by Erk KO. In contrast, at extragenic regions RNAPIIS5p occupancy tends to 
decrease after Erk KO irrespectively of H3K27me3 (Fig 5.19b). Total RNAPII enrichment is 
also diminished at extragenic RNAPII regions without H3K27me3 (Fig 5.19c). The decrease at 
extragenic regions without Polycomb mark was an unexpected result that may inform about the 
mechanisms that recruit and regulate RNAPII at extragenic regions. To explore which RNAPII 
state at extragenic enhancers was also sensitive to Erk inhibition, I analysed all extragenic 
RNAPII classes and found that surprisingly the extragenic regions that loose RNAPIIS5p or total 
RNAPII occupancy are the ones positive for RNAPIIS2p (Fig 5.19d). 
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Fig 5.19: Erk KO reduces RNAPII binding at extragenic regions. a) Single region view of extragenic RNAPII regions (left), 
Polycomb repressed gene Gata6 (center), and active gene Nanog (right). Tracks of Erk2, H3K27me3, RNAPIIS5p before and 
after Erk KO and total RNAPII before and after Erk KO are shown. Control (Input) is also shown. Tracks always show 0 and a 
smoothing function of 2 was applied. Images generated with the IGV software. b) RNAPIIS5p absolute levels before and after 
Erk KO at extragenic RNAPII region with or without H3K27me3 and at Polycomb repressed genes, Active genes and Inactive 
genes. Log of normalised read counts calculated with DESeq2 are shown. c)  total RNAPII absolute levels before and after Erk 
KO at extragenic RNAPII region with or without H3K27me3 and at Polycomb repressed genes, Active genes and Inactive genes. 
Log of normalised read counts calculated with DESeq2 are shown. d) RNAPIIS5p and total RNAPII absolute levels before and 
after Erk KO at extragenic RNAPII classes and at Polycomb repressed genes, Active genes and Inactive genes. Log of 
normalised read counts calculated with DESeq2 are shown.  
In conclusion, Erk2 is bound preferentially at H3K27me3-RNAPIIS5p extragenic regions, but its 
knockout perturbs RNAPII binding at all extragenic RNAPII regions, especially very active 
ones, without affecting RNAPII occupancy at active genes. 
These results suggest that RNAPII regulation at extragenic regions shares many of the features 
of regulation at coding regions.  
5.5 Discussion 
RNAPII marks putative enhancer regions, which are missed by other approaches. Different states 
of extragenic RNAPII have diverse enrichment for transcription factors, histone modifications, 
and proteins related with chromatin architecture. Moreover, extragenic RNAPII transcribes 
RNAs with different levels of maturation that are degraded by the Exosome machinery. 
Transcription at enhancers is also regulated by kinases that act on the CTD and on transcription 
pausing factors. 
 
5.5.1 Extragenic RNAPII marks putative regulatory regions 
RNAPII was previously described to bind enhancers in macrophages upon stimuli (De Santa et 
al., 2010) and poised enhancers when they get activated (Cruz-Molina et al., 2017). The results 
in the current chapter show that RNAPII is present at ~50% of extragenic enhancers identified by 
other strategies. However many extragenic RNAPII regions are not recovered in published 
enhancer lists, although they are enriched in enhancer marks, both canonical and non-canonical, 
and in Polycomb mark H3K27me3. Extragenic RNAPII regions are associated with RNAPII 
complexes in different states of activation, from poised to fully active. They show diverse 
enrichment of transcription factors, histone modifications, and proteins involved in chromatin 
looping, suggesting different mechanisms lead to their formation. For example, Brd4, Med1 and 
Cohesin are found enriched at increasingly active extragenic RNAPII regions, whereas CTCF, a 
protein involved in chromatin insulation, is not enriched at any of the extragenic RNAPIIS5p 
regions, suggesting that extragenic RNAPII and CTCF are not involved in the same processes. 
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Therefore, extragenic RNAPII identifies candidate regulatory regions and its state relate with 
their chromatin state. 
5.5.2 RNAPII transcription at extragenic regions is regulated similar 
to genes 
RNAPII presence at extragenic regions does not by itself imply a role or a function in gene 
regulation, and leads to the synthesis of detectable extragenic RNAs, with varying abundance 
and maturation levels.  
Transcription at extragenic regions is regulated at multiple levels. RNAPII kinases play a major 
role at extragenic regions, as their impairment by chemical inhibition or knockout can drastically 
reduce RNA transcription and affect RNAPII occupancy. Inhibition of Cdk9 leads to a reduction 
in RNA transcription at extragenic regions, detected at the level of nascent transcripts, with 
higher effects on regions occupied by RNAPIIS5p-S7p and RNAPIIS5p-S7p-S2p. Erk2 knock 
out strongly affects RNAPII occupancy at all extragenic regions leading to a lower occupancy of 
total RNAPII and RNAPIIS5p, whereas at coding regions it has a specific effect at Polycomb-
repressed regions occupied by poised RNAPIIS5p but not at active genes associated with 
elongating forms of RNAPII (Tee et al., 2014). Sensitivity of RNAPII to perturbation by 
different transcription regulators suggests that transcription at enhancers may be less stable than 
at genes, as was proposed for enhancers detected in Drosophila and dependent on Spt5 activity 
(Henriques et al., 2018). 
RNAs transcribed by extragenic RNAPII are under the control of the Exosome machinery, as 
shown increase RNA detected from extragenic regions after Exosome knock down, and by the 
measurable occupancy of Exosome subunit Dis3 at the same regions. This is in line with 
previous reports that showed eRNA sensitivity to Exosome degradation (Andersson et al., 2014a; 
Arner et al., 2015; Flynn et al., 2011). RNAs were not detected from H3K27me3-RNAPIIS5p 
regions even after Exosome KD, suggesting that RNAPII may not transcribe these regions to 
detectable levels. The mechanisms of transcription present at extragenic regulatory regions may 
have functional role in enhancer activity, while transcripts may in most cases simply be a by-
product to be kept under control. 
In conclusion, in the current chapter, I used RNAPII to identify extragenic putative regulatory 
regions and I showed that RNAPII actively produces RNAs with different maturation states, 
which are concordant with RNAPII state, and that transcription and transcripts are finely 
regulated. 
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5.6 Figures Appendix 
 
Fig 5.A1: Density distribution of datasets at extragenic RNAPIIS7p, RNAPIIS2p, H3K27me3 regions from Ferrai (dark 
coloured) and Brookes/Mikkelsen 2007 for H3K27me3 (light coloured). Solid lines represent regions overlapping between 
datasets; dotted lines represent regions not overlapping within datasets. 
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Fig 5.A2: Combinations of enhancer marks at Whyte and Cruz Molina extragenic enhancers. 
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Fig 5.A3: a) Boxplots showing the absolute enrichment of selected features at extragenic RNAPIIS5p regions. Grey area marks 
enrichment at random regions (25-75% percentile). 
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Fig 5.A4: a) Nascent RNA (RNAChIP) from OS25 cells datasets. b) polyA-RNA from OS25 datasets. Log10 TPM + pseudo 
count are shown for clarity. Active genes (exon coverage) and PROMPTs regions (500bp) are shown as reference. 
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Fig 5.A5: a) total RNA. b) Nascent RNA (RNAChIP). c) polyA-RNA at extragenic Whyte enhancers. Log10 TPM + pseudo 
count are shown for clarity. Active genes (exon coverage) and PROMPTs regions (500bp) are shown as reference. d) Normalised 
reads of total RNA levels after Exosome KD at extragenic Whyte enhancers. Ctrl: cells treated with a control Si. Si: cell treated 
with Si against exosome. Active genes (exon coverage) and PROMPTs regions (500bp) are shown as reference. e) Normalised 
reads of nascent RNA levels after Flavopiridol treatment. Ctrl: untreated cells. Si: cell treated with Flavopiridol (1h; 10 uM). 
Active genes (exon coverage) and PROMPTs regions (500bp) are shown as reference. 
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Fig 5.A6: Comparison of sensititvity to Flavopiridol treatment (1h; 10 uM) or Exosome KD. Log of foldchanges calculate with 
the Deseq2 package in R are shown. Highlighted in blue: regions sensititve to Flaopiridol treatment, in gold: regions sensititve to 
Exosome KD, in pink: regions sensitive to Flavopiridol treatment and Exosome KD. Every dot represents an extragenic RNAPII 
region. 
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6. Extragenic RNAPII identifies active 
enhancers in neuronal differentiation 
The previous chapter dealt with states of activation of extragenic RNAPII in mESC and its 
relation with enhancer marks and regulation of transcription. In this chapter, I explore whether 
extragenic RNAPIIS5p regions can function as enhancers in vivo. 
6.1 Introduction 
6.1.1 Validation of putative enhancers 
Putative enhancers can be functionally validated using different strategies. Enhancer regions can 
be cloned in a vector upstream of a weak promoter, and the expression of a reporter gene can be 
measured as a proxy of enhancer activity (Kvon, 2015). This analysis can be performed at single 
genes or using high throughput approaches, such as CapSTARR (Vanhille et al., 2015). 
Recently, a public resource of functionally tested enhancers in mouse and humans has been made 
available: the VISTA enhancer browser (Visel et al., 2007). This database contains thousands of 
tested regions in reporter assays in mouse and human (2893 regions tested; 18/4/2018). 
Specifically in mouse, regions of interest are injected in mouse eggs and tested for reporter 
activity mainly at the developmental stage E11.5. Regions which give consistent reporter signal 
(at least 3 positive embryos with a clear pattern) are considered positive enhancer regions. 
Candidate enhancer regions that are registered as negative in the VISTA database may either not 
have enhancer function, be active in another developmental time not captured at E11.5, or not 
have a clear and consistent pattern in at least 3 embryos. Nevertheless, the VISTA enhancer 
browser is a valuable resource to explore the in vivo validity of enhancer predictions.  
6.1.2 Neuronal differentiation 
To take advantage of the VISTA database for in vivo validation of extragenic RNAPIIS5p 
regions as regulatory enhancer regions, I analysed RNAPII ChIP-seq datasets produced through 
a neuronal differentiation that captures early stages of development into dopaminergic neurons 
(Ferrai et al., 2017; Fraser et al., 2015). The neuronal differentiation from Ferrai et al. 2017 
focuses on 5 time points: mESC (Day 0), early neuronal differentiation (Day1 and 3), and late 
neuronal differentiation (Day16 and 30). At each stage, cells express markers specific for their 
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stage (Fig 6.1). At Day 1, cells decrease the expression of pluripotency markers, such as Nanog. 
At Day 3, cells start to express early neuronal markers, such as Fgf5. At Day 16, cells have a 
neuronal phenotype, with limited spontaneous firing. At Day 30, cells are post-mitotic and fully 
developed as dopaminergic neurons. ChIP-seq datasets were publically available for 
RNAPIIS5p, RNAPIIS7p, and H3K27me3 at all time points. Total RNA-seq datasets were 
unpublished, but available in the laboratory (A.M. Fernandes, C. Ferrai, unpublished). 
 
Fig 6.1: Schematic representation of the neuronal differentiation from Ferrai et al. 2017.  Scheme representing the time points of 
the neuronal differentiation and the expression dynamics of cellular marks. 
6.2 Aims of the chapter 
Enhancer activity is cell, time, and stimulus specific. This is reflected in a high numbers of 
enhancers described in different cell types (up to 50000 (Andersson et al., 2014a; Nord et al., 
2013)) and also in high variability of enhancer usage between different cell types. Understanding 
how the activity of enhancer changes during differentiation is important to understand their 
function and their mechanism of action.  
To test whether extragenic RNAPII regions identify new genomic regions with enhancer activity 
during neuronal differentiation, I defined extragenic enhancer regions in each time point of the 
Ferrai datasets, and classified them according to RNAPII state and Polycomb occupancy 
(Example of possible dynamic states in Fig 6.2).  
Figure 6.1
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Fig 6.2: Schematic of chapter 6. Schematic representing the possible dynamics of RNAPII and Polycomb during neuronal 
differentiation   
6.3 Contribution disclosure 
Elena Torlai Triglia mapped and processed the RNAPII and H3K27me3 datasets and calculated 
their peaks. Total RNA-seq datasets were produced by Ana Miguel Fernandes and Carmelo 
Ferrai. 
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6.4 Results 
6.4.1 Datasets used in the current chapter 
To study the dynamics of extragenic RNAPII during neuronal differentiation, I took advantage 
of previously published (Ferrai et al., 2017), and unpublished datasets from the lab (AM 
Fernandes and C Ferrai, unpublished). For each time point of the neuronal differentiation 
analysed (Days 0, 1, 3, 16 and 30) were considered ChIP-seq datasets for RNAPIIS5p, 
RNAPIIS7p and H3K27me3 (Table 6.1) and unpublished total RNA-seq (Table 6.2).  
Table 6.1: RNAPII and Polycomb dataset. Table indicating the datasets of RNAPII and H3K27me3 used in the current chapter. 
RNAPII and H3K27me3 datasets were mapped and processed by Dr Elena Torlai Triglia 
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Table 6.2: Total RNA-seq datasets. Table indicating the total RNA-seq datasets used in the current chapter. Datasets were 
produced by AM Fernandes and C Ferrai in the lab 
 
6.4.2 Definition of RNAPII extragenic regions across neuronal 
differentiation 
To investigate extragenic RNAPII regions across differentiation, I defined extragenic RNAPII 
peaks per time point and classified the regions for their enrichment in RNAPIIS5p, as in Chapter 
5. Because this analysis was performed during a differentiation timeline and the transcriptional 
profile of cells varies between time points, I considered as intragenic all the regions overlapping 
with a RNAPII peak covering a gene at any time point. I then calculate the RNAPIIS5p 
enrichment at extragenic peaks per time point and the 5% false positive cut-off on matched 
extragenic random regions, as previously (Chapter 5, section 5.4.2). Extragenic regions 
identified in this manner in each time point were then merged together to constitute a single list 
of extragenic regions marked by RNAPIIS5p in at least one time point across neuronal 
differentiation (Fig 6.3a). RNAPII extragenic peaks at Day 0 were defined in the previous 
chapter (Chapter 5, section 5.4.4). At Day 1, 93% extragenic RNAPIIS5p peaks were enriched in 
RNAPIIS5p signal above the 5% calculated threshold; 89% at Day 3; 91% at Day 16; and 92% 
at Day 30 (Fig 6.3b). 
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Fig 6.3: Pipeline to define extragenic RNAPIIS5p regions during neuronal differentiation. a) Scheme of the steps of the pipeline 
to define extragenic RNAPII regions per time point. b) Density plot showing the enrichment per time point of RNAPIIS5p at 
extragenic RNAPIIS5p regions.  Pink thick lines represent maximum enrichment of RNAPIIS5p at RNAPIIS5p extragenic 
regions per time point. Grey lines represent enrichment at random extragenic regions. Dotted vertical line represent 5% FP cut-
off calculated on random regions enrichment.  
The full list of RNAPIIS5p regions was then filtered for the ENCODE black list (Consortium, 
2012) and merged to obtain a non-redundant list of 16609 extragenic RNAPII regions during 
neuronal differentiation (Table 6.3). 
Table 6.3: Positive extragenic RNAPII. Table indicating the extragenic RNAPII regions before and after applying the 5% false 
positive threshold per time point and the total of regions after merging and filtering obtain. 
 
As shown previously, these regions are highly variable between datasets and mainly restricted to 
one time point (Fig 6.4). With these regions, I moved forward to analyse the extragenic RNAPII 
dynamics during neuronal differentiation. 
 
Fig 6.4: Co-localisation of extragenic RNAPII regions across time points. Plot showing the number of combinations of co-
localising extragenic RNAPII regions before merging. The majority of regions are unique for a time point or restricted to two. 
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6.4.3 Classification of extragenic RNAPII states during neuronal 
differentiation 
To analyse the state activation of extragenic RNAPII during neuronal differentiation, I classified 
the regions according to presence or absence of RNAPIIS5p, RNAPIIS7p and H3K27me3, per 
each time point (Fig 6.5a), as described in Chapter 5, section 5.4.8. All regions were classified as 
positive or negative for H3K27me3, RNAPIIS5p, and RNAPIIS7 (Fig 6.5b). The signal of 
H3K27me3 at extragenic RNAPII regions is very close to the signal of extragenic random 
regions, leading to a low number of positive regions for this modification, as seen previously for 
mESCs (Day 0; section 5.4.8). 
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Fig 6.5: Classification of extragenic RNAPII states during neuronal differentiation. a) Pipeline showing the steps taken for 
extragenic RNAPII states classification per region, feature and time point. b) Classification of H3K27me3, RNAPIIS7p and 
RNAPIIS5p at RNAPIIS5p extragenic regions. Thin purple lines: enrichment of the considered feature at all extragenic 
RNAPIIS5p regions; thick purple lines: enrichment of the considered feature at extragenic RNAPIIS5p region overlapping a peak 
of the featured considered; grey dotted curved line: enrichment at extragenic random regions. Vertical dotted line: 5% FP cut-off. 
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6.4.4 Extragenic RNAPII is found in different states during neuronal 
differentiation  
RNAPII extragenic regions are found in different states of activation throughout all the neuronal 
differentiation, which is concordant with previous results in mESC (Fig 6.6).  
 
Fig 6.6: Extragenic RNAPII is found in different activation states during neuronal differentiation. Plot showing the number of 
classes per RNAPII states recovered divided per time point. 
 
In each time point around 30% of the regions are occupied by H3K27me3 and/or RNAPII (Table 
6.4). RNAPIIS5p is the most represented class in every time point (30 - 75% of active/Polycomb 
regions), followed by RNAPIIS5p-S7p (16-42%). H3K27me3 can be found alone (<1-17% of 
active/Polycomb regions) or together with RNAPIIS5p or RNAPIIS5p-S7p (4-13% of 
active/Polycomb regions). Classifier enrichment per classes per time point and total RNA 
transcription can be found in Appendix Fig 6.A1 and show robust classification among time 
points. Remarkably, H3K27me3-RNAPIIS5p-S7p regions are among the most transcribed 
classes. 
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Table 6 4: Extragenic RNAPII states during neuronal differentiation. Table showing the number of extragecni RNAPII activation  
 
In conclusion extragenic RNAPII regions are found in different states of activation during 
neuronal differentiation. Regions can be repressed by H3K27me3 alone or together with 
RNAPII, or be in an active state, occupied by RNAPIIS5p and/or RNAPIIS7p. As expected for 
enhancer regions, a great number of regions are not occupied by either RNAPII or H3K27me3 at 
each time point, and classified as inactive. Extragenic RNAPIIS5p regions are therefore 
dynamically regulated. 
6.4.5 Extragenic RNAPII regions undergo waves of activation during 
neuronal differentiation 
First, to understand the dynamics of RNAPII and Polycomb at extragenic regions, I analysed the 
changes in: Active states, with RNAPIIS5p and/or RNAPIIS5p-S7p; Repressed states, with 
H3K27me3, with or without RNAPIIS5p and/or RNAPIIS5p-S7p; and Inactive states, not 
occupied by RNAPII and H3K27me3. 
Extragenic RNAPII regions dynamically change their activation state during neuronal 
differentiation. The majority of extragenic regions are active in a single time point or in 
restricted time frames (Fig 6.7a). Active regions are ~5000 per time point, with a remarkable 
drop at Day 3, where Polycomb regions are at their highest (1342). Polycomb regions greatly 
vary between time points with a drop of Polycomb marked regions in differentiated neurons (to 
345 in Day 16 and 653 in Day30).  
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Fig 6.7: Extragenic RNAPII regions dynamic through neuronal differentiation. a) Dynamics of H3K27me3 and RNAPII at 
extragenic regions during neuronal differentiation. Active regions comprise: RNAPIIS5p, RNAPIIS5p-S7p, RNAPIIS7p and are 
shown in blue. Polycomb regions comprise: H3K27me3, H3K27me3-RNAPIIS5p, H3K27me3-RNAPIIS5p-S7p and are shown 
in blue. Inactive regions are shown in cream. b) Dynamics of extragenic RNAPII states during neuronal differentiation. All 
RNAPII classes specified. c) Schematic representing the most represented transition for selected states and time points from Day 
16 to Day 30. 
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To further understand how RNAPII states differ throughout differentiation, I analysed the 
transitions all the RNAPII classes (Fig 6.7b). The percentage of transitions of extragenic 
RNAPIIS5p regions across the differentiation can be found in Appendix Fig 6.A2. The majority 
of the transitions at active regions keep the RNAPII state or change to Inactive state, while 
Polycomb repressed regions tend to acquire RNAPII. For example, of the 2358 RNAPIIS5p 
regions at Day 0, 962 (40%) keep the activation state, 237 (10%) acquire RNAPIIS7p and 953 
(40%) become inactive at Day 1 (Fig 6.7c).  H3K27me3 regions, on the other hand, 
preferentially keep their state (Day 0 to Day 1: 54%) or acquire RNAPIIS5p (Day 0 to Day 1: 
25%). Inactive regions trough the different time points stay inactive >70% of the time, gain 
RNAPIIS5p 10-25% of the time, and seldom gain Polycomb (~1%). 
In conclusion, these results show that extragenic RNAPII regions are highly dynamic in their 
state; repressed regions decrease during neuronal development, however they are still present in 
fully differentiated neurons. This is in contrast with current literature on poised enhancers, which 
describe the poised state as mainly restricted to embryonic stem cell, as only a minority of poised 
enhancer were found in differentiated cells (Cruz-Molina et al., 2017; Rada-Iglesias et al., 2011; 
Zentner et al., 2011). RNAPII and Polycomb states show dynamic changes during neuronal 
differentiation. These regions are time specific and can be either in a repressed or in an active 
states, which changes through time, resembling the highly specificity of enhancers. 
6.4.6 Extragenic RNAPII regions identify enhancer regions active in 
vivo  
To investigate whether extragenic RNAPII regions function as enhancers in vivo, I analysed the 
co-localisation of extragenic RNAPII regions with previously tested enhancers of the VISTA 
enhancer browser (Visel et al., 2007). The VISTA enhancer browser contains ~3000 of tested 
regions for enhancer activity in mouse embryo at stage E11.5.  
To proceed with the comparison, I selected regions from the late development in neurons (Day 
16 and Day 30), which should be in part captured in E11.5 (Fig 6.8a). To test whether regions 
with different states between Day 16 and Day 30 might have different activity in the VISTA 
database, I selected all the extragenic regions that are active in Day 16 and/or Day 30 (total of 
~10000 regions). I compared these regions with regions from the VISTA browser: positive in 
brain, heart or limb at E11.5; and negative for a specific signal in E11.5. Many (40%) of VISTA 
regions are negative for specific enhancer signal at E11.5, ~ 30% positive for brain, 20% or less 
positive for limb and heart (Fig 6.8b). Regions in the VISTA database can be positive for more 
than one tissue. The analysis with the VISTA enhancer database was conducted with all the 
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extragenic regions and with the extragenic regions newly identified by extragenic RNAPII and 
not-colocalising with other published enhancers (Cruz Molina et al. 2017, Whyte et al. 2013, 
Chen et al. 2012). Strikingly, the results show that extragenic RNAPII regions active are 
significantly enriched for enhancer activity in vivo in brain. Of the newly identified regions: 48% 
of Active (Day 16) – Active (Day 30) were active in brain, against 32% negative; 48% of Active 
(Day16) – Inactive (Day30) were active in brain, against 25% negative.  
 
Fig 6 8: Extragenic RNAPII regions identify active enhancers in vivo. a) Dynamics of extragenic RNAPII regions from Day 16 
to Day 30. Highlighted are interesting transitions. Active regions comprise: RNAPIIS5p, RNAPIIS5p-S7p, RNAPIIS7p and are 
shown in blue. Polycomb regions comprise: H3K27me3, H3K27me3-RNAPIIS5p, H3K27me3-RNAPIIS5p-S7p and are shown 
in blue. Inactive regions are shown in cream. b) Overlap of different transition groups with enhancers from the VISTA database. 
Bar represent percentage of regions overlapping with VISTA enhancers: in white – negative VISTA enhancers, in grey – positive 
VISTA enhancers. P-value calculated with hypergeometric test. 
Taken together, these results show the power of RNAPII states to mark active enhancer regions 
in vivo. These regions have brain specific activity, in accordance to being defined in neuronal 
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cells. Similar analysis conducted in the transition between Days 1 and 3 yielded comparable 
results (Appendix Fig 6.A3). 
6.4.7 RNAPII states are linked with enhancer activity in vivo  
In the previous chapter I showed that RNAPII activity states correlates with enhancer marks 
enrichment and activation state. To test whether more active RNAPII is more likely to be present 
at enhancer active in vivo, I analysed the state of RNAPII at these regions in more detail. Active 
enhancers in vivo tend to have a more active RNAPII (Fig 6.9a), however to a similar degree to 
the negative regions. Regions with enhancer activity in vivo that undergo inactivation from Day 
16 to Day 30 are more transcribed than negative regions (Fig 6.9b), while regions active in both 
time points are transcribed at similar level regardless of their enhancer activity in vivo.  
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Fig 6.9: Extragenic regions acting as enhancers are in a active state. a) State of extragenic RNAPII regions positive in brain and 
negative in the VISTA enhancer database. Active to Active and Active to Inactive regions are shown. b) Total RNA in Day 16 
and Day 30 of extragenic RNAPII regions positive and negative in the VISTA enhancer database divided by group of transition. 
Log normailised read counts + 0.001 shown for clarity. Normalised read counts were calculated with the DESeq package in R. 
Every dot represent a region. 
Taken together, these results show that extragenic RNAPII regions co-localising with VISTA 
regions are bound by RNAPII in an active state, which is likely to transcribe through these 
regions. Future analyses will explore available RNA-ChIP-seq datasets produced for some of the 
data points considered (Robert A. Beagrie, Carmelo Ferrai, unpublished).  
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6.5 Discussion 
In the current chapter, I show that extragenic RNAPII regions are highly dynamic during 
differentiation, and have enhancer activity in vivo. 
6.5.1 Extragenic RNAPII states dynamics during neuronal 
differentiation 
Extragenic RNAPII is present in different activation states through neuronal differentiation, 
concordant with previous results in mESC (Chapter 4-5). The dynamics of RNAPII and 
Polycomb at extragenic regions are more variable than the ones previously seen at promoters in 
the same neuronal differentiation (Ferrai et al., 2017). Enhancers are more variable in their 
activity than genes (Nord et al., 2013), which supports the finding that of all the extragenic 
regions characterised during neuronal differentiation 50-70% are inactive per time point. 
Noticeably, closer time points share more regions than time points further apart, which is in line 
with enhancer specific activity. Same extragenic regions in related cells can regulate cell identity 
genes, which need to be activated. Cells in very different differentiation states, on the other hand, 
should have fewer expressed genes in common, and possibly fewer shared regulatory regions. In 
line with this, active regions in one time point tend to either remain active or to turn to inactive 
and few regions are active at early time points, become inactive, and turn active again. 
Interestingly, Polycomb regions seldom turn to inactive, while more often either remain 
repressed or acquire RNAPII. It is possible to speculate that these regions are kept poised and 
ready to be activated. More studies are needed to understand their target genes and their function.  
Some extragenic regions remain active throughout neuronal differentiation. These regions are 
mainly bound by RNAPII without Polycomb (data not shown) and could constitute enhancers 
recently described to regulate housekeeping genes (Arnold et al., 2013). While an investigation 
of these regions was not conducted for time constrains, it would be of interest to analyse these 
regions further, especially their enrichment for binding sites of expressed TFs, or TF binding 
profiles, if available, and their involvement in chromatin architecture. 
6.5.2 Extragenic RNAPII marks enhancers active in vivo 
To assess the power of extragenic RNAPII as an approach to identify regulatory regions, I 
compared these regions with the regions of the VISTA enhancer browser. The VISTA enhancer 
browser contains thousands of regions tested for their reporter activity in mouse embryos (Visel 
et al., 2007). The majority of regions were tested at E11.5, and are the ones used for comparison 
in the current chapter. Remarkably, regions identified with extragenic RNAPII are significantly 
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enriched in enhancer with specific activity in brain. Regions positive for enhancer activity in vivo 
have an active transcribing RNAPII. This reflects the findings of chapters 4 and 5, where I 
showed that RNAPII state are indicative of enhancer state. These results were obtained for 
regions active in Days 1 and 3 (early development) and Days 16 and 30 (late development) and 
highlights that extragenic RNAPII can specifically identify regions with enhancer activity in 
vivo. Regions active specifically in Day 30 and co-localising with VISTA enhancers were few 
and mainly negative, as expected as Day 30 neurons have mature electrophysiology responses 
and fully developed dopaminergic neurons develop between E11 and E14, which can explain 
why they are not captured in the comparison with VISTA regions (Ang, 2006).  Extragenic 
RNAPII was able to recover specifically regions active in brain development. It would be of 
interest to apply this method to heart development, for example, as it is also covered in the 
VISTA database.  
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6.6 Figures Appendix 
 
Fig 6.A1: Extragenic RNAPII activation states across differentiation are robust. a) Boxplots showing the enrichment of classifiers 
per time point per class. Active TSSs in the specific time point and extragenic random regions are shown as reference. Active 
TSSs were downloaded from Ferrai et al. 2017 and are +/- 2kb from the active TSS. Boxplots show the log average count of 
ChIp-seq reads per region + pseudo count are shown for clarity. b) Total RNA transcribed per class of extragenic RNAPII per 
time point. Log TPM + 0.001 shown for clarity.  
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Fig 6.A2: Transition of all extragenic RNAPII states. Plots showing the total percentage of the transition per day pair of 
extragenic RNAPII states.  
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Fig 6.A3: extragenic RNAPII dynamics in early differentiation identify enhancer regions involved in development. Dynamics of 
extragenic RNAPII regions from Day 1 to Day 3. Highlighted are interesting transitions. Active regions comprise: RNAPIIS5p, 
RNAPIIS5p-S7p, RNAPIIS7p and are shown in blue. Polycomb regions comprise: H3K27me3, H3K27me3-RNAPIIS5p, 
H3K27me3-RNAPIIS5p-S7p and are shown in blue. Inactive regions are shown in cream. b) Overlap of different transition 
groups with enhancers from the VISTA database. Bar represent percentage of regions overlapping with VISTA enhancers: in 
white – negative VISTA enhancers, in grey – positive VISTA enhancers. 
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7. Discussion 
The work presented in the current thesis is part of a fast-moving field that tries to characterise 
regulatory regions and understand their features, and at the same time aims to find new, powerful 
approaches to identify regulatory regions. This is particularly important to discover target genes 
affected by disease-associated sequence variation in non-coding regions of the genome, which 
are likely to have regulatory or enhancer functions. Enhancers are described as regions outside 
promoters, which regulate target gene expression. However, it is not clear what is the difference 
between enhancers identified using different strategies and which features are most powerful to 
identify and characterise enhancer activation states.  
Enhancer identification approaches 
In Chapter 3, I compared the genomic position and other features of candidate enhancer regions 
identified genome-wide using different approaches. Each approach uses different chromatin 
occupancy features, which leads to differences in the type of regions identified. However, the 
size and implications of this effect have been often overlooked. Not only different regions are 
detected in different approaches, but perhaps more difficult, regions classified in different 
activation states can co-localise, such as super enhancers and poised enhancers. Results in 
chapter 3 show that similar approaches can identify enhancers with different characteristic, 
probably for technical reasons such as differences in datasets, peak calling methods or the 
thresholds used. An important result of my research was the finding that regions enriched for 
enhancer marks and transcription factors are also bound by RNAPII, independently of the 
approach used for the identification. 
Different states of activation of RNAPII at extragenic enhancer regions 
While different studies analysed RNAPII occupancy at extragenic regions and remarkably some 
also used different RNAPII modifications datasets(Cruz-Molina et al., 2017; De Santa et al., 
2010; Estarás et al., 2015; Koch et al., 2011), the state of RNAPII at enhancers was not 
previously investigated in depth. In Chapter 4, I showed that RNAPII at extragenic enhancers 
exists in different states of activation from transcription initiation, marked by RNAPIIS2u and/or 
RNAPIIS5p, to elongation, marked by RNAPIIS2p. The activation state of RNAPII mirrors the 
enhancer activation state, which suggests that RNAPII states can be used as readout of enhancer 
states and for enhancer identification in the genome.  
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Identify of candidate regulatory regions using RNAPII occupancy in mESC 
In Chapter 5, I produced a list of candidate enhancers identified based on RNAPIIS5p occupancy 
at extragenic regions and showed that almost all of them overlap with enhancer marks: only 30% 
of them had been previously catalogued as enhancers with other approaches. Remarkably, 
extragenic RNAPII regions show the same correlation between the state of RNAPII and the 
enrichment for enhancer marks, irrespectively of whether they overlay with previously identified 
candidate enhancers. RNAPII occupancy is therefore a valuable approach to identify regulatory 
regions. Moreover, the observation that RNAPII at extragenic regions transcribes RNAs with 
different states of maturation, some with properties of eRNAs, confirms the occupancy of 
RNAPII at these extragenic regions and shows that the RNAPII state reflects the maturation state 
of the RNA. Transcription at extragenic regions is regulated through modifications of the 
RNAPII-CTD that are important for promoter pausing release mechanism. 
RNAPII regions in a neuronal differentiation time course  
In Chapter 6, to test the power of RNAPII to identify enhancers, I detected extragenic RNAPII 
regions in a neuronal differentiation time course, and showed that these regions undergo 
extensive dynamic states between time points, from inactive, to Polycomb repressed, to active. 
Importantly, the candidate regions identified using in vitro differentiated neurons with extragenic 
RNAPII show enhancer activity in vivo specific for the brain, both for candidate regulatory 
regions newly identified or previously identified by other approaches.  
Differences between enhancer identification approaches: what we 
can learn 
Enhancers are known since 1981 and were first described in SV40-infected HeLa cells as a 
genomic element capable of activating a target gene independently of the orientation or the 
position in respect to the target gene(Banerji et al., 1981). Since then, various approaches were 
developed to identify and characterise enhancers. Putative enhancers can be defined in different 
states of activation, which are indicative of their functions: for example, active enhancers will 
enhance, while poised enhancer repress target gene expression(Buecker et al., 2014; Calo and 
Wysocka, 2013). Approaches to identify enhancer regions can vary in their methodology, 
leaving open the question of which has a higher sensitivity and specificity. An interesting study 
(Benton et al., 2017) aimed to understand if enhancers regions identified with more than one 
approach have a tendency to be more active. The authors showed that not only this was not the 
case, but also that different approaches found regions with different characteristics, such as 
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conservation, GC content, etc. Benton and colleagues (2017) focused on active enhancers. In the 
current work, I compared not only enhancer lists defined with different approaches, but also 
enhancers classified in different states of activation. 
The major conclusion that emerges from the comparisons between enhancer lists is that each 
enhancer detection approach has its specific biases depending on the chromatin occupancy 
features used as input. These biases should be taken into account depending on which type of 
enhancer one aims to discover. For example, candidate enhancer regions bound by TFs can be 
actively transcribed by RNAPII, and enhancers occupied by histone modifications that mark 
active enhancers, such as H3K27ac, can be bound by proteins involved in chromatin looping, 
such as CTCF (Hansen et al., 2016). Enhancer regions identified by different criteria may exert 
different functions. As suggested by Benton and colleagues (2017), it is possible that enhancer 
regions as currently defined are an aggregate of different types of regions, which may regulate 
through diverse mechanisms. For example, an interesting finding emerging from the current 
work is the diverse relation between specific transcription factors and RNAPII at enhancers. 
E2f1 enrichment showed a high correlation with RNAPII binding, whereas Smad1 enrichment is 
inversely correlated, in line to repressive roles of the Smad family in gene regulation(Vincent et 
al., 2009). E2f1 was shown to regulate Brd4, an important factor bound at super enhancers(Ma et 
al., 2003). These observations suggest that regulatory regions can exert different functions, 
repressive or activating, based on their respective marks, which are complex and yet to be fully 
understood. 
In the future more studies on the relation between regulatory regions and their functions, such as 
involvement in direct contacts or in insulator mechanisms, as well as dynamics during cell 
differentiation or after stimuli, will help clarify the diversity of regulatory regions and potentially 
distinguish between regions with diverse function. 
RNAPII state as readout for enhancer state 
Enhancers were described to exist in different states of activation (Calo and Wysocka, 2013) and 
to transcribe enhancer RNAs (eRNAs). eRNA transcription is linked with enhancer activity (Kim 
et al., 2010;Kaikkonen et al., 2013), and it has been used to identify enhancers in the genome 
(Arner et al., 2015; Henriques et al., 2018). I decided to take a complementary approach and 
define enhancers based on extragenic RNAPII occupancy, with the aim of understand if it is 
possible to define the state of enhancers and genes with a minimal dataset. To conduct analyse 
RNAPII states at enhancer regions, I focused on extragenic regions, to avoid the confounding 
effect of gene-coding transcription. Though enhancers are known to also reside inside gene 
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introns, these regions were not considered in this work. A future possibility to study RNAPII at 
intragenic regions would be to consider enhancers inside inactive genes; inactive genes would be 
transcriptionally silent, so it would be possible to identify RNAPII states at intronic or exonic 
enhancers of inactive genes.  
Enhancers bound by RNAPII show features associated with active and poised enhancers, such as 
variable levels of transcription and typical chromatin marks, e.g. H3K27ac, H3K4me1, TFs and 
P300. Interestingly, TF binding alone is not able to distinguish between differently active 
enhancers, in line with what was previously shown for super enhancers and normal enhancers 
(Hnisz et al., 2013; Whyte et al., 2013). 
RNAPII states at enhancers recapitulate the states found at genes. This finding clarifies an open 
question in the field about whether or not RNAPII at enhancers shows differences from RNAPII 
at genes. Although previous work failed to identify RNAPIIS2p at enhancer regions (Koch et al., 
2011; Li et al., 2016), the work presented in this thesis clearly shows that a subset of enhancer 
regions are bound by RNAPIIS2p and transcribe detectable polyA-RNA. Low levels of polyA-
RNAs originating from enhancer regions were previously described (De Santa et al., 2010). 
Although RNAPIIS2p-positive enhancers are the most transcribed enhancers in nascent and total 
RNA-seq datasets, the level of expression is considerably lower than that of active genes. 
Moreover, RNAPIIS2p enhancers, together with the other RNAPII-bound enhancers, are 
sensitive to transcription perturbation using Cdk9 inhibition, Erk2 knockout, and Exosome 
knockdown, the latter contrary to active coding genes.  
One interesting observation was the identification of candidate enhancer regions occupied by 
RNAPIIS2u alone. RNAPII at genes is phosphorylated on Ser5p upon binding (Brookes and 
Pombo, 2009). Detection of RNAPIIS2u alone is uncommon at genes, while it is a numerous 
class at extragenic regions. It is possible that phosphorylation at enhancers is less efficient, 
maybe because of the lower abundance of kinases such as Cdk8 and Cdk7 at extragenic regions 
compared to promoters (data not shown). In line with this theory are the results that show that 
RNAPIIS2u at extragenic regions has intermediate enrichments of active features and low 
transcription levels. However, it is also possible that RNAPII at these regions is present in a 
different form not considered in the current work. For example, RNAPIIS2u could be in an 
initiating stage marked by RNAPIIK7me1/2, modifications of the distal non-consensus CTD that 
was linked with early stages of transcription at active genes (Dias et al., 2015). Less probable 
would be the presence of Tyr1p, which was associated with elongating RNAPII (Mayer et al., 
2012a). 
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Finally, it remains to be understood whether regions bound by TFs, but depleted of RNAPII, 
have a different enhancer state or act with different mechanisms. For example, it is possible that 
enhancer regions without RNAPII would be involved in longer chromatin loops (Rao et al., 
2014) which define the preferential space of activity of other enhancers in the chromatin locus. 
Topological Associated Domains (TADs) are described as regions of preferred interaction 
(Dixon et al., 2016), and at least some TAD borders which are enriched in CTCF act as 
insulators. Loops and TADs, however they are defined, are similar in concept, where structural 
proteins confine large stretches of chromatin to interact between themselves. TADs and loops 
were found to be to some degree cell specific(Fraser et al., 2015; Rao et al., 2014). In this frame, 
enhancers with and without RNAPII can be different genomic elements that work together to 
regulate gene expression. For example, enhancers without RNAPII could have a structural role, 
while enhancers with RNAPII could contact the genes and create regions enriched for TFs and 
co-factors which can promote transcription (Beagrie and Pombo, 2016; Merika and Thanos, 
2001). It has to be noted that TAD boundary can be enriched in RNAPII (Fraser et al., 2015) and 
this could also suggest that TAD boundaries have different natures.  
Extragenic RNAPII as a powerful approach for enhancer 
identification 
Identification of putative enhancers remains a major challenge in the field. In the current work, I 
present a novel way to identify enhancers using RNAPII occupancy. Extragenic regulatory 
regions identified with this approach overlap >95% of the time with known enhancer marks and 
show typical enhancer features, such as Exosome sensitive transcription and high dynamic states 
during differentiation. Previously, De Santa and colleagues showed that RNAPII marks putative 
enhancers regions in macrophages (De Santa et al., 2010), however the work presented in this 
thesis substantially advance their initial findings, demonstrating that different states of activation 
of RNAPII distinguish differently active enhancers. Furthermore, I demonstrate that extragenic 
RNAPII regions are able to find enhancer regions active in vivo in specific cell types. The use of 
extragenic RNAPII to identify enhancers proved to be powerful also in identifying Polycomb 
repressed enhancers, that would be missed by methods based on transcription, due to the low to 
not detectable levels of eRNAs originating from these regions (this work and Rada-Iglesias et 
al.(Rada-Iglesias et al., 2011), Cruz Molina et al.(Cruz-Molina et al., 2017)). Another advantage 
of using RNAPII to identify regulatory regions is the possibility, with a minimal dataset, to be 
able to evaluate the activation state of both promoters and enhancers of a cell. RNAPIIS5p, 
RNAPIIS7p, and H3K27me3, plus RNA-seq were proven to be sufficient to characterise 
promoter states in mESC and during differentiation (Brookes et al., 2012; Ferrai et al., 2017). 
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This works adds the opportunity to identify and characterise the enhancers with the same 
datasets. Not only would it be possible to have promoter and enhancer states at the same time, 
but even more importantly RNAPII datasets do not need previous knowledge on TFs important 
in the specific cell type or reaction to stimuli, reducing a potentially issue to experimental design. 
Potentially, RNAPII extragenic regions specific for a developmental stage or a stimuli response 
could be used to infer TF binding via transcription factor binding motif algorithms. For example, 
it would be interesting to understand which TFs bind enhancers bound by RNAPII at early and 
late stages of neuronal differentiation Interestingly, some extragenic RNAPII regions identified 
in this work during neuronal differentiation are active across all the time points (data not shown). 
It would be of interest to understand the specificity of these regions, for example if they regulate 
housekeeping genes. Housekeeping genes were recently shown to be regulated by constitutive 
enhancers (Zabidi et al., 2014). Extragenic RNAPII could potentially be able to identify also 
these regions, together with poised enhancers and time-specific enhancers. 
In the future, it would be of great interest to understand whether specific RNAPII activation 
states at enhancers are indicative of target gene promoter states, and whether this information 
could be used to identify target genes. For example, poised enhancers can regulate repressed 
genes and the specificity of this regulation could be mediated by RNAPII. RNAPII states at 
enhancers and promoters could be used to infer target genes. Although this idea needs to be 
proven, it would potentially lead to the possibility of characterising enhancer states, promoter 
states, and enhancer promoter contacts with a minimal datasets featuring RNAPIIS5, 
RNAPIIS7p, and Polycomb. 
Transcription at extragenic RNAPII identified enhancer is regulated 
similarly to genes 
Enhancers were found to transcribe RNAs (Andersson et al., 2014a; Arner et al., 2015; Kim et 
al., 2010;Kaikkonen et al., 2013). eRNAs are detected with techniques such as CAGE 
(Andersson et al., 2014a; Arner et al., 2015), total RNA (Koch et al., 2011), GRO-seq (Danko et 
al., 2015), Start-seq (Henriques et al., 2018), which give indications of the nature of these 
transcripts. My analysis showed that nascent RNA has the highest signal in the different 
extragenic RNAPII regions classified. eRNAs were shown to be transcribed and degraded by the 
Exosome machinery (Andersson et al., 2014a), which happens also at RNAPII extragenic 
regions. Moreover, extragenic regions are sensitive to Flavopiridol, a drug that inhibits Cdk9. 
Cdk9 inhibition block productive elongation because it interferes with RNAPIICTD 
phosphorylation and promoter proximal pausing release. Recently, Henriques and colleagues 
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characterised the role of the pausing factor Spt5 in transcriptionally active enhancers in 
Drosophila (Henriques et al., 2018), which is in line not only with the finding on Flavopiridol 
sensitivity, but also with the observation that Spt5 and Nelfa bind extragenic RNAPII regions. 
Interestingly, RNAPIIS7p and RNAPIIS2p presence correlates with Spt5 and Nelfa binding, 
with Nelfa more enriched at RNAPIIS7p regions without RNAPIIS2p and Spt5 enriched in both. 
Spt5 travels with elongating RNAPII while Nelfa detaches after promoter proximal pausing 
release. This observation would suggest that RNAPIIS5p-S7p-S2p extragenic regions would be 
in a more active and elongating phase of transcription compared with the RNAPIIS5p-S7p 
regions. It would be of interest to understand whether regions more transcribed have some other 
transcriptional feature compared to other regions, such as unidirectional versus bidirectional 
transcription. 
I find that extragenic RNAPII enhancer regions are sensitive to Erk2 knock out (KO). Erk2 is 
known to regulate poised genes (Jia et al., 2012), while enhancers in different activation states 
are sensitive to Erk2 KO. Erk2 occupancy at extragenic regions is very low, however the effect 
on total RNAPII depletion after Erk2 KO suggests either an indirect effect and that RNAPII 
binding at enhancer regions might be less stable than at gene, therefore perturbation of its 
regulatory machinery could have stronger effect. For example, Cdk8 and Med12, two proteins 
involved in transcription re-initiation, are not enriched at extragenic enhancers (data not shown), 
which could be one of the reasons of less stable RNAPII binding and transcription at enhancers. 
More studies on the players involved in RNAPII recruitment at enhancer regions and 
transcription regulators would clarify whether transcription at promoters and enhancers is 
initiated and regulated similarly and also help understand the nature of transcriptionally active 
enhancers. 
Enhancer and promoters share substantial similarities 
Recently, active promoters were shown to transcribe a short-lived species of RNA on the reverse 
strand (Duttke et al., 2015; Flynn et al., 2011). It is still debated if all active promoters show bi-
directional transcription (Duttke et al., 2015; Lepoivre et al., 2013), however it was shown that 
the two transcription events originate from distinct regions, 180bp apart (Andersson et al., 
2014b) which suggests that reverse transcription is not due to wrong orientation of RNAPII at 
the promoter; remarkably upstream-transcribed regions are also occupied by RNAPIIS2p (Preker 
et al., 2011). Transcripts originating from upstream regions are short, not-polyadenilated and 
Exosome sensitive (Andersson et al., 2014b; Flynn et al., 2011; Pefanis et al., 2014), remarkably, 
these features are shared with eRNAs. Bidirectional transcription was described as a feature of 
  
197 
enhancer regions (Andersson et al., 2014a) and enhancers show similar pre-initiation complex 
(PIC) formation to promoters (Core et al., 2014; Scruggs et al., 2015). 
I show that RNAPII states at enhancers are similar to the one found at promoters, however in 
most cases enhancer transcripts do not reach full maturation. Possible differences in the RNA 
maturation could be derived by the differential recruitment of RNA maturation machinery, which 
are still to be investigated. The current work and others (Hah et al., 2013; Henriques et al., 2018) 
have shown that players active at coding regions, such as Spt5, Erk2, and Cdk9 are also involved 
at enhancer to regulate transcription. 
Recent work on promoter upstream regions showed premature termination due to non-sense or 
early termination sites (Ntini et al., 2013). Therefore, transcription at upstream regions can be 
regulated similarly to active coding region, however the transcription will be aborted after the 
encounter with a non-sense termination site. This finding, together with the finding that 
bidirectional promoters can act as enhancers (Dao et al., 2017; Mikhaylichenko et al., 2018) and 
enhancer can act as weak promoters (Arnold et al., 2013; Mikhaylichenko et al., 2018; Serfling 
et al., 1985) suggest a theory where promoters are specialised enhancers, which are followed 
downstream by an evolutionary conserved region, that is the coding gene (similar model 
proposed in Andersson et al. (Andersson, 2014)). 
In line with this theory, I find that RNAPII states and RNAPII regulation to be similar between 
enhancers and promoters, notably with comparable levels of nascent RNA. It was also shown 
that evolutionary younger promoters tend to have a bi-directional transcription that stabilise to 
unidirectional during co-evolution with the coding regions (Jin et al., 2017). One could speculate 
that with time, the transcribed region of the enhancer could potentially mutate and the eRNA 
acquire a function. This could then lead to an evolutionarily constrain of the enhancer regions, 
similarly to what happens with coding genes. It would be of interest to investigate whether more 
evolutionary conserved enhancers tend to have unidirectional transcription and whether eRNAs 
originating from these regions are more likely to have a function.  
Polycomb extragenic regions are similar to Polycomb repressed 
genes 
Enhancers marked by the Polycomb mark H3K27me3 attracted major interest for their role on 
the regulation of neuronal genes (Cruz-Molina et al., 2017; Rada-Iglesias et al., 2011). In my 
analysis of extragenic regions, I also focused on Polycomb enhancer regions, their transcription, 
and their dynamics during neuronal differentiation. The neuronal differentiation datasets were an 
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optimal choice for the study of poised enhancers as they have been previously described in the 
neuronal differentiation pathway (Cruz-Molina et al., 2017; Rada-Iglesias et al., 2011). In my 
study I show that Polycomb extragenic regions in mESC tend to acquire RNAPII in later stages 
of differentiation and become active, while their inactivation was a less likely event. Polycomb 
extragenic regions also showed a preferential localization in proximity to repressed genes. This 
finding correlates with previous studies, showing that poised enhancers tend to be closer to 
repressed genes (Koenecke et al., 2017; Rada-Iglesias et al., 2011). This preferential localization 
might be connected with poised enhancer function. For example, poised enhancers might be 
upstream of the target gene promoter, inside a repressive locus. Interestingly, it was shown that 
Polycomb repressed regions can reside in extended repressive loci (Ferrai et al., 2017; Koenecke 
et al., 2017). When the target gene needs to be activated, RNAPII could be recruited to the 
poised enhancer region, track the DNA to find the promoter and start productive transcription at 
coding genes.  
Interestingly, extragenic Polycomb regions shared features described at Polycomb repressed 
genes. H3K27me3 can be found together with RNAPIIS5p and RNAPIIS7p, as was describe at 
genes (Brookes et al., 2012; Ferrai et al., 2017; Stock et al., 2007). Fascinatingly, I found that  
Polycomb repressed states at extragenic regions are also present in fully differentiated 
dopaminergic neurons, as was recently described for genic regions in Ferrai et al. 2017 (Ferrai et 
al., 2017). This observation is in partial contrast with the enhancer field, where poised enhancers 
are usually described as ESC specific (Cruz-Molina et al., 2017; Rada-Iglesias et al., 2011), 
however low numbers of poised enhancer were previously reported in other studies and not 
explored (Cruz-Molina et al., 2017). It would be of interest to investigate the target genes of 
poised enhancer in fully differentiated neurons, to understand for example whether they regulate 
recently identified Polycomb-repressed genes encoding for TFs not related with the neuronal 
lineage (Ferrai et al., 2017). Furthermore, It would be of great interest to understand if enhancer 
poising is specific for the neuronal lineage as currently hypothesized (Creyghton et al., 2010; 
Rada-Iglesias et al., 2011) or can be found in other differentiated cells. 
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